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Abstract 
 
Obesity is the single most important risk factor for the development of cardio-metabolic disease. 
As white adipose tissue dysfunction plays an essential role in inflammation and metabolic 
health, it would be beneficial to therefore investigate the influence of surgery, endocrine 
hormones, and medication that mitigate adipose tissue inflammation and as a result improve 
cardio-metabolic disease. As such subcutaneous adipose tissue (SAT) biopsies and 
anthropometric and biochemical data were collected from obese-diabetic women before and 
after bariatric surgery. Inflammatory markers, endotoxin, cardio-metabolic markers, fibroblast 
growth factor (FGF)-19 and FGF-21, AGT protein expression and insulin sensitivity, were 
assessed by utilizing ELISA, western blot, anthropometric and biochemical data analysis. 
Collectively the findings of this study identified that combination (restrictive and 
malabsorptive) type of bariatric surgery compared to restrictive procedures, lead to the 
persistence of an inflammatory status, with less improvements in cardio-metabolic components, 
lower disease resolution and lack of significant improvement in FGF-19 and FGF-21 endocrine 
hormones, at 6 months post surgery. Therefore despite the significant weight loss with the 
combination type of surgery, it may still place patients at risk of cardiovascular disease at 6 
months post surgery. In regards to medications that may affect adipose tissue inflammation, 
effects of liraglutide on adipose tissue specific angiotensinogen (AGT) was analysed to assess 
the possible antihypertensive qualities of this medication.  The findings of this study indicated 
that liraglutide can down-regulate AGT in a time and dose depended manner in obese mature 
adipocytes. Furthermore liraglutide appeared to reduce cell proliferation, and improve insulin 
sensitivity. Finally, recognising the likelihood of improvement in Type 2 diabetes mellitus 
(T2DM) status post bariatric surgery is not only beneficial in supporting the preoperative weight 
loss criteria, but it will also identify individuals that may need more support post operatively to 
maintain improved cardio-metabolic outcomes. Therefore having a convenient, non-invasive, 
and cost effective detection and predictive test for T2DM, in such a circumstance can be useful. 
Urinary volatile organic compounds (VOC) have been used for the detection of many diseases 
such as different types of cancers, therefore the potential of VOCs for detecting T2DM was 
analysed. Urine from the same bariatric cohort was collected and tested by field asymmetric ion 
mobility spectrometry. The findings indicated that VOCs have the capability of distinguishing 
pre from post operation urine, in addition to post-operative T2DM status was predicted with the 
use of pre-operative VOCs. Therefore VOCs have the potential of being used as a screening and 
detection test for T2DM, and as a predictive test for the outcome of T2DM status post-bariatric 
surgery.  
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1. Introduction  
The global rise in obesity is contributing to the increase in cardio-metabolic disease 
such as insulin resistance, hypertension, dyslipidaemia and cardiovascular disease. 
Notably obesity, T2DM and hypertension, also known as the “deadly trio’’ orchestrate 
together to exacerbate metabolic dysfunction and disease. The pathogenesis of disease 
through the “deadly trio’’ occurs often utilising many common intracellular pathways 
between them. Yet often screening tools for early detection of obese diabetic 
individuals is problematic. Noting that provision of a non-surgical and cost effective 
monotherapy for these individuals is currently absent.  
 
The key element for increased metabolic risk lies in how the body stores and regulates 
fat (adipose tissue) function, which will be explored further. Adipose tissue is an active 
endocrine organ, in which in humans predominately stores white adipose tissue (WAT) 
and interacts with the local and systemic environment through regulation of cytokines 
(known as adipocytokines) and endocrine hormones. This chapter will explore the role 
of adipose tissue and how it leads to obesity-related cardio-metabolic disease, and how 
the renin angiotensin system, a key regulator of blood pressure, is important in lipid 
metabolism and adipogenesis. Further discussion will review the impact of factors that 
alter the regulation of adipose tissue-renin angiotensin system, when influenced by gut 
derived bacterial fragments, endotoxin/lipopolysaccharides (LPS), in the circulation; 
which are raised in cases of obesity and cardio-metabolic disease.  
 
This chapter will also explore the effectiveness of the current medicines available to 
treat obesity-related hypertension, ranging from variety of antihypertensive, weight-
loss, and anti-diabetic medications such as Liraglutide, in addition to more invasive 
treatments such as different types of bariatric surgery for the treatment of obesity related 
cardio-metabolic disease will be further discussed.  
 
There will also be a focus on the importance and yet difficulties of early detection of 
hyperinsulinemia and pre-diabetes state in diabetic individuals, and how current 
screening strategies are inefficient, invasive and/or expensive. This review will set the 
scene to consider alternative strategies to provide detection and prediction of disease 
 19 
using volatile organic compounds (VOCs) produced in urine. Finally, this chapter will 
detail the research aims for the studies conducted in this thesis. 
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1.1 Obesity and cardio-metabolic syndrome  
 
The 21st century is currently faced with serious public health challenges; this is in part 
due to the rising population numbers and life expectancy coupled with increased obesity 
levels. The World Health Organisation (WHO) has estimated that globally more than 
1.9 billion adults are overweight, of these over 600 million are obese (WHO,2015). The 
impact of obesity has also affected children to such an extent, that the prevalence of 
childhood overweight and obesity has risen substantially worldwide in less than one 
generation (Lobstein, T. et al.,2015, WHO,2015) making obesity a global paediatric 
health risk factor.  
 
Obesity is a state of chronic inflammation, consisting of excessive body fat (adipose 
tissue) accumulation, which causes damaging effects to health while shortening life 
expectancy. Currently people categorised as either overweight (BMI≥25Kg/m2) and/or 
obese (BMI≥30 Kg/m2) are linked to higher rate of mortality worldwide than those 
considered as lean healthy individuals (WHO,2015). Increasing body mass index 
(BMI), which is a measure of weight (kilograms) relative to height (meters), seems to 
have an almost linear relationship with components of cardio-metabolic disorders such 
as elevated blood pressure (≥ 130/85 mmHg) and impaired glucose concentrations 
(fasting plasma glucose ≥ 5.6 mmol/L), dyslipidaemia (Triglyceride ≥ 1.7 mmol/L and 
high density lipoprotein (HDL) < 1.29 mmol/L (in female)), and increase in central 
obesity (waist ≥ 80 cm in European female)(Alberti, K. G. et al.,2006, Bays, H. E. et 
al.,2007, Chung, J. O. et al.,2012, Nordestgaard, B. G. et al.,2012). Longitudinal studies 
have shown that the presence of these cardio-metabolic risk factors during paediatric 
years is a precursor to chronic diseases such as T2DM and cardiovascular disease in 
adults (Morrison, J. A. et al.,2007, Sun, S. S. et al.,2008).   
 
At present, the National Health Service is spending approximately £6 billion on obesity 
and cardio-metabolic disease and by 2030 the cost of obesity is expected to increase to 
£12 billion (McKinsey Consultancy,01/2015). Given the health and economical burdens 
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of obesity it is imperative to further understand the role of adipose tissue regarding 
development of cardio-metabolic disorders, such as, obesity related-hypertension for 
possible identification of novel molecular target for the treatment of this disease. 
 
1.2 Adipose tissue as an endocrine organ 
 
Adipose tissue is a complex endocrine organ, and its metabolic function is now 
recognised beyond the classical actions of fat storage (Hassan, M. et al.,2012) and 
thermoregulation. Adipose tissue is predominantly composed of fat cells (adipocytes) 
and stromal pre-adipocytes.  However, there are other important components such as 
macrophages, connective and nerve tissues, endothelial, stromovascular, and immune 
cells, which act as the building blocks of this tissue (Frayn, K. N. et al.,2003).  
 
Adipocytes are known to secrete a range of bioactive peptide, known as adipokines, 
which can act locally (autocrine/paracrine) and systemically (endocrine). In addition to 
these signals, the various receptors expressed by adipose tissue provide the opportunity 
of responding to signals from different hormone systems as well as the central nervous 
system (Kershaw, E. E. et al.,2004). Therefore, this tissue contains the metabolic 
machinery to enable interaction with other organs. These interactive network 
connections permits adipose tissue to be involved in an array of biological processes 
such as differentiation of pre-adipocytes into adipocytes (adipogenesis), development of 
new blood vessels (angiogenesis), extracellular matrix dissolution and reformation, 
steroid metabolism, immune response, in addition to its original thought function of 
energy homeostasis (Cao, Yihai,2007, Zhong, J. et al.,2010). 
 
In this section, metabolism of this multifunctional endocrine tissue and the hormones 
that can govern this metabolism will be discussed.  
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1.2.1 Adipose tissue structure and metabolism 
 
Depending on morphology, function, development, and location, adipose tissue is 
divided into two categories. Firstly, located in the interscapular, axillar, perineal, 
paravertebral, cervical and distributed in arterials and surrounding organs is brown 
adipose tissue (BAT) (Pacheco, M.M et al.,2018). The abundance of this tissue with 
mitochondria provides the substantial energy production, which is utilised in the form 
of heat production often known as non-shivering thermogenesis (Saely, C. H. et 
al.,2012). 
In contrast to BAT, secondly is WAT, which contains adipocytes with large single lipid 
droplets and much less mitochondria in comparison with BAT. WAT is located in 
several depots throughout the body such as abdominal, inguinal, perirenal, retrosplenial 
and gonadal(Pacheco, M.M et al.,2018). This tissue is principally considered as either 
subcutaneous adipose tissue (SAT), which lies below the basal skin membrane, or 
visceral adipose tissue situated inside the abdominal cavity and between the organs.  
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1.2. 1 White and brown adipose tissue distribution in human body. 
White adipose tissue is dispersed all over the body, with the SAT and visceral intra-
abdominal being the main depots for fat storage. Brown adipose tissue is abundant in 
infancy (interscapular) and although less present in adulthood, it is located in the 
cervical, supraclavicular and paravertebral. Figure from (Pacheco, M.M et al.,2018).   
 
WAT has the ability to fluctuate energy supply in the form of uptake and storing energy 
during fed state and inversely break down and releasing energy in a fasted state. WAT 
plays an important role in systemic energy regulation, which it does through regulating 
anabolic and catabolic pathways to reserve energy in the body in the form of 
triglycerides (TG). WAT adipocytes take up energy in the form of lipids (nonesterified 
fatty acids-NEFA) and carbohydrates (glucose) from the blood. This energy is mainly 
stored as TG, which is subsequently broken down through lipolysis and released as 
NEFA upon conditions of high metabolic demand or negative energy balance.  
 
Adipocytokines with endocrine functions such as adiponectin, leptin, tumour necrosis 
factor alpha (TNF-α), interleukin-6 (IL-6) and proteins of the renin angiotensin system 
(RAS), have the capability which include altering WAT metabolism (Saltiel, A. 
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R.,2001, Yamauchi, T. et al.,2001, Banerjee, R. R. et al.,2004). As an example, TNF-α 
represses genes involved in uptake and storage of NEFAs and glucose and supress 
genes for transcriptional factors involved in adipogenesis and lipogenesis (combination 
of fatty acid (FA) and TG synthesis) in adipose tissue (Ruan, H. et al.,2002, Kershaw, 
Erin E. et al.,2004). Proteins of RAS secreted from adipose tissue not only contribute to 
blood pressure regulation; they are also positively correlated with adiposity in humans 
(Engeli, S. et al.,2003, Goossens, G. H. et al.,2003). The effects of these proteins on 
adipose tissue inflammation and in other processes will be discussed in further detail 
later on in this chapter.    
 
Mediating WAT adipocyte metabolism can also occur through hormonal and neuronal 
stimuli that initiate a cross talk between systemic metabolic organs, in which WAT 
predominantly supplies the body’s energy demands. For example during the fasting 
state glycogen stores in the liver becomes depleted causing a liver-brain-adipose neural 
axis, that can shift energy source from carbohydrates to TG in adipocytes to maintain 
energy balance (Izumida, Y. et al.,2013). Inversely, in the fed state glycogen is 
accumulated in the liver, and lipogenesis is stimulated in adipocytes (Liu, M. et 
al.,2014). Hormonal stimuli such as those observed in the fibroblast growth factor, 
(FGF) family regulate glucose, and lipid metabolism via WAT during periods of 
nutritional stress.  
 
1.2.2 Endocrine regulation of white adipose tissue metabolism  
 
Recognition of WAT as an energy storage depot, and as an endocrine organ exposes 
adipocytes to various degrees of endocrine, metabolic, and neuronal regulations. While 
insulin (Kim, W. et al.,2008, Guo, S.,2014) is known as a classic endocrine regulator, 
due to exerting its dramatic effects on lipid metabolism in WAT, there are other vital 
key endocrine regulators that can also control WAT physiology and metabolism.   
 
FGF-19 and FGF-21 are secreted signalling proteins that have the capability of targeting 
multiple tissues by predominantly acting as endocrine hormones. The ability of binding 
to both FGF receptors (FGFR) and transmembrane co-receptor betaKlotho (β-klotho) 
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specifically permits FGF-19 and FGF-21 to exert their regulatory effects on WAT 
metabolism. Although both hormones are stimulated under different conditions, they 
present significant functional overlap regarding insulin sensitivity and glucose tolerance 
improvements, weight reduction, lipid, and energy metabolism (Zhang, F. et al.,2015). 
Under conditions of metabolic stress such as T2DM, obesity prolonged fasting and 
cardio-metabolic disease; FGF-19 levels are reduced, while simultaneously FGF-21 is 
elevated in human subjects (Gallego-Escuredo, J. M. et al.,2015). 
 
Human FGF-19 (mouse ortholog FGF-15) is a regulator of bile acid synthesis. As a 
response to feeding, bile acid activates farnesoid X receptor (FXR) expression in the 
terminal ileum of the small intestine, resulting in increased transcription of FGF-19 
(Inagaki, T. et al.,2005). Upon secretion into the blood circulation FGF-19 binds to 
FGFR4/ β-klotho and activates various signalling cascades such as extracellular-
regulated kinases (ERK) and c-Jun N-terminal kinase (JNK) within liver cells (Song, 
Kwang-Hoon et al.,2009). By doing so FGF-19 supresses bile acid, glucose, and 
triglyceride synthesis while stimulating glycogen synthesis and fatty acid 
oxidation(Degirolamo, C. et al.,2016).  
 
Even though the major site of endogenous functions of FGF-19 is the liver, this 
endocrine hormone can also exert its biological effects in WAT. Several mouse studies 
have indicated that pharmacological effects of FGF-19 depends on WAT binding and 
activation of the FGFR1-β-klotho complex to improve blood glucose homeostasis (Wu, 
Xinle et al.,2009, Wu, Ai-Luen et al.,2011, Adams, Andrew C. et al.,2013). Chronic 
treatment of obesity with FGF-19 has resulted in increased energy expenditure and 
weight reduction followed by improvements in lipid profile (Nies, Vera J. M. et 
al.,2015), however, it remains unclear whether these effects are solely mediated via 
WAT, or further signalling through other metabolic tissues such as liver is required.   
 
Secreted by the liver, FGF-21 applies its regulatory effects via signalling in various 
tissues. However, during episodes of metabolic stress the main focus of FGF-21 action 
appears to be on WAT. Similarly to FGF-19, circulating FGF-21 primarily binds with a 
high affinity to the FGFR1-β-klotho complex of mature adipocytes (Yang, C. et 
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al.,2012). Binding to this ternary complex initiates multiple FGF-21 regulatory actions 
on WAT metabolism:   
 
1. FGF-21 stimulates insulin-independent glucose uptake within both mouse and human 
adipocytes (Kharitonenkov, Alexei et al.,2005, BonDurant, Lucas D. et al.,2017). It 
does this by phosphorylation of the ERK 1/2 pathway and activating Glucose Transport 
Protein 1 (GLUT1), resulting in increased glucose uptake. Studies have indicated that 
obesity impairs FGF21-mediated GLUT1 expression in WAT, therefore, creating a 
FGF-21 resistant state (Fisher, ffolliott M. et al.,2010, Ge, X. et al.,2011).       
 
2. As a response to fasting or fibrate drugs, FGF-21 has an inhibitory effect on lipolysis 
in WAT (Potthoff, Matthew J. et al.,2012). In this state the pituitary gland secretes 
growth hormone (GH) in order to stimulate lipolysis in adipocytes to yield free fatty 
acids (FFAs). As a response to this action, hepatic FGF-21 production is induced by 
peroxisome proliferator-activated receptor alpha (PPARα) activation. Increase in 
hepatic FGF-21 levels therefore sends a negative feedback signal to terminate GH-
induced lipolysis in adipocytes (Chen, W. et al.,2011). This feedback control maintains 
the balance of lipid distribution among adipose tissue and liver, in addition to 
preventing increased hepatic steatosis and lipotoxicity caused by sustained FFAs 
accumulation. Studies also indicate that the “fine-tuning” of lipolysis in this manner 
may provide a possible explanation for FGF-21 promoting its insulin-sensitivity 
properties in human (Arner, P. et al.,2008).   
3. FGF-21 acts as the key mediator of PPARγ actions. Contrary to the fasting state, 
circulating FGF-21 is mainly expressed and secreted by adipocytes in response to the 
fed state or thiazolidinedione drugs (TZDs) (Dutchak, Paul A et al.,2012). Both animal 
and human studies have indicated that in the latter conditions FGF-21 production is 
governed by PPARγ activation (Wang, H. et al.,2008, Zhang, X. et al.,2008), resulting 
in elevated adipocyte FGF-21 expression during fed state and reduced in fasting state, a 
reverse pattern to that in hepatocytes (Dutchak, Paul A et al.,2012).    
 
FGF-21 knockout (KO) mice study has indicated a reciprocal regulation amongst FGF-
21 and PPARγ.  Based on this relationship, studies have suggested that FGF-21 presents 
two independent physiological functions: firstly, secreted by the liver FGF-21 behaves 
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in an endocrine mode in order to synchronise the adaptive response to fasting/starvation 
state. Secondly, during the fed state, WAT secreted FGF-21 responses in an autocrine or 
paracrine mode to regulate adipocyte function (Dutchak, Paul A et al.,2012).      
 
4. FGF-21 is also involved in the transformation of WAT adipocytes into a ‘’brown-
like’’ state (Fisher, F. M. et al.,2012). FGF-21 KO mice exhibition a lack of ability to 
adjust to chronic cold exposure as browning of WAT reduces (Fisher, F. M. et 
al.,2012). FGF-21 achieves this effect by activation of mitochondrial brown fat 
uncoupling protein 1 (UCP1) via the sympathetic nerve(Lin, Xiaolong et al.,2017). By 
regulating UCP1 through the 5’-AMP_activated protein kinase (AMPK)/sirtuin-1 
(SIRT1)/ peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC1α) pathway (Bartelt, A. et al.,2014), this hormone can enhance mitochondrial 
oxidation and increase heat dissipation (Chau, M. D. et al.,2010).     
 
These multifunctional governing capabilities of FGF-19 and FGF-21 on WAT 
metabolism and on other tissues, collectively arise during obesity and its related cardio-
metabolic disease state. Understanding the physiological roles and molecular pathways 
essential to the actions of these two hormones will contribute to the development of 
better therapeutic strategies for these diseases.  
 
1.3 White Adipose tissue dysfunction and inflammation 
 
In obesity WAT dysfunction is considered the main cause of cardio-metabolic disease 
(Lewandowska, E. et al.,2016). Adipose tissue dysfunctional is characterised by adipose 
tissue lipid metabolism impairments, reduction in adipose tissue blood flow, and 
elevated production of pro-inflammatory cytokines by hypertrophic adipocytes 
(adipocytes increased in size) and adaptive and innate immune infiltration (Figure 1.3 
A) (Goossens, Gijs H. et al.,2015). These impairments induce insulin resistance locally 
within the adipose tissue, as well as, on a larger scale in the kidney, liver, and skeletal 
muscle through lipotoxicity, leading to systemic low-grade inflammation.  
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1.3.A. Adipose tissue dysfunction in obesity. 
Excess energy intake leads to weight gain and increase in adipocyte size (adipocyte 
hypertrophy), which is accompanied by modifications in adipokine secretion and lipid 
metabolism disturbances resulting in a pro-inflammatory phenotype. The pro-
inflammatory factors, which disrupt adipocyte differentiation, are further boosted with 
immune cell infiltration leading to inflammation and insulin resistance locally. These 
effects can be harmful to the entire body as well, since lipid spillover in the circulation 
and subsequent lipid accumulation in the non-obese tissues can result in insulin 
resistance and obesity related cardio-metabolic disease. Figure from (Goossens, Gijs H. 
et al.,2015).  
 
During this low-grade inflammation hypertrophic adipocytes secrete chemotactic 
adipokines, which recruit macrophages from the blood into adipose tissue. It is 
considered that these macrophages contribute significantly more to the inflammatory 
response than residential macrophages in adipose tissue (Lumeng, C. N. et al.,2007). 
These macrophages and adipocytes secrete monocyte chemoattractant protein-1 (MCP-
1), which has a key role in the development of adipose tissue inflammation 
(Kalupahana, N. S. et al.,2011). An increase in MCP-1 expression is associated with 
increase in macrophage adipose tissue infiltration (Surmi, Bonnie K. et al.,2008). 
Additionally, MCP-1 production is stimulated by increased amount of circulating FFA, 
insulin and pro-inflammatory TNF-α, IL-6, all of which have a positive correlation with 
adipocyte size. Simultaneously while this takes place, the production of adipocytokine 
adiponectin, a key contributor to insulin sensitivity and cell size, is reduced (Xu, H. et 
al.,2003).  
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Therefore, MCP-1 secreted by adipocytes stimulates a substantial macrophage 
infiltration of adipose tissue, causing an increase in typical macrophage cytokine release 
leading to an increase in adipose tissue inflammation (Xu, H. et al.,2003). Additionally, 
TNF-α acts as a key pro-inflammatory cytokine further adding to this condition by 
reducing adiponectin gene expression, leading to reduced adiponectin anti-
inflammatory activity (Mlinar, B. et al.,2007). 
 
Besides MCP-1 secretion from adipocytes, hypoxia, which develops due to failure of 
vasculature expansion alongside adipocyte hypertrophy (Pasarica, M. et al.,2009), and 
necrosis, can be the additional mechanisms for the macrophage recruitment (Figure 1.3 
B). Research suggests that inducing fibrosis by hypoxia could be an early upstream 
event of macrophage infiltration (Halberg, N. et al.,2009) with excessive fibrosis 
leading to a decrease of capillary density causing hypoxia, which subsequently leads to 
inflammation (Pasarica, M. et al.,2009). As fibrosis usually occurs in a constant state of 
inflammation stimulus, it has been considered as a secondary event (Wynn, Thomas 
A.,2007).  
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1.3.B. Overview of excess caloric intake leading to cardio-metabolic disease. 
Obesity leads to adipocyte increasing in size and numbers activating hypoxia, oxidative 
stress and Endoplasmic reticulum (ER) stress. These three pathways lead to macrophage 
infiltration and inflammation, which would ultimately lead to different obesity related 
cardio-metabolic disease. Figure from (Mlinar, B. et al.,2011). 
 
 
MCP-1 as the key player in mediating recruitment of macrophages during WAT 
inflammation also has a critical role in accelerating the development and progression of 
obesity-related insulin resistance, oxidative stress, and endoplasmic reticulum stress, all 
of which play a vital role in pathogenesis of chronic cardio-metabolic disease.  
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1.3.1 Adipose tissue dysfunction, Endoplasmic reticulum stress and insulin 
resistance  
 
Excess caloric intake through weight gain can lead to the development of endoplasmic 
reticulum (ER) stress due the sustained pressure placed on the cellular environment to 
produce more functional proteins to manage the excess calorie intake within adipose 
tissue. Ultimately continual ER stress can propagate inflammation and insulin resistance 
(Kawasaki, N. et al.,2012). The role of ER in adipocytes in addition to protein synthesis 
and folding is controlling FFA uptake, TG synthesis, lipid droplet formation, and 
regulation of de novo cholesterol and FFA synthesis (de Ferranti, S. et al.,2008). 
Adipocyte hypertrophy enhances protein synthesis, however, hypertrophy can cause 
insufficient chaperon protein production, which support correct protein folding. As such 
accumulation of misfolded proteins can occur in the cytosol, leading to cellular 
dysfunction. Ultimately, an uncontrolled unfolded protein response in adipocyte will 
lead to apoptosis to take place (Gregor, M. F. et al.,2007), followed by activation of 
inflammation via nuclear factor kappa-light-chain-enhancer of activated B cells  
(NF-κB) pathway (Deng, J. et al.,2004, Hu, Ping et al.,2006). Prior to an apoptosis 
event, ER stress can also lead to inhibition of lipid formation leading to excess FFA 
release from adipocytes into the circulation. A substantial increased in circulating FFA, 
coupled with an increase in TNF-α leads to conversion of FFA into ceramides and other 
substrates (Hotamisligil, G. S.,2006, Watt, M. J. et al.,2006), causing activation of 
serine/threonine kinases followed by phosphorylation of insulin receptor and insulin 
receptor substrates; therefore causing interruptions in the insulin signalling (Mlinar, B. 
et al.,2007, Capurso, C. et al.,2012). Whilst studies highlight that a reduction in FFA 
plasma concentrations results in an improvement in insulin sensitivity in obese and 
T2DM subjects. Additionally, reduction of FFA by medication also improves insulin 
signalling in muscle within the insulin resistant subjects (Liang, H. et al.,2013).  
 
 
 
 32 
 
1.3.2 Adipose tissue dysfunction and oxidative stress 
 
The disequilibrium between the production of reactive oxygen species (ROS), and the 
body’s ability to detoxify these reactive intermediates cellular damage via antioxidant 
neutralisation is called oxidative stress (Dias, Vera et al.,2013). Studies have indicated 
that obesity can induce oxidative stress resulting in irregular adipokine production, 
which contributes to insulin resistance and the development of cardio-metabolic disease 
(Esposito, K. et al.,2006). Biomarkers of oxidative stress such as C-reactive protein 
(CRP) have been shown to be higher in obese individuals and have a direct correlation 
with body fat percentage, BMI, TG levels, and low-density lipoprotein (LDL oxidation) 
(Pihl, E. et al.,2006); additionally antioxidant defence markers are inversely correlated 
with central obesity (Chrysohoou, C. et al.,2007, Hartwich, J. et al.,2007). Furthermore, 
it has been reported that diets high in carbohydrates and fats consumed by obese 
subjects induces a significant increase in oxidative stress and inflammation (Patel, C. et 
al.,2007).  
 
There are few mechanisms by which obesity produces oxidative stress; the first of these 
is the secretion of angiotensin II by adipose tissue, which stimulates the oxidase activity 
of nicotinamide adenine dinucleotide phosphate (NADPH), resulting in ROS production 
in adipocytes (Morrow, J. D.,2003). Another mechanism is via the mitochondrial and 
peroxisomal oxidation of fatty acids that create ROS in oxidation reactions (Duvnjak, 
M. et al.,2007). Whilst again, high fat diets and build-up of cellular damage during 
weight gain are alternative mechanisms generating ROS and altering oxygen 
metabolism (Khan, N. I. et al.,2006). In adipose tissue through these mechanisms an 
environment is created, in which there is a high ROS production and low antioxidant 
capacity that can lead to multiple abnormalities such as impaired insulin signalling, 
decrease mitochondrial biogenesis, inflammation and atherosclerosis (Fernández-
Sánchez, Alba et al.,2011), thus similarly to ER stress, associating excess caloric intake 
to metabolic dysfunction. 
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1.3.3 white adipose tissue dysfunction and endotoxin  
 
Endotoxin (also referred to as LPS) is a gram-negative bacterial fragment derived from 
the outer cell membrane (Raetz, Christian R. H. et al.,2002) that can enter the circulation 
by crossing the gut mucosa. LPS can act as a primary inflammatory mediator that can 
contribute to metabolic dysfunction in adipose tissue as well as other tissues. In a 
healthy individual, LPS combined with chylomicrons (lipoproteins that transport dietary 
lipids through the intestine barrier (Ghoshal, S. et al.,2009)) and dietary lipids, pass 
through the intestinal barrier then move into the systemic circulation, whereby they are 
eliminated by the liver cells.  
 
However, in obese individuals liver lipotoxicity reduces the capability of removing LPS, 
leading to elevated levels of circulating this endotoxin (Piya, M. K. et al.,2013). 
Therefore, increase in dietary saturated fatty acids in combination with elevated levels of 
circulating LPS facilitates chronic low-grade systemic inflammation. This inflammation 
leads to activation of the toll-like receptor 4 (TLR4) pathways, secretion of pro-
inflammatory cytokines, and increase in intestinal permeability - also known as a leaky 
gut (Creely, S. J. et al.,2007, Baker, A. R. et al.,2009, Youssef-Elabd, E. M. et al.,2012). 
As leaky gut cannot protect the internal environment of the intestine, bacteria and toxins 
followed by other molecules can enter the bloodstream (Agustí, Ana et al.,2018). This 
change in gut composition, due to leaky gut, has been identified as the main contributor  
to obesity and its cardio-metabolic disease (Figure 1..3.3.1)
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1.3.3. 1 The effect of endotoxin on obese versus healthy individuals. 
In obesity high fat diets (HFD) and stress can lead to reduction in the intestinal microbiota diversity (Dysbiosis) resulting in change in 
the neurotransmitters released which can have a negative effect on psychological mood. Additionally dysbiosis can result in toll-like 
receptor (TLR) activation, leaky gut, and increase in LPS absorption. These effects contribute to endotoxaemia, which increase 
inflammation and immune response followed by neuroinflammation and changes in the central nervous system (CNS). A healthy diet 
leads to increase in gut microbiota diversity (Eubiosis) and therefore prevents leaky gut, supports immune homeostasis, and normal 
CNS function. Figure from (Agustí, Ana et al.,2018) 
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As mentioned above, TLR4 has a vital role in increasing leaky gut in obesity. The 
activation of TLR4 by LPS is via two signalling pathways: the myeloid differentiation 
factor 88 (MyD88)-dependent and MYD88 independent pathways. In the MyD88-
dependent pathway, as a response to LPS, TL4 uses co receptor CD14, which only binds 
to LPS in the presence of LPS-binding protein (LBP). With the assistance of myeloid 
differentiation factor 2 (MD2), TLR4 binds to the LPS presented by the LPS-LBP- 
CD14 complex. At this stage, the MD2-LPS-TL4 bind to Toll/interleukin-1 receptor 
(TIR) domain containing adaptor protein (TIRP also known as MAL) and Myd88 in the 
cytoplasm. Subsequently, MyD88 binds to and activates the interleukin-1 receptor-
associated kinase-4 (IRAK-4) complex, which is crucial for inflammation and host 
immune response (Flannery, S. et al.,2010, Yamamoto, T. et al.,2014). Then, this 
complex dissociates from MyD88 and interacts with tumour necrosis factor (TNF) 
receptor-associated factor 6 (TRAF6). TRAF6 forms a complex with transforming 
growth factor-β-activated kinase 1 (TAK1) and two of its binding proteins, in order to 
bind to two ubiquitin ligases. This binding leads to the activation and phosphorylation of 
inhibitory κB (IκB) kinase (IKK). The phosphorylated IκB activates the transcription of 
NF-κB. The released NF-κB transits into the nucleus, where it governs the expression of 
TNFα, IL-6 and other pro-inflammatory genes (Takeda, K. et al.,2004, O'Neill, L. A. et 
al.,2007).  
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1.3.3. 2 MyD88 dependent pathway. 
LPS is presented to TLR4 via the LPS-LBP-CD14 complex. TLR4 binds to LPS with 
the assistance of MD2 and connects to the ‘Myddosome’ complex, which is combined of 
MyD88-MAL and IRAK4-IRAK1/2, in the Cytoplasm. IRAK4 dissociates from MyD88 
and activates TRAF6. By forming a complex with TAK1, and two of its binding proteins 
TAB2 and TAB3, TRAF6 binds to ubiquitin ligases (UBC14 and UE1A). Activation of 
TAK1 results in the activation of IKKα/IKKβ/ IKKγ and, therefore IκB phosphorylation. 
Phosphorylated IκB is separated and directly transits into the nucleus where it mediates 
the expression of pro-inflammatory chemokines such as TNFα, IL-6. ERK, extracellular 
signal-regulated kinase; GP, glucan phosphate; IKK, inhibitory κB (IκB) kinase; JNK, c-
Jun N terminal kinase; MAL, MyD88-adaptor like; UBC13, ubiquitin-conjugating 
enzyme 13; UEV1A, ubiquitin-conjugating enzyme variant 1A. Figure from (Yang, Y. 
et al.,2016).  
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The MyD88-independent pathway responds to LPS via TLR4 the same as in the 
dependent pathway, however, MD2-LPS-TL4 binds to the TIR domain-containing 
adaptor-inducing interferon /TRIF-related adaptor molecule (TRIF/TRAM) in the 
cytoplasm. By interacting with TRAF-family member-associated NF-κB activator-
binding kinase 1 (TBK1) and IKK, TRIF phosphorylates and activates two members of 
the interferon-regulatory factor (IRF) (Tatematsu, M. et al.,2010).  Activated IRFs then 
transit into the nucleus and produce antiviral molecules such as inflammatory cytokines 
and interferons (IFNs) (Takeda, K. et al.,2004, O'Neill, L. A.,2006). Additionally, TRIF 
can promote NF-κB activation through TLR4 signalling pathways. Similarly to the 
MyD88-dependent pathway, TRIF utilises TRAF6 to activate TAK1, which as a result 
leads to the NF-κB and mitogen-activated protein kinase (MAPK) pathway activation 
(Sato, S. et al.,2003). Also TRIF can activate MYD88-independent NF-κB through the 
adapter receptor-interacting protein 1 (RIP1) (Meylan, E. et al.,2004). RIP1 has the 
capability to bind to TRIF, causing both apoptosis and NF-κB activation (Gay, N. J. et 
al.,2014). Therefore, by activating IRFs TRIF interacts with TBK1 and IRAK1 in order 
to activate NF-κB through interactions with RIP1.  
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1.3.3. 3 the MyD88 independent pathway. 
 (a). LPS is presented to TLR4 via the LPS-LBP-CD14 complex. TRIF-TRAM binds to 
this complex in the cytoplasm. In order to phosphorylate IRF3, TRIF activates TBK and 
IKK. TRIF can additionally activate NF-κB through RIP1, which can also lead to cell 
apoptosis. (b) Cross talk between MyD88- dependent and independent pathways. IKK-ε, 
inhibitory κB (IκB) kinase ε; IRAK1, interleukin (IL)-1 receptor-associated kinase1; 
IRF, IFN-regulatory factor; TANK, TRAF family member-associated NF-κB activator; 
TRIF, TIR-domain-containing adaptor-inducing interferon-β; TLR4, Toll-like receptor 
4. Figure from (Yang, Y. et al.,2016)  
 
 
 
 
 
 
 
 
 39 
1.3.4 White adipose tissue dysfunction and hypertension 
 
Healthy adipose tissue sustains a specifically balanced adipokine profile that governs 
vascular homeostasis through endocrine and paracrine signalling pathways (Linscheid, 
P. et al.,2005, Eringa, E. C. et al.,2007). Adipose tissue dysfunction and inflammation 
can alter adipocytokine expression and their physiological effects on the vessels. 
Obesity leads to increase in blood pressure in the majority of patients with essential 
hypertension (Garrison, R. J. et al.,1987). Hypertension occurs as the result of irregular 
flow/resistance relationship, whereby conductance vessels generate the systolic blood 
pressure, and diastolic blood pressure consists of peripheral resistance (de Simone, G. et 
al.,2001). Excess weight is positively correlated with cardiac output and blood volume, 
which can be due to the sympathetic nervous system (SNS) and RAS activation, in 
combination with renal sinus being compressed by ectopic adipose tissue (Foster, 
Meredith C. et al.,2011). SNS activation followed by the compression of the renal sinus 
both result in RAS activation, and pharmacological blocking of RAS or SNS has shown 
to significantly reduce obesity related hypertension (Davy, K. P. et al.,2004).  
Several key players such as hyperinsulinemia, angiotensin II, FFAs and leptin have 
been suggested to have governing effects on obesity related hypertension. 
Hyperinsulinemia can cause elevated blood pressure by enhancing sodium retention 
(Creager, M. A. et al.,1985, Hall, J. E.,1993). Angiotensin II (AGT II) is a product of 
angiotensinogen, which is secreted by adipocytes (Cassis, Lisa A. et al.,2008). This 
potent vasoconstrictor promotes water and sodium absorption (Campbell, D. J.,1987). 
FFAs release and accumulation can lead to hypertension through adrenergic 
stimulation, increase in oxidative stress, endothelial dysfunction, or stimulation of 
vascular cell growth (Zhou, Junlan et al.,2012). Regulatory effect of leptin in blood 
pressure through activating SNS has been demonstrated using animal models (Carlyle, 
M. et al.,2002, Hall, J. E. et al.,2010).  
As a result of these adipocytokine dysfunctions, changes occur in the structure and 
function of vessels through endothelial dysfunction, vascular smooth muscle cell 
proliferation and migration, and vascular inflammation. Collectively these changes 
cause increase in peripheral resistance, which is the fundamental contributor to elevated 
arterial pressure.   
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1.4 Adipose tissue renin-angiotensin system  
RAS is the key mechanism in the control of blood pressure regulation, fluid, and 
electrolyte balance (Schmieder, R. E. et al.,2007). In lean individuals the key precursor 
peptide, angiotensinogen (AGT) is secreted by the liver and then cleaved by renin, 
which is mainly produced by the kidneys, to form angiotensin I (ANG I). ANG I is 
further cleaved by angiotensin converting enzyme (ACE) to produce the main effector 
ANG II within RAS. ANG II utilises ANG II type 1 (AT1) and type 2 (AT2) receptors 
to apply its physiological effects. Upon stimulation, AT1 induces vasoconstriction and 
secretion of aldosterone from the adrenal cortex leading to blood pressure increase 
along with water and sodium retention (Schmieder, R. E. et al.,2007). Inversely AT2 
stimulation results in decrease in blood pressure (Figure 1.4). 
 
 
1.4. 1A. Compound of the renin-angiotensin system. 
Angiotensinogen (AGT) is cleaved into angiotensin II (ANG II) by renin and 
angiotensin converting enzyme  (ACE). ANG II additionally can be produce by 
cathepsins, through a non-ACE route. ANG II can further be metabolized to small 
biological peptides such as ANG (1-7), ANG III (2-8) and ANG IV (3-8). ANG II 
activates ANG II type I (AT1) to induce vasoconstriction leading to elevated blood 
pressure. Inversely by stimulating AT2, ANGII reduces blood pressure. Figure from 
(Kalupahana, Nishan S. et al.,2012) 
 
Besides liver, all or some of RAS components exist in various other tissues (Massiera, 
F. et al.,2001), therefore giving these tissues the capacity of altering blood pressure. 
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However, amongst these tissues WAT not only contains all the RAS components, it is 
also known to be the second main extra hepatic synthesis site of AGT (Massiera, F. et 
al.,2001), especially in obese individuals. Additionally, AGT secreted in adipose tissue 
can be cleaved by specific proteases to produce ANG II by avoiding the renin-ACE axis 
(Karlsson, C. et al.,1998), therefore, making the production of AGT the main regulatory 
step of adipose tissue-RAS. This step is controlled by TNF-α, insulin and other 
hormones (Jones, B. H. et al.,1997, Serazin-Leroy, V. et al.,2000), as well as nutrients 
such as fatty acids and glucose (Safonova, I. et al.,1997).  
 
This structure and function of adipose tissue-RAS permits for local autocrine/paracrine 
regulation, whereby, adipose tissue-RAS adipocytes can influence local macrophage 
activation and recruitment to promote inflammation, adipogenesis, and lipid metabolism 
amongst other effects.  In this next section, these regulatory effects of adipose tissue-
RAS on inflammation, lipid metabolism and adipogenesis, in addition to the effects of 
endotoxins on adipose tissue-RAS will be addressed.   
 
1.4.1 Adipose tissue-RAS and adipose tissue inflammation 
 
High caloric intake up-regulates adipose tissue-RAS (Rahmouni, K. et al.,2004), giving 
ANG II a role in the mediation of adipose tissue inflammation. Human in vitro studies 
have shown that ANG II increases the secretion of MCP-1 by pre-adipocytes (Asamizu, 
S. et al.,2009), as well as IL-6 and IL-8 by adipocytes (Skurk, T. et al.,2004) through 
the NF-κB dependent pathway. Additionally in vitro murine studies indicate that ANG 
II increases the secretion of MCP-1 and adipocytes resistance through an NADPH 
oxidase and NF-κB dependent pathway (Kalupahana, N. S. et al.,2012). Inversely, RAS 
inhibition decreases macrophage infiltration and expression of MCP-1 in high fat-
induced obese mice (Lee, M. H. et al.,2008). Taken together these findings illustrate 
that ANG II promotes adipose tissue inflammation in a NF-κB dependent pathway.  
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1.4.1. 1 Adipose tissue RAS regulation of inflammation. 
ANGII activates NADPH oxidase resulting in the stimulation of ROS, leading to the 
activation of NF-κB pathway. This activation causes the transcription of MCP-1 and 
other pro-inflammatory cytokines in the nucleus, promoting an inflammatory state in 
the adipose tissue. Figure from (Kalupahana, Nishan S. et al.,2012) 
 
1.4.2 Adipose tissue-RAS and lipid metabolism  
 
Within RAS, energy sensing (Frederich, R. C., Jr. et al.,1992) and modulation of 
adipogenesis, lipogenesis, and lipolysis are dependent on ANG II. In an acute state of 
energy influx, adipose tissue stimulated AGT secretes high levels of local ANG II, 
which induces local vasoconstriction, and thus results in reduced rates of lipolysis 
(Goossens, G. H. et al.,2004). Inversely, in a fasting state, vasodilation occurs due to 
lower levels of local ANG II, which results in increase in lipolysis rates. ANG II exerts 
these lipolysis effects via AT1 (Yvan-Charvet, L. et al.,2006) and increases lipogenesis 
via AT2 (Jones, B. H. et al.,1997). In line with these effects, ANG II additionally plays 
a role in the uptake of insulin-stimulated glucose by adipocytes (Juan, C. C. et al.,2005). 
From these findings the paracrine effect of ANG II can be described as inhibiting 
lipolysis, while promoting lipogenesis, and finally, increasing lipid accumulation and 
inflammation in adipose tissue (Yvan-Charvet, L. et al.,2011).  
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Reports on the effects of chronic energy influx on adipose tissue-RAS have been 
inconsistent due to multiple factors such as regulation of AGT expression by nutritional 
and hormonal signals, genetic factors (Prat-Larquemin, L. et al.,2004), the lack of AGT 
overexpression in metabolically healthy obese individuals (Karelis, A. D. et al.,2004), 
and gene-environment interactions (Kalupahana, N. S. et al.,2011).  
 
1.4.3 adipose tissue-RAS and adipogenesis 
 
In a state of excess caloric intake, adipogenesis leads to adipocyte hyperplasia 
(increased adipocyte number), and adipogenesis inhibition in combination with 
increased lipogenesis cause adipose tissue dysfunction.  
 
The effects of RAS and its components on adipogenesis have been extensively 
researched. Various rodent models of obesity have been used to indicate that AT1 
blockers (ARB) and ACE inhibitors (ACEI), which block RAS, reduce adipocyte size 
(Furuhashi, M. et al.,2004, Zorad, S. et al.,2006, Munoz, M. C. et al.,2009). 
Additionally, in diabetic rats ARB has shown to increase the number of small-
differentiated adipocytes (Lee, M. H. et al.,2008). Together these in vivo studies show 
that blocking RAS inhibits lipogenesis and promotes adipogenesis. It has been reported 
that transgenic mice over expressing adipose tissue AGT become relatively obese with 
adipocytes increasing in size (Massiera, F. et al.,2001) and reducing in number in 
comparison to wild-type mice (Yvan-Charvet, L. et al.,2009). Additionally, in AGT-
deficient mice overexpression of adipose tissue AGT leads to reduction in adipocyte 
number (Massiera, F. et al.,2001). Taking these findings into consideration, it can be 
suggested that a rise in local levels of ANG II inhibits adipogenesis in vivo. Other 
research has demonstrated that the inhibitory activity of ANG II is mediated by AT2 
(Yvan-Charvet, L. et al.,2009). Therefore, from these studies and various others it can 
be suggested that ANG II has inhibitory effects on adipogenesis, while promoting 
lipogenesis, therefore facilitating adipose tissue dysfunction.  
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1.4.4 Effects of endotoxin on adipose tissue-RAS 
 
Prior studies have also shown that offspring from prenatal rats exposed to endotoxin 
have elevated blood pressure, coupled with an impact on weight gain, and abnormal 
adipocyte development (Gao, Meng et al.,2014). In the juvenile phase of these offspring, 
prenatal stimulation was noted to activate the local adipose tissue-RAS leading to 
adipocyte differentiation, which resulted in smaller adipocytes while stimulating 
hyperplasia. Inversely in the adult phase of these offspring, excessive prenatal 
stimulation inhibited cell differentiation causing hypertrophy. Additionally, RAS 
components were also activated during endotoxin stimulation. This study also 
highlighted that NF-κB inhibitor could reverse the influence of endotoxin stimulation 
during pregnancy (Gao, Meng et al.,2014).  Further in vivo studies on the role of TLR4 
signalling pathway in activating RAS in adipocyte cells has indicated that stimulation 
with endotoxin results in increase in mRNA and protein expressions of TLR4, AGT, and 
ATR1, therefore activation of TLR4 signalling pathway promotes the activation of local 
RAS in adipose cells (Luo, J. et al.,2014).  
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1.5 Obesity-related cardio-metabolic management 
 
Most management guidelines identify weight loss as one of the most effective strategies 
in management of obesity related cardio-metabolic disease. The WHO has 
recommended that at least 5 kg reduction in initial body weight is linked to 
improvement in obesity risk factors (WHO,2013). For individuals with BMI ≥25Kg/m2 
diet (e.g. balance-diets, very low-calorie diets, low-fat/carbohydrate diets and high 
protein diets) (Hill, J. O.,2006), physical activity, and behavioural changes such as 
slower rate of eating, nutrition education, and meal planning, has appeared to be an 
effective way of weight loss followed by improvements in hypertension, insulin 
sensitivity and dyslipidaemia (Sharma, A. M.,1992). However, this regime alone is not 
a realistic solution for individuals with BMI ≥ 27 Kg/m2 with comorbidity or BMI ≥ 30 
Kg/m2 (Stamler, R. et al.,1987), therefore, in parallel to diet and exercise, achievable 
weight loss for these individuals that can be maintained long term by pharmacological 
approaches. Bariatric surgery is mainly advised for individuals with BMI ≥ 35 Kg/m2 
with comorbidity or BMI ≥ 40 Kg/m2 alongside behavioural changes to reduced food 
intake, and increase in physical activity once this is possible.  
 
1.5.1 Obesity-related hypertension management through pharmacology 
 
Hypertensive individuals with BMI ≥ 27 Kg/m2 with comorbidity or BMI ≥ 30 Kg/m2, 
require one or more antihypertensive medication in addition to weight loss and other 
lifestyle adjustments. Diuretics have shown to reduce blood pressure by reducing 
intervascular volume and cardiac output (Duarte, Julio D. et al.,2010) in obese-
hypertensive individuals however, the adverse effect of this medication, which is insulin 
resistance and dyslipidaemia (Duarte, Julio D. et al.,2010) appears to be dose 
dependent. Inhibitors of the RAS are usually the first-line anti-hypertensive for most 
patients. ACE inhibitors and possibly angiotensin II receptor blockers are safe and 
effective treatments for reducing blood pressure, increasing insulin sensitivity and 
reducing diabetes risk (Lindholm, L. H. et al.,2002, Scheen, A. J.,2004). However, ACE 
inhibitors are considered to be the more suitable as they exert a variety of hypotensive 
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effects (Thomopoulos, C. et al.,2015). They inhibit RAS and the sympathetic nervous 
system, which leads to decrease in arterial pressure (Tsuda, K.,2012), in addition, they 
can positively influence conditions such as left-ventricular hypertrophy, congestive 
heart failure (Messerli, F. H. et al.,1983), renal hyperfiltration, and microalbumuria 
(Mokdad, A. H. et al.,2003).  
 
It has been reported that β –blockers effectively reduce blood pressure in obese rather 
than lean hypertensive individuals, this may be that this agent reduces cardiac output 
and plasma renin activity, both of which are increased in obese individuals (Williams, 
M. et al.,1997) (Williams, M. et al.,1997). However, this medication can have adverse 
side effects such as weight gain, disruption in glucose metabolism and increase in 
triglycerides, and decrease in high-density lipoprotein cholesterol concentrations 
(LaGuardia, Heather A. et al.,2012). Therefore use of β-blockers as first line agents for 
obese- hypertensive individuals with T2DM is still questionable, especially since there 
still has not been overwhelmingly evidence regarding prevention of stroke recurrence 
by this medication (De Lima, L. G. et al.,2013). Calcium channel blockers are a 
preferred substituted in this category of individuals (Schumann, Sarah-Anne et 
al.,2008). Calcium channel blockers do not have metabolic adverse effects (de Courten, 
M. et al.,1993), and their use is not associated with diabetes development (Blackburn, 
David F. et al.,2006), and α-blockers have shown reduced blood pressure, improved 
insulin sensitivity and lipid metabolism (Blackburn, David F. et al.,2006), however, 
there has not been strong evidence for the use of both these medications as first line 
agents in obesity-related hypertension.   
 
Although RAS inhibitors are the first choice of treatment for most obese-hypertensive 
cases, antihypertensive monotherapy is rarely sufficient to control blood pressure 
(Landsberg, L. et al.,2013, Mancia, G. et al.,2013). Over half of these cases are treated 
with two or more antihypertensive medications.    
 
One option that may have monotherapeutic potential for obesity-related hypertension is 
a medication that indirectly lowers blood pressure through significant weight loss. 
Clinical data on anti-obesity medications, Orlistat, has shown 5-10% reduction in 
weight loss, which is maintained for up to two years (Jain, Suyog S. et al.,2011). 
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Orlistat is a gastrointestinal lipase inhibitor that restricts the absorption of dietary fat by 
about 35% (Guerciolini, R.,1997). Research has indicated that this medication in 
addition to weight loss, mirrors the results expected from many antihypertensive 
medications used as monotherapy treatment (Filippatos, Theodosios D. et al.,2010). 
Orlistat has been shown to substantially improve cardiovascular risk factors in long-
term studies (Davidson, M. H. et al.,1999, Rossner, S. et al.,2000); in addition, it 
significantly enhances metabolic parameters both in non-diabetic (Sjostrom, L. et 
al.,1998) and T2DM patients (Hollander, P. A. et al.,1998). Due to lack of 
cardiovascular adverse effects, this medication can be well suited for the obese-
hypertensive patients, however, the gastrointestinal side effects may result in 
discontinuation of Orlistat in some patients.  
 
Liraglutide (Victoza), a long acting glucagon-like peptide-1 receptor agonist (GLP-1) 
that is used for treatment of T2DM, which has clinically been shown to sustain 
glycosylated haemoglobin (HbA1c) reduction in patients and lower the rates of 
hypoglycaemia events. Importantly it may also lead to moderate weight loss at a 
specific dose (1.8 mg) (Shyangdan, D. S. et al.,2011) and has beneficial effects on the 
cardiovascular system (Moretto, T. J. et al.,2008, Koska, J. et al.,2010). Recent research 
on rats implanted with dihydrotestosterone (DHT) to mimic a polycystic ovary 
syndrome model, noted that treatment with Liraglutide, resulted in significant 
improvement of the mean arterial pressure in these hypertensive rats, in addition to 
significant decrease in body weight and improved metabolic outcomes (Hoang, V. et 
al.,2015). Human studies have shown that at the dose nearly twice that used in T2DM 
patients, led to a weight loss of 7.8 Kg, maintained over a period of 2-years. This weight 
loss was associated with reduction of 12.5 mm Hg in systolic blood pressure and 
increase heart rate of 3 beats per minute (bpm) (Astrup, A. et al.,2012). Although 
Liragutide (Victoza) appears to be multifunctional and may be suitable as a first line 
treatment for obese-hypertensive individuals with T2DM, it is not recommended for 
chronic weight management (Victozapro,2015).  
 
FDA approved Liraglutide injection with the dose of 3 mg (Saxenda) (Nordisk, 
novo,27/04/2017) is also on the market as a chronic weight management in individuals 
with BMI ≥ 27 Kg/m2 with at least one weight-related comorbidity or BMI ≥ 30 Kg/m2. 
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The results of the 1-year study have shown an average weight loss of 5% with this 
medication and significant improvements in blood pressure and other cardio-metabolic 
risk factors (Saxendapro,2017).    
 
1.5.2 Obesity-related cardio-metabolic disease management through bariatric 
Surgery  
 
Bariatric surgery is a suitable weight loss treatment for individuals with BMI ≥ 35 
Kg/m2 with comorbidity or BMI ≥ 40 Kg/m2, for whom all conservative measures, 
including pharmacotherapy has failed. Long-term observational studies with 10 year 
(Hess, D. S. et al.,2005, O'Brien, P. E. et al.,2006) and 20 year (Sjöström, L.,2013) 
follow-up, have reported that morbidly obese individuals that undergo bariatric surgery 
experience up to 30% reduction in weight loss, in addition to improvements in their 
cardio-metabolic parameters (Henry, Robert R. et al.,2013). However, success of the 
surgery is dependent on duration of obesity and its comorbidities, gender, age, genetics, 
choosing the suitable surgery and postoperative behavioural and lifestyle changes 
(Pories, W. J. et al.,1992, Schauer, Philip R. et al.,2003).  
 
1.5.2. 1 Different types of bariatric surgery. 
Laparoscopic adjustable gastric banding (LAGB), a procedure where the size of the 
stomach is reduced by placing a gastric band around the stomach. B. Sleeve gastrectomy 
(SG), the size of the stomach is reduced from its original size and the small stomach pouch 
is reconnected to the intestine. C. Biliopancreatic diversion (BPD) involves the reducing of 
the stomach size followed by the attachment of the small stomach to the lower section of 
the intestine, while bypassing the upper section of the small intestine. Figure from (Eldar, S. 
et al.,2011) 
 
Bariatric surgical procedures were traditionally divided into restrictive and 
malabsorptive, or a combination of both procedures. Restrictive procedures such as 
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sleeve gastrectomy (SG) and laparoscopic adjustable gastric banding (LAGB) involve 
limiting the size of the stomach and, therefore reducing the caloric intake. SG is 
currently the most common restrictive surgical procedure, where more than 80% of the 
stomach is resected (WHO,2004).  The remnant small stomach patch that has the initial 
filling volume of less than 100 ml, is then tubularized (WHO,2004). Comparatively, 
less invasive than other surgeries, LAGB procedure uses an adjustable gastric band for 
dividing the stomach into a small pouch and a larger residual compartment (Kang, 
Jenny H. et al.,2017). Purely Malabsorptive procedures that involved diverting the 
biliopancreatic secretions and thus reducing nutritional absorption in the intestine, was 
abandoned due to the high morbidity and mortality rates (J. D. Halverson et al.,1978, 
Buchwald, H. et al.,2002). Combination of restrictive and malabsorptive surgery such 
as the highly invasive and less performed biliopancreatic diversion (BPD), firstly 
involve reducing the size of the stomach similar to that in the SG surgery. This is then 
followed by leaving the valve that releases the food to the small intestine along with the 
first part of the small intestine (duodenum). The ileum is then connected to the small 
stomach pouch, completely bypassing the upper segment of the small intestine 
(Anderson, Blaire et al.,2013). The malabsorption in this surgery occurs as most of the 
small intestine contains either digestive fluids without food or vice versa, with the 
absorption limited to the terminal ileum where these two are briefly combined in a 
common channel prior to entering the colon (Overduin, Joost et al.,2004).   
 
Besides gastric restriction, which can lead to early satiety and reduced caloric intake, 
there are other mechanisms underlying the effects of these bariatric surgeries that 
contribute to the weight loss and improvements in cardio-metabolic diseases. The 
T2DM regulation post PBD surgery for instance has been suggested to be due to the 
hindgut hypothesis, which suggests that expedited delivery of nutrients to the distal 
colon produces a physiological signal that improves glucose homeostasis (Thomas, 
Susan et al.,2010). The potential mediators of this effect are the secretion of specific 
incretin (GLP-1 and gastric inhibitory polypeptide (GIP)) and non-incretin (peptide 
tyrosine tyrosin (PYY)) hormones that may reduce food intake and increase glucose 
tolerance (Park, Chan W. et al.,2011).  
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Impairment in the secretion of ghrelin can be another contributing factor to the 
improvement of cardio-metabolic disease post bariatric surgeries. Ghrelin, which is a 
hormone that stimulates appetite, is mainly produced from the fundus of the stomach 
and to a lesser extent in the duodenum (Overduin, Joost et al.,2004). The concentration 
of this hormone increases before meals and it is suppressed postprandially in proportion 
to the amount of calories consumed, thus highlighting a possible role in meal initiation 
and long-term body weight regulation (Cummings, D. E. et al.,2001, Callahan, H. S. et 
al.,2004). Some studies have indicated that the exclusion of fundus of the stomach that 
take place in SG and BPD surgeries leads to a decrease in fasting ghrelin levels post-
operatively (Adami, G. F. et al.,2003, Langer, F. B. et al.,2005, Wang, Y. et al.,2009). 
Post-prandial ghrelin suppression has been speculated to play a major role in appetite 
reduction, excess weight loss and most importantly T2DM remission as a result of both 
SG and BPD surgeries. In regards to change in ghrelin levels post LAGB, some studies 
have reported an increase in fasting ghrelin levels(Fruhbeck, G. et al.,2004, Stoeckli, R. 
et al.,2004), while others have demonstrated a sharp postprandial decrease in this 
hormone(Leonetti, F. et al.,2003, Korner, J. et al.,2009). Additionally many studies 
were not able to show any changes in ghrelin levels post LAGB (le Roux, C. W. et 
al.,2006, Shak, J. R. et al.,2008).  
 
In addition to ghrelin, other hormones such as FGF-19 and FGF-21 contribute to the 
effectiveness of bariatric surgeries in weight loss and improvements in cardio-metabolic 
disease (Haluzikova, D. et al.,2013). Studies have shown that both these hormones play 
a role in energy expenditure, however FGF-19 is mainly involved in glucose regulation 
and lipid metabolism, while FGF-21 promotes insulin sensitivity and fatty acid 
oxidation, post bariatric surgery (Dimitriadis, G. K. et al.,2017). However what remains 
unclear is whether the behaviour of these two hormones is surgery specific, which will 
be further discussed in chapter 4 of this thesis.    
 
At different extent, these three surgeries are successful at achieving weight loss, T2DM 
remission, blood pressure and lipid profile improvements eventually. BPD has been 
reported to result in a greater percentage of excess weight loss in comparison to the 
other two restricted procedures. However, this is at the expense of a complicated and 
more time consuming surgical procedure, placing the patient at a higher risk of 
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complication during the operation, and a higher malnutrition/metabolic related 
complications post-operation (Anderson, Blaire et al.,2013).  
 
1.6 Screening of obese-diabetics  
 
The most dangerous characteristic of T2DM is that it can act as a silent killer. Many 
individuals who meet the current criteria for T2DM remain asymptomatic and unaware 
of developing this disease for many years (Engelgau, M et al.,2003), resulting in the late 
diagnosis of this disease. Late detection and diagnosis of T2DM is problematic, firstly it 
is highly likely to be accompanied by one or more cardio-metabolic diseases, and 
secondly, 80% of the cost of treating T2DM by the NHS is spent on treatments for 
associated complication and cardio-metabolic diseases (NHS,2016). It is therefore 
possible that early detection of T2DM, through screening for hyperinsulinemia and pre-
diabetes state (impaired glucose tolerance and impaired fasting glucose), can 
significantly reduce medical expenditure, but most importantly help with early 
management of this disease and potentially prevent or reduce the serious complications 
that can effect the quality of life.   
 
The problem is that the current tests for diagnosis of pre-diabetes and T2DM are far 
from perfect. For instance routinely used HbA1c test cut-off values (pre-diabetes 5.7%-
6.4% (39-47 mmol/mol), Diabetes ≥ 6.5% (≥ 48 mmol/mol), and for asymptomatic 
adults ≥ 5.7% (39 mmol/mol) (ADA,2017) for determining disease status have proven 
to be controversial. Some data suggest that these cut-off values vary based on ethnicity, 
age, gender, and population prevalence of diabetes (Bennett, C. M. et al.,2007, Herman, 
W. H. et al.,2012, Waugh, N. R. et al.,2013). This test also appears to be very unreliable 
in certain cases such as hemoglobinopathies and thalassemia syndrome; as these 
diseases impact red blood cell survival (Herman, W. H. et al.,2012).  Although HbA1c 
test is expensive and invasive due to the use of needles, it does not require individuals 
to fast before being tested.  
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However, due to the inconsistency in results, HbA1c test is usually confirmed by a 
second HbA1c test, fasting plasma glucose (FPG) test, or an oral glucose tolerance test 
(OGTT). Besides repeating tests being costly and resource intensive, the main issue is 
that the agreement between these three tests is poor. Some studies have observed that 
HbA1c would diagnose significantly fewer individuals with diabetes than OGTT and 
vice versa (Mostafa, S. A. et al.,2010, Cosson, E. et al.,2011, Farhan, S. et al.,2012), the 
same trend being true between FPG and HbA1c tests. The agreement between FPG and 
OGTT also remains poor [160, (Bernal-Lopez, M. R. et al.,2011).  
Previously known as the ‘’gold standard” of T2DM testing, OGTT is more sensitive, 
however, it is time-consuming to undertake, inconvenient, and difficult to reproduce, 
with a low uptake in contrast to HbA1c test (Waugh, N. R. et al.,2013). Similarly, FPG 
is a preferred diagnostic tool used for many years, which has also proven to have its 
own challenges, such as, requiring patient compliance with fasting, invasiveness, and 
having a high intraindividual variability (Selvin, E. et al.,2007, Malkani, S. et al.,2012). 
Additionally, FPG has been noted as a weak predictive biomarker of cardio-metabolic 
disease than HbA1c (Bonora, Enzo et al.,2011). Therefore, there is a need for a 
convenient, non-invasive and cost effective test that would act as an early detection of 
T2DM and classify patients, allowing only those at need to undergo further 
investigations. 
 
1.6.1 Volatile Organic Compounds as a potential screening tool 
 
Significant development in analytical procedures for identifying VOCs in urine has 
created the opportunity for patients’ urine to be used as a screening and detection tool in 
different types of cancer (Arasaradnam, R. P. et al.,2014, Khalid, Tanzeela et al.,2015, 
Mazzone, Peter J.,2015, Navaneethan, U. et al.,2015) and infectious diseases 
(Guernion, N. et al.,2001, Banday, K. M. et al.,2011). Therefore, there is also an 
opportunity to use urinary VOCs as a non-invasive early detection-screening test for 
T2DM. This method of detection may encourage those at risk to seek suitable diagnosis 
for any disease they are likely to have, something they may not have otherwise done. 
This insight could therefore result in an earlier diagnosis and more importantly better 
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prognosis for patients.  Beyond the use of VOCs to detect T2DM status, it could also be 
further considered as a factor to assess whether T2DM remission has occurred 
following lifestyle, medical or surgical weight loss (Rubino, F. et al.,2016, Schauer, P. 
R. et al.,2016).  
 
Currently the most successful way to achieve T2DM remission appears to be through 
surgery. As surgery is expensive, many healthcare systems have eligibility criteria in 
place to ensure that the majority of patients achieve a successful outcome. Predicting 
who will achieve the best outcome is challenging, however, most bariatric clinics 
worldwide have a preoperative weight loss requirement, which patients must meet in 
order to be eligible for surgery. This requirement is put in place as it increases the 
probability of weight loss maintenance post-surgery (Ali, M. R. et al.,2007, Alger-
Mayer, S. et al.,2008, Solomon, H. et al.,2009). It may also improve the status of 
diabetes and other co-morbidities post-surgery, however, the evidence on this is 
inconsistent (Brethauer, S.,2011, Ochner, C. N. et al.,2012). Therefore, a predictive test 
that would identify a patient’s likelihood of improving their T2DM status post bariatric 
surgery would be beneficial in supporting the preoperative weight loss criteria, and 
identifying patients that may need more support post-operatively to sustain good health 
outcomes. Urinary VOCs may suggest a means for such a medical test due to their 
potential alignment to metabolic health risk markers.  
 
 
 
 54 
1.7 Research Hypothesis, Amis and Objectives  
 
1.7.1 Research Hypothesis 
 
Adipose tissue acts as an important site for gut derived LPS to enhance inflammation 
and increased cardio-metabolic risk, these studies will explore the influences of surgery, 
endocrine hormones, and medication to mitigate this risk as well as stratify such risk 
factors.   
 
1.7.2 Research Amis   
 
1. To study the effects of different types of bariatric surgery on cardio-metabolic 
markers and endocrine hormones (FGF-19 and FGF-21) in obese T2DM women.  
 
2. To examine the effectiveness of liraglutide on adipose tissue angiotensinogen 
and LPS in lean and obese mature adipocytes.  
 
3. To investigate whether urinary organic compounds can be used as a biomarker 
for detection of T2DM status and any change within the same individual over time.  
 
1.7.3 Objectives 
 
1. Bariatric surgeries effect obesity related cardio-metabolic disease at different 
extent. Glucose homeostasis improvement after bariatric surgery typically occurs before 
significant weight loss (Batterham, Rachel L. et al.,2016), however improvement in 
other cardio-metabolic risk factors such as dyslipidaemia and hypertension, is very 
much weight dependent. Although with some bariatric surgeries significant weight loss 
is achieved, the resolution and the rate of improvement in such cardio-metabolic 
components are lower in these surgeries. In order to assess the effects of different types 
of bariatric surgeries on cardio-metabolic disease and whether weight reduction 
independently has a role on cardio-metabolic disease improvement, pre-and post-
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operative SAT biopsies and anthropometric data will be collected from obese-T2DM 
women that had undergone one of the three different types of bariatric surgeries. 
Inflammatory markers and endotoxin, in addition to cardio-metabolic markers will be 
studied through ELISA, western blotting, anthropometric and biochemical data analysis. 
 
2. Cardio-metabolic improvements as a result of bariatric surgery, is partially 
mediated by endocrine hormones, FGF-19 and FGF-21. Bariatric surgery types however 
impact these hormones in different ways, therefore resulting in some surgeries to be 
more successful at reducing the cardio-metabolic risks factors. To explore the different 
impacts of bariatric surgery on these hormone, pre-and post anthropometric and 
biochemical data, followed by serum from obese-T2DM women that had undergone one 
of the three different bariatric surgeries, will be collected and analysed by ELISA.  
 
3. All components of RAS in specific AGT are produced in adipose tissue and are 
secreted from mature adipocytes. In obesity, adipose tissue specific AGT influences and 
contributes to the systemic RAS, which plays a role in pathogenesis of obesity-related 
hypertension and insulin resistance. Endotoxin LPS as an inflammatory mediator can 
induce adipose AGT expression adding to the impact of hypertension. Liraglutide used 
as an antihyperglycaemic and antiobesity therapy has shown to have beneficial effects 
on obesity related hypertension as well. Additionally this treatment appears to have an 
effect on RAS and its components in different tissues such as kidney and lung. It is 
therefore possible that firstly, liraglutide may exert its antihypertensive influence by 
having a direct effect on AGT and inflammatory insult of LPS in obese mature 
adipocytes. Secondly, liraglutide may improve insulin resistance in obese adipose 
tissue, further contributing to the antihypertensive quality of this treatment. To assess 
this, lean and obese human adipocytes will be cultured and treated with liraglutide, LPS 
or a combination of the two, at different time points. AGT expression will be examined 
by western blot analysis. Insulin sensitivity and cellular proliferation will also be 
examined.  
 
4. Early detection and diagnosis of T2DM can be beneficial in the treatment of 
hyperglycaemia and the cardio-metabolic risks that accompany this disease, therefore 
reducing mortality rates. At present, a convenient, non-invasive, and cost effective early 
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detection test for T2DM is not available. Urinary-based volatile organic compounds 
have been successfully utilized for the screening and detection of variety of diseases 
including some cancers. Therefore there maybe a potential for volatile organic 
compounds to be used as detection and prediction test in T2DM status. To investigate 
this, pre-and post biochemical, anthropometric and urine samples will be collected from 
obese-T2DM women that had undergone bariatric surgery. The urine analysis will be by 
field asymmetric ion mobility spectrometry.  
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CHAPTER 2:  
Subjects, materials and methodology 
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2.1 Ethical approval 
 
2.1.1 Bariatric study 
 
The Bariatric study has been funded by the European Foundation for the Study of 
Diabetes (EFSD) via the New Horizons Collaborative Research Initiative (EFSD New 
Horizons research grant no. 1113 09), whilst the ethical approval for the same was 
provided by The Ethics Committee of the Institute of Endocrinology, Prague, Czech 
Republic, with participants providing written and informed consent in accordance with 
Declaration of Helsinki, and, underwent bariatric surgery at the OB Clinic, Prague, 
Czech Republic. 
 
2.2 Subjects 
2.2.1 Subjects who underwent bariatric surgery 
 
At the obesity clinic Prague, Czech Republic, a group of forty-two Caucasian adult 
women with morbid obesity (BMI ≥35 kg/m2) and cardio-metabolic comorbidities were 
recruited for the bariatric study. They underwent bariatric surgery: SG (number (n)=14), 
LAGB (n=14) or BPD (n=14).   
Participant cardio-metabolic disease inclusion criteria were; central obesity (BMI ≥ 30 
kg/m2 does not require waist circumference measurement), triglycerides ≥ 1.7 mmol/L 
or taking fibrates or nicotinic acid, serum HDL-cholesterol < 1.29 mmol/L or if on 
specific treatment for lipid abnormality, hypertension if their BP ≥ 130/85 mmHg, or on 
antihypertensive medication, fasting blood glucose ≥ 5.6 mmol/L or with a previous 
diagnosis of T2DM. All the participants were imminently investigated prior to the 
surgery (baseline) along with 6 months following the procedure, during both visits 
anthropometry and biochemical analysis was undertaken. Serum and abdominal SAT 
was collected on the day of the surgery and six months post-surgery, additionally, using 
the bioimpedance method (Tanita TBF-300) the fat mass was measured.  
 59 
 
2.2.2 Subjects for the liraglutide study 
 
For the liraglutide study, abdominal SAT from lean (n=3) and obese (n=3) participants 
who underwent elective surgery was collected at the University Hospital Coventry and 
Warwickshire, in accordance with the Declaration of Helsinki. All the participants 
provided written and informed consent. The ethical approval for the collection of 
human adipose tissue was provided by The University Hospital Coventry and 
Warwickshire NHS trust Research and Development Department, issuing approval 
number SK06/9309.  
 
2.3 Tissue culture 
2.3.1 Extracting primary human preadipocytes 
 
Under sterile conditions, a category 2 tissue culture room was used in order to minimize 
lysis of the fat and within 1 hour, the procedure was carried out – and as mentioned 
previously, adipose tissue-derived stromal cell isolation was collected(Schaffler, A. et 
al.,2007). A 50mL falcon containing 10 mL 2 mg/mL collagenase (Worthington, UK) 
was used to place 3 cm3 - 10 cm3
 
of WAT, which was pre-warmed to 37 C. To ensure 
fat pieces were no larger than 2mm in diameter, the WAT was cut using an autoclaved 
scissors cleaned with 70% industrial methylated spirit, and in order to reach a smooth 
lipid and collagenase mixture, the falcon was positioned on to a rack in a shaking water 
bath with a temperature of 37 °C for 30 minutes, which was briskly shaken by hand at 
10 minute intervals. By filtering the mixture through sterile cotton mesh into a sterile 50 
mL falcon and centrifuging it at 2000 rpm for 5 minutes allowed for the supernatant to 
be discarded, and the preadipocyte pellet suspended again in 5 mL lysis buffer which 
was incubated for 5 minutes at room temperature then centrifuged at 2000 rpm for 5 
minutes. The remaining pellet was suspended in a 5mL primary adipocyte growth 
media, whilst the supernatant was discarded. It was then moved to a 75 cm2 tissue 
culture flask (T75) (corning, UK) which contained 15 mL primary adipocyte growth 
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media, which had been pre-incubated in a 37 C, 5 % CO2 humidified incubator for 15 
minutes. The labeled flask was then stored in a 37 C, 5% CO2 humidified incubator 
with the media being changed every 48 hours. 
Collagenase: 
• 50 mL Hank’s balanced salt solution (HBSS)  
• 445 mL sterile water  
• 5 mL Penicillin/streptomycin 
From the above solution 20 ml was pipetted into a bottle of collagenase (1g), mixed 
and placed back into the solution. This was repeated three times until all collagenase 
was dissolved. The mixture was Aliquoted 10 mL into 50 mL falcons, labelled with 
collagenase and stored -20 °C until further use.  
Lysis Buffer:  
• 1.001 g Potassium bi-carbonate (KHCO3)  
• 8.29 g Ammonium chloride (NH3Cl)  
• 0.0372 g Ethylenediaminetetraacetic acid (EDTA)  
• Made up to 1 L with sterile deionised water  
 
2.3.2 Cell culture media composition 
 
As stated earlier, cell culture media was used (Alhusaini, S. et al.,2010). 
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Primary adipocyte growth media: 
• DMEM/Ham’s F-12 phenol-free medium 500 mL (Invitrogen #11039047)  
• Penicillin/streptomycin/L-glutamine 100x, 5 mL (1 %) (Invitrogen #10378-016)  
• Fetal bovine serum, 50 mL (10 %) (Biosera #S1810)  
• Fibroblast growth factor-basic (FGF-basic), recombinant human 5 ng/mL (Fisher 
Scientific #VXPHG0026)  
• Transferrin, human 5 μg/mL (Fisher Scientific #VX0030124SA) 
 
Differentiation media (PromoCell Supplements): 
• DMEM/Ham’s F-12 phenol-free medium 500 mL (Invitrogen #11039047)  
• Fetal bovine serum, 15 mL (3 %) (Biosera #S1810)  
• Preadipocyte differentiation supplement pack x1 (Promocell #C39436) The media 
contained the following supplements at their final concentration:  
• Insulin, recombinant human 0.5 μg/mL  
• Dexamethasone 400 ng/mL  
• D-biotin 8 μg/mL  
• Isobutylmethylxantine (IBMX) 44 μg/mL  
• L-thyroxine 9 ng/mL  
• Ciglitazone 3 μg/mL 
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Nutrition media (PromoCell Supplements):  
• DMEM/Ham’s F-12 phenol-free medium 500 mL (Invitrogen #11039047)  
• Adipocyte nutrition supplement pack x1 (Promocell #C39439). The media contained 
the following supplements at their final concentration:  
• Insulin, recombinant human 0.5 μg/mL  
• Dexamethasone 400 ng/mL  
• D-biotin 8 μg/mL  
• Fetal calf serum 0.03 mL/mL (3%) 
 
2.3.3 Propagation and differentiation of preadipocytes  
 
Given that media height above the cell layers affects adipocyte differentiation, the same 
volume of media was used in experiments as was in control and treatment flasks 
(Sheng, Xia et al.,2014). T75 flasks were used to isolate and culture primary human 
pradipocytes as mentioned earlier, and at 80% confluent the cells were passed into 
further 3 T75 flasks. 
Trypsinization and passages of cells: using sterile phosphate buffered saline (PBS), the 
media was aspirated and washed thrice and pre-warmed to 37 C, then for 5 minutes it 
was incubated with 5 mL 0.05 % trypsin – EDTA (Life Technologies #25300-062). To 
form pellets of cells, the flask was gently tapped to removed the cells from the bottom 
and trypsin was neutralized with 15mL growth media then centrifuged at 1000 rpm for a 
period of 5 minutes. The cells were resuspended in 5mL growth media and moved to a 
new T75 with the supernatant removed. The preadipocytes were tallied using a 
hemocytometer, seeded at a density of 4000 cells/cm2 onto treated polystyrene sic well 
culture plates (Corning) via a 2 mL primary adipocyte growth media in each well which 
was changed every 48 hours, and incubated in growth media for another 2 days once 
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confluent. Then at day 0, differentiation was initiated via the change of media to 
differentiation media. Throughout day 0-6 of adipogenesis media was consistently 
changed every 48 hours with differentiation media, then from day 6-14 it was changed 
to nutrition media every 48 hours. 
 
2.3.4 Cell count 
 
After seeded cells were trypsinized, 100 μl of sample was diluted with a 100 μl of 
Trypan blue 0.4% (Fisher 15250061), and the cells were the counted in the 
hemocytometer. Mean cell number was calculated by counting 4 replicates for each 
point of every experiment, and blue stained dead cells were excluded.   
 
2.3.5 Treatments 
 
In order to eliminate the effects of growth factors and any other components in nutrition 
media, they were switched to detoxification media for a period of 24 hours before the 
optimization treatments (DMEM/Ham’s F-12 phenol-free medium containing only 3 % 
serum). Both treatments and control were placed in fresh detoxification media, which 
was made on the day of the treatment. 
Mature adipocytes were treated with LPS (Sigma L2630) concentrations of (10 ng/ml 
and 100 ng/ml) or Liraglutide (Lir) (gifted from Novo Nordisk) or a combination of 
LPS and Liraglutide; (LPS 10 ng/ml + Liraglutide 10 nM), (LPS 10 ng/ml + Liraglutide 
100 nM), (LPS 100 ng/ml + Liraglutide 10 nM), and (LPS 100 ng/ml  + Liraglutide 100 
nM) for the following lengths of time: 24hr, 48hr and 72hr, with fresh treatment 
exposure every 24 hours. Adipocytes in untreated media were used as controls. Filter 
(0.22 μM) was used to filter through all treatment samples.  
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2.3.6 Collection of protein  
 
A lysis buffer was prepared via 5 mL 1x radioimmunoprecipitation (RIPA) (Millipore 
UK) with 100 μL of dissolved protease and phosphatase inhibitors (2 Roche Complete 
Mini protease inhibitor cocktail tablets and 8 mg sodium fluoride (NaF, Fisher 
Scientific) and 20 mg sodium vanadate (Na3VO4, Acros Organics) in 2 mL 1x RIPA) 
for the collection of protein. The to each well 250 μl of the protein lysis buffer was 
added at 4 C, then using sterile scrapers the cells were scraped for 60 seconds in each 
well, and the contents were collected and stored at -80 C. 
 
2.4 Analysis of samples 
2.4.1 Analysis of blood samples 
 
Intravenous blood was taken from patients who had been on a 10 hour overnight fast, 
the samples were placed into chilled tubes containing EDTA with aprotinin as well as 
without for the measurements of glucose, insulin, and C-peptide levels, they were 
aliquoted and kept at -80 C till examined. Via Cobas 6000 analyzer insulin, circulating 
glucose, C-peptide, HbA1c and lipids were measured. As previously stated (Matthews, 
D. R. et al.,1985), for the assessment of insulin resistance (HOMA-IR), the homeostatic 
model was utilized as per the following equation: HOMA-IR = [fasting glucose 
(mmol/L) x fasting insulin (μU/L)] / 22.5. LDL cholesterol was calculated according to 
the Friedewald formula (Friedewald, W. T. et al.,1972)  
 
2.4.2 Immunoprecipitation  
 
For immunoprecipitation SureBeads Protein A Magnetic Beads (Bio-Rad #161-4013) 
were used. 100 μl of the SureBeads were resuspended and washed with PBS-Tween, 
then magnetized. 5 μg of angiotensinogen antibody in final volume of 200 μl was added 
to the beads and resuspended and rotated for 10 minutes at room temperature.  The 
magnetized and washed beads were then added to 500 μl of treatment containing 
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samples, and rotated for 1 hour at room temperature. The beads were magnetized and 
washed three times, and the resuspended beads were transferred into new tubes. The 
tubes were centrifuged for few seconds, magnetized and the residual buffer was 
aspirated from the tubes. 40 μl 1x laemmli buffer was added to the tubes and incubated 
for 10 minutes at 70°C, the beads were then magnetized and the eluent was moved into 
new vials.  
 
2.4.3 Protein analysis 
 
In 250 μL protein lysis buffer, made with 5 mL 1x RIPA (Millipore UK) with 100 μL of 
dissolved protease and phosphatase inhibitors (2 Roche Complete Mini protease 
inhibitor cocktail tablets and 8 mg sodium fluoride (NaF, Fisher Scientific) and 20 mg 
sodium vanadate (Na3VO4, Acros Organics) in 2 mL 1x RIPA) the human WAT was 
homogenized and resuspended. Bio-Rad detergent 5’-compatible protein assay kit (Bio-
Rad Laboratories, CA) with standard concentrations of albumin from bovine serum 
(BSA) (Sigma A9647) was utilized for the determination of protein concentrations and 
quantified using a nanospectrophotometer (GeneFlow, UK). An earlier mentioned 
method was used for the analysis of western blot (Alhusaini, et al., 2010). In summary, 
20 μg of protein samples was used to analyze the inflammatory markers TLR4, 
MYD88, TRAF6, IκB, NFκB, and 8 μg of protein sample was used for the AGT study. 
These proteins were added onto a 10% denaturing polyacrylamide gel (GeneFlow, UK). 
The Proteins were separated by electrophoresis and transferred at 4 ° C and 100 V for 1 
hour onto a 0.4 μm pore size Immobilon-P PVDF membrane (IPVH00010 Sigma). 
Membranes were then cut depending on the specific protein molecular weight by using 
ponceau stating (P7170 Sigma), and washed by PBS thoroughly and blocked in 0.2% 
BPS-tween (BPST) at 4 °C for 24 hours. Membranes were then incubated in a mixture 
of 0.2% I-block PBS-tween and primary antibodies AGT 1:5000 for 4 hours, and TLR4 
1:500, MYD88 1:1000, TRAF6 1:240, IκB 1:1000, NFκB 1:1000 overnight, at 4 ° C 
cold room. To confirm equal protein loading β-actin was used. PBST was used to wash 
the membranes six times for five minutes, and incubated in anti-rabbit IgG (whole 
molecule), horseradish peroxidase antibody produced in goat, IgG fraction of antiserum, 
buffered aqueous solution (Sigma A9169). The visualization of the bands was enabled 
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by a chemiluminescent detection system, ECL/ECL+ (GE Healthcare, UK), with the 
intensity being confirmed via the use of densitometry and the Image J software.  
 
2.4.4 Glucose uptake assay 
 
Glucose uptake was performed as previously described (Liu, Fang et al.,2001).  Cells 
were grown to confluence in 6 well plates. These cells were then washed with PBS and 
incubated with Krebs-Henseleit buffer (KHB) with BSA 0.01% and glucose 5 mmol/L 
at 37 °C for 3 hours, for insulin and serum starvation. Mature adipocytes were then 
treated with DMSO (for control) and insulin 100nM  (Sigma 19278). 2-deoxy-[3 H]D-
glucose [1 μCi/μl) (PerkinElmer) was added to incubate for 10 minutes. Ice-cold PBS 
was used to wash the cells three times, which was then followed by transferring the 
cells into 4 mL of scintillation fluid. Scintillation counter was then used to measure 
radioactivity. Protein quantification and glucose uptake was performed with the 
remaining 100μL cell lysate.  
The following reagents were used to make 1 L 5xKHB buffer, 
 
 
 
 
 
 
These reagents were added to 900mL of distilled and autoclaved dH2O in a 1 L beaker, 
which contains a stir bar. Once dissolved the volume was adjusted to 1000mL with 
dH2O and stored at 4 °C.  A day prior to glucose uptake, 500 mL of the listed two 
reagents were made and filter sterilized;  
1. 1 x KHB, low glucose – 5mM (450mg), 0.01% BSA (50mg), 10 nM Hepes 
Chemical 5X(nM) 5X(g/L) 
NaCl 555 32.53 
KCL 23.5 1.75 
MgSO4 10 1.20 
Na2HPO4 6 0.85 
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(1.19g), pH 7.4 
2. 1x KHB, no glucose, no BSA, 10 mM Hepes (1.19g), pH 7.4 
 
2.4.5 Enzyme linked immune sorbent assay (ELISA) 
 
Blood samples were centrifuged and serum was immediately removed and aliquoted 
and stored at – 80 °C for future use. ELISA kit was used for the measurement of the 
following; CRP (DCRP00, R&D Systems), IL-6 (D6050, R&D Systems), FGF-19 
(DF1900, R&D Systems) and FGF-21 (DF2100, R&D Systems). In summary, the 
reagents and standards were prepared. 100μl of assay diluent was added to all the 96 
wells of microplate, which already have been coated with a monoclonal antibody 
specific for the study. Additional 100μl of standard, control or sample is the added per 
well, which is then incubated for 2 hours at room temperature. Each well is washed four 
times with wash buffer and entire fluid is aspirated. 200μl of the conjugate is added to 
each well and incubated in dark for 2 hours at room temperature. To each well, 50 μl of 
stop solution is then added. A microplate reader determined the optical density of each 
well. Concentrations were calculated using linear regression. All measurements were 
done in duplicates.  The assay detection range for CRP was 0.8-50 ng/mL, coefficient of 
variance of 3.8% intra-assay, and 7% inter assay precision. IL-6 had a assay detection 
range of 3.1-300 pg/mL, coefficient of variance of 3.1% intra-assay and 2.5% inter-
assay precision. FGF-19 had a detection range of 15.6-1000 pg/mL, and a coefficient of 
variation of 4.5 % for intra-assay and 5.5 % inter-assay precision. FGF-21 had a 
detection range of 31.3-2000 pg/mL, and the coefficient of variation of the intra-assay is 
2.9% with 6.4% inter-assay precision.  
 
 
2.4.6 Quantification of endotoxin LPS 
 
Chromogenic quantification of endotoxin LPS (Sigma L2630) was performed by using 
Limulus Amebocyte Lysate (LAL) detection kit (#QCL-1000TM Lonza). In brief, 
samples were set to the pH range of 6.0-8.0 by using endotoxin-free sodium or 
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hydrochloride acid. Once the reagents are prepared, the microplates were pre-
equilibrated at 37 °C in heating block adapter. 50μl of sample or standard was added to 
some wells, while 50μl of LAL reagent water was added to the blank wells. After 10 
minutes, 100μl of pre-warmed substrate solution was added to the wells and mixed. 
After 16 minutes, 100μl of stop reagent is added to all wells and mixed. A microplate 
reader determined the absorbance of each microplate well, and the concentrations 
(EU/mL) were calculated by using linear regression model. All measurements were 
done in duplicates.  
 
2.5 Statistical Analysis 
 
IBM SPSS Statistics 24.0 software was used to preform all statistical analyses. To test 
data normality Shapiro-Wilk test was preformed. The two-tailed paired sample t-test or 
one-way ANOVA was used for the parametrically distributed data, and Kruskal-Wallis 
ranks test was used for the non-parametrically distributes data. Multivariate linear 
regression (forward model) was preformed for ΔFGF-19 and ΔFGF-21 as dependent 
variables with the variables (Δ) that had shown significant correlation with ΔFGF-19 
and ΔFGF-21 as independent variables. Pearson correlation analysis was done for 
correlation between variables, this was followed by calculations to test the difference 
between two independent correlations coefficients. Changes in variables (Δ), were 
calculated as percentage absolute change [((post surgery-pre surgery)/pre surgery) 
x100]. All data is presented as mean value ± standard error of the mean (SE). P≤0.05 
was considered statistically significant and significance levels are indicated as follows; 
p-value: *≤0.05, **≤0.01, ***≤0.001 and where more than one comparison was made: 
#≤0.05, ##≤0.01, ###≤0.001. 
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2.6 Chemical Analysis and Instruments 
 
2.6.1 Field Asymmetric Ion Mobility Spectrometry (FAIMS) 
 
A Lonestar (Owlstone Ltd, UK) FAIMS unit was used to analyse the headspace of pre 
and post-operative urinary VOC samples from all participants. The FAIMS device used 
a 63Ni ionization mechanism. Upon ionisation, the sample is passed through an 
oscillating electric field with an asymmetric high voltage waveform. Ions “zigzag” 
through the field and only ion species with no overall transverse motion pass through 
without deionising, based on properties of the waveform and the ion species. Certain 
properties of the waveform are then manipulated to identify the different ion species 
present in the analyte. 
 
2.6.2 FAIMS Analysis 
 
Urine samples were defrosted to 5◦C overnight. For each sample a 5ml aliquot was 
pipetted into a 20ml glass sample bottle. This was then placed into an Owlstone ATLAS 
At-Line Sampling module attached to the Lonestar FAIMS unit. The ATLAS module 
heats the sample to 40◦C, and introduces the headspace of the sample into the FAIMS 
for analysis. Four full sweeps of the dispersion field strength were carried out in 
succession for each sample. Before the first sample and between each sample, an air 
blank was run for three sweeps to allow any residue from the previous sample or other 
experiments to clear from the machine. No data was collected for these sweeps. 
 
 
2.6.3 Data Analysis 
 
Each sample yielded eight 512 × 51 matrices, four positive and four negative ion counts 
across the tested compensation voltages and dispersion field strengths, for a total of 
208,896 variables per sample. As an initial step in the analysis of this data, the matrices 
were transformed using a discrete wavelet transformation. The levels of the transform 
 70 
corresponding to the two smallest-bandwidth passes were discarded to eliminate noise. 
Wavelet transformation is a common step in signal processing, and can help in 
separating structure from noise in an image, compressing the informative variables into 
fewer dimensions and consequently reducing the dimensionality of the data. After 
transforming the data, there were 52,224 variables per sample. Similarly to Fourier 
transforms, wavelet transforms create a representation of an image in an alternative 
basis space. However, in comparison to Fourier transforms, wavelet transforms capture 
information about both the size (or wavelength) of structures in the image, and 
information about where those structures occur. This helps to concentrate the useful 
information in the image into fewer predictors, which helps when selecting relevant 
features for classification tasks. To assess the ability of FAIMS analysis of urine 
samples in predicting diabetes status post-surgery, HOMA-IR was considered as a 
classification task. For HOMA-IR, the cohort was divided into two classes. Binning the 
data was necessary due to the small sample size (both FAIMS and indicator data were 
available for 25 participants) and the high dimensionality of the FAIMS data (52,224 
features), which hampered regression analysis. To perform the binning for this 
indicator, participants were divided into those with an indicator value which was less 
than or equal to the median value of the cohort (the “Low” group for that indicator), and 
those with a value above the median value of the cohort (the “High” group for that 
indicator). Participants who lacked data for this indicator were excluded from further 
analysis. FAIMS data was available for 25 participants, and indicator data was available 
from at least 24 participants for each indicator.  
 
2.6.4 Statistical Analysis 
 
Mann-Whitney-Wilcoxon test was used to rank features according to how well they 
separate the cohort into High and Low classes. The top number features were then taken 
forward and used to train a classification model, with n and the classification model 
selected using a separate cross-validation analysis. Four learning algorithms were 
considered: radial support vector machine (SVM), sparse logistic regression, logistic 
regression, and random forests. To assess the performance of HOMA-IR, 10-fold cross 
validation was used to produce predicted classes for each participants, with both feature 
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selection and model creation being carried out in the cross-validation. Classification 
performance was assessed by using the Receiver Operating Characteristic (ROC) curve, 
which is defined by the area under the curve (AUC).  
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CHAPTER 3: 
The short-term effect of bariatric surgery on cardio-metabolic 
markers in obese T2DM women 
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3.1 Introduction  
 
Studies have shown that measures of abdominal or central obesity such as waist to hip 
ratio (WHR) and most importantly measures of fat distribution (i.e. excess fat mass%) 
(Alberti, K. G. et al.,2006, Ramírez-Vélez, Robinson et al.,2017) are positively 
associated with metabolic components such as dyslipidaemia, hypertension and 
dysglycemia (Bener, A. et al.,2013, Gonzalez-Muniesa, P. et al.,2017, Ramirez-Velez, 
R. et al.,2017). The ‘grouping’ of metabolic abnormalities determined in participants 
with excess abdominal obesity, referred to as metabolic disease, appears to carry a 
significantly higher cardiovascular risk as well in comparison to the risk associated with 
each individual abnormality (Golden, S. H. et al.,2002, Sattar, N. et al.,2003). Within 
the pre-diabetic state, hyperglycaemia and dyslipidaemia have also been shown to 
increase the risk of cardiovascular disease (Sattar, N. et al.,2003). Whilst it is also 
evident that in the state of obesity, increase in components of the metabolic disease, 
results in a higher mortality rate of cardiovascular disease.  
 
The underlining association between obesity and cardio-metabolic disease is reported to 
be due to a low-grade systemic inflammatory environment. This systemic inflammation 
has been considered in part to arise through endotoxaemia, in which gut dysbiosis 
triggered by high fat diets, disrupts the intestinal barrier leading to increased gut 
permeability, and therefore, the translocation of endotoxin also known as LPS into the 
blood circulation (Kallio, K. A. Elisa et al.,2015). LPS then promotes inflammation by 
activating specific pathways in adipose tissue and up-regulates pro-inflammatory 
cytokine secretion, resulting in obesity related cardio-metabolic disease (Eckel, Robert 
H. et al.,2011, Farb, Melissa G. et al.,2011, Park, Hyeong Kyu et al.,2017).  
 
Studies have demonstrated that reduction in adipose tissue inflammation can arise as a 
result of ‘weight loss’. Weight loss can have a two-fold influence on health, firstly, 
reduction in fatty diets results in a decrease endotoxin induced adipose tissue 
inflammation, and secondly reduced adipose tissue also reverses the exacerbated 
inflammatory response caused by the cardio-metabolic risk profile (Farb, Melissa G. et 
al.,2011). Therefore, health care professionals have placed great emphasis on preventing 
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or delaying cardio-metabolic diseases by advocating lifestyle changes to aid weight 
loss. However, in cases where weight loss through diet, exercise, and pharmacological 
treatments alone is unmanageable, bariatric surgery can act as an alternative therapeutic 
intervention; which again indirectly can impact endotoxin induced inflammation as the 
gut microbiota and anatomy is altered.  
 
Although invasive, bariatric surgery results in significant long-term weight loss, which 
in return improves survival by 10-15 years for obese participants (Sjostrom, L. et 
al.,2007, Carlsson, L. M. et al.,2012, Sjostrom, L. et al.,2012). A long-term study 
assessing weight loss with a 20-year follow-up, has reported that participants who have 
undergone different types of surgery such as gastric bypass, LAGB and vertical-banded 
gastroplasty, on average, had an 18% weight loss in comparison to a weight loss of 1% 
in the control group that had nonsurgical obesity interventions, at 20 years (Neovius, M. 
et al.,2012). Various other studies have consistently reported that weight loss in addition 
to substantial improvements in T2DM, as well as other components of cardio-metabolic 
disease, can also lower the risk of some cancer developments (Buchwald, H. et al.,2004, 
Sjostrom, L. et al.,2009, Schauer, D. P. et al.,2017). Besides the health benefits of 
bariatric surgery, reduction in medication use in specific anti-diabetic and 
antihypertensive medication post-surgery has also lead to reduction in medication costs 
for obese participants (Neovius, M. et al.,2012).    
 
While bariatric surgery is beneficial in improving cardio-metabolic disease, different 
surgeries types impact cardio-metabolic components independent of one another, in 
various degrees, leading to prolonged recovery in terms of cardiovascular risk markers 
in some cases. Therefore, participants need to be selected for each specific bariatric 
surgery depending on their cardio-metabolic risk profile, and additionally they need to 
be kept under observation for the first 6 months post-surgery as some participants may 
still be at cardiovascular risk.  
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As such, the aims of this study were to:  
 
1. Assess the rate of improvement in cardio-metabolic components and disease      
resolution in obese-diabetic women post-surgery. 
 
2. Evaluate the effect of bariatric surgery on inflammatory/cardiovascular markers. 
 
3. Investigate the relevance of circulating endotoxin LPS on health outcomes, by 
assessing three different types of bariatric surgeries; SG, LAGB and BPD. 
 
3.2 Subjects and Methods 
 
For this study, a cohort of 42 Caucasian adult women participants with morbid obesity 
(BMI ≥ 35 kg/m2) and cardio-metabolic comorbidities, who underwent one of the three 
types of bariatric surgery, SG (n=14), LAGB (n=14) and BPD (n=14).  
 
3.2.1 Anthropometric and biochemical measurements 
 
All measurements were performed at baseline and at 6 months post-surgery. Blood was 
taken from all participants after a 10 hour fast.  HbA1c, serum glucose and lipids were 
measured using the Cobas 6000 analyzer. HOMA-IR was used to quantify insulin 
resistance by the following equation: HOMA-IR= fasting glucose (mmol/L) x fasting 
insulin (mIU/L) / 22.5 (Matthews, D. R. et al.,1985). LDL cholesterol was calculated by 
using the Friedwald formula (Friedewald, W. T. et al.,1972). Height and weight were 
measured via standardised protocol. BMI was calculated as weight (in kilograms) / 
height2 (meters), and percentage excess weight loss was calculated by using the 
following equation: (preoperative weight - postoperative weight) / (preoperative weight 
- ideal body weight) x 100. Body fat mass was measured using the bioimpedance 
method (Tanita TBF-300; Tanita corporation). Blood pressure data, which is presented 
as systolic over diastolic values, with the average of three blood pressure readings with 
5-minute resting period in between; these readings were taken by using an automated 
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device. Mean Arterial Pressure (MAP) was calculated by using: [(2diastolic blood 
pressure + systolic blood pressure)] / 3 (Brzezinski., Walter A.,1990).     
 
3.2.2 Quantitation of bacterial LPS, and inflammatory markers 
 
Chromogenic quantification of bacterial LPS (Sigma L2630) was performed by using a 
LAL detection kit (#QCL-1000TM Lonza). LAL LPS detection assay was carried out in 
duplicate with a five-part standard curve per plate, and all samples processed in the 
same experiment. Concentrations (EU/mL) were calculated using linear regression 
model. The concentrations of CRP and IL-6 were assessed through ELISA. The 
concentration of CRP were assessed through ELISA (DCRP00, R&D Systems), with 
the assay detection range of 0.8-50 ng/mL, coefficient of variance of 3.8% intra-assay, 
and 7% inter assay precision. The IL-6 concentration was determined by using human 
IL-6 ELISA (D6050, R&D Systems), with an assay detection range of 3.1-300 pg/mL, 
coefficient of variance of 3.1% intra-assay and 2.5% inter-assay precision. Protein 
analysis was preformed by using western blot method as previously described 
(Alhusaini, Saif et al.,2010). Primary antibodies utilised were: TLR4 1:500 (ab13556, 
UK), MYD88 1:1000 (ab2064, UK), TRAF6 1:240 (ab33915, UK), IκB 1:10000 
(ab32518, UK), and NFκB 1:1000 (ab16502, UK).     
 
3.2.3 Cardio-metabolic disease criteria 
 
Cardio-metabolic disease was characterised by using the International Diabetes 
Federation criteria (IDF) (Alberti, George et al.,2006). Participants with central obesity 
(BMI ≥ 30 kg/m2 ) does not require waist circumference measurement) fulfilled the first 
requirement of this criterion. Participants with triglycerides ≥ 1.7 mmol/L or taking 
fibrates or nicotinic acid fulfilled the criteria for hypertriglyceridemia. Serum HDL-
cholesterol was considered low if it was < 1.29 mmol/L in women or if specific 
treatment for lipid abnormality was taken. Participants fulfilled the criteria for 
hypertension if their blood pressure ≥ 130/85 mmHg, or if they have been placed on 
antihypertensive medication from a previous diagnoses. A fasting blood glucose ≥ 5.6 
mmol/L or with a previous diagnosis of T2DM fulfilled this criterion. IDF states that 
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additional measures such as CRP and IL-6 can be further used for the classification of 
this disease. Based on the cutoff points set by the European guidelines on 
cardiovascular disease prevention and the American Heart Association, participants 
with CRP > 3 mg/L were considered at high cardiovascular risk (Pearson, T. A. et 
al.,2003, Perk, J. et al.,2012). Cardio-metabolic disease was classified as ≥ 2 of these 
components with obesity as a diagnostic criterion.  
 
3.2.4 Statistical Analysis 
 
Data were reported as mean and SE. Shapiro-Wilks test was applied to normalise the 
data. Parametrically distributed data, and within surgery group statistical significance 
(pre to post), was determined by paired two-tailed t-test, while Kruskal-Wallis ranks test 
was used for non-parametrically distributed data. Pearson correlation analysis was done 
between changes in variables (Δ), which was calculated as percentage absolute change 
[((post surgery-pre surgery)/pre surgery) x100]. IBM SPSS Statistics 24.0 software was 
used to preform all statistical analyses.  
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3.3 Results 
3.3.1 Body composition and metabolic variables  
 
Clinical and anthropometric data obtained from 42 obese-T2DM women participants 
before undergoing SG (n=14), LAGB (n=14) and BPD (n=14) surgeries, and 6 months 
post-surgery were collected and analysed (Table 3.3.1). Although post-surgery all 
participants were still within the obese range (BMI ≥ 30 kg/m2), significant 
improvements in weight markers (body weight, BMI, % Fat mass loss) were observed 
in all three surgeries. All participants were observed to be in T2DM remission (HbA1c 
p≤0.01) at 6 months with significant reduction in other diabetic markers (HOMA-IR, 
plasma glucose and insulin). Blood pressure improved in all surgeries, however systolic 
blood pressure (p≤0.05) had significantly improved in the SG group alone.  In regards to 
the lipid profile, total cholesterol (p≤0.001), LDL (p≤0.001) and HDL (p≤0.001) 
significantly reduced in the BPD category, whilst significant reduction in triglycerides 
(p≤0.01) was only observed within LAGB. Both SG and LAGB categories have shown 
a significant improvement in triglyceride/HDL ratio (p≤0.05).  
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         3.3. 1 Anthropometric and metabolic variables at pre (Baseline) and post (6 months) surgeries. 
       Continues variables are represented as mean and standard error. SG-sleeve gastrectomy; LAGB- laparoscopic adjustable gastric      
banding; BPD- biliopancreatic diversion; BMI-body mass index; WHR-waist to hip ratio; MAP-mean arterial pressure; HbA1c-
glycated haemoglobin; HOMA-IR- Homeostatic assessment model of insulin.  LDL-low density lipoprotein; HDL-high density 
lipoprotein. (* Represents p-values: * p≤0.05, ** p≤0.01, *** p≤0.001) 
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3.3.2 Number of improvements in cardio-metabolic components, and the resolution 
in this disease was higher in SG and LAGB at 6 months post-surgery.  
 
The prevalence of cardio-metabolic risk factors at 6 months post SG shows a decrease 
in proportion of individuals with; triglycerides ≥ 1.7 mmol/L (50% to 28%; p≤0.05), 
HDL < 1.29 mmol/L (92% to 78%; p≤0.05), and BP ≥ 130/85 mmHg (50% to 28%; 
p≤0.05) (Figure 3.3.2. A). In SG surgery 42.8% of participants achieved resolution in 3 
or more components, 28.5% of participants in 2 components, and the other 28.5% 
attained resolution in 1 component of their cardio-metabolic disease post-surgery. In 
LAGB category there was a decrease in proportion of individuals with; triglycerides ≥ 
1.7 mmol/L (57% to 21%; p≤0.05), HDL < 1.29 mmol/L (85% to 71%; p≤0.05), and BP 
≥ 130/85 mmHg 64% to 21% p≤0.05) post surgery (Figure 3.3.2 B). In this surgery 
71.4% of the participants achieved resolution in 3 or more components, and the 
remaining participants (28.5%) attained resolution in 2 components of their cardio-
metabolic disease. At 6 months post BPD, there was an increase in the proportion of 
individuals with; triglycerides ≥ 1.7 mmol/L (21% to 34%; p≤0.05) and HDL < 1.29 
mmol/L (85% to 100%; p≤0.05), while there was a decrease in proportion of individuals 
with; BP ≥ 130/85 mmHg (57% to 28%; p≤0.05) and CRP > 3 mg/L (57% to 28%; 
p≤0.05) (Figure 3.3.2 C). In this surgery 28.5% of the participants had resolution in 3 or 
more components, 35.7% achieved resolution in 2 components, and 28.5% reached 
resolution in 1 component surgery. While 7.1% showed no resolution in any 
components of the cardio-metabolic disease.  
 
As all the participants in this study were obese at 6 months post surgery (BMI ≥ 30 
kg/m2 ), the criterion for central obesity was fulfilled. Additionally all these participants 
were in diabetes remission at 6 months as well, therefore glucose and BMI were not 
included in the analysis of the cardio-metabolic disease prevalence post surgery.  
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3.3. 2 Prevalence of cardio-metabolic components over time due to the effects of 
surgery. 
Percentage of participants with each cardio-metabolic component; triglycerides, HDL, 
BP and CRP, at baseline and 6 months post- (A) Sleeve gastroctomy - (B) laparoscopic 
adjustable gastric banding, - (C) and biliopancreatic diversion. (* Represents p-value:  * 
p≤0.05) 
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3.3.3 All inflammatory markers in the MYD88-dependent pathway significantly 
reduced in SG, LAGB and BPD at 6 months.  
 
The protein expression of all five inflammatory markers examined at 6 months reduced 
significantly in comparison to baseline in SG surgery, however MYD88 (p=0.005), 
TRAF6 (p=0.004), and NFκB (p=0.012) had a significantly greater reduction than 
TLR4 (p=0.03) and IκB (p=0.04) (Figure 3.3.3 A). Participants that underwent the 
LAGB surgery were observed to significantly reduce five markers of inflammation 
post-surgery in this group. The inflammatory markers were TRAF6 (p=0.007), which 
had the greatest significant reduction, followed by MYD88 (p=0.003), NFκB 
(p=0.0004), IκB (p=0.02), and finally TLR4 (p=0.01) (Figure 3.3.3 B). Similar to the 
other two surgeries every inflammatory marker in the MYD88-dependent pathway was 
reduced after BPD, MYD88 (p=0.0007) and TRAF6 (p=0.001) achieved the greatest 
significant reduction, followed by NFκB (p=0.009), TLR4 (p=0.01), and IκB (p=0.002) 
respectively (Figure 3.3.3 C).   
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3.3. 3 Protein expression of inflammatory markers in MYD88 pathway pre-and 
post-surgery. 
Western blot analysis was used to measure the following markers; TLR4 (molecular 
weight: 95 KDa), MYD88 (molecular weight: 33 KDa), TRAF6 (molecular weight: 58 
KDa), IκB (molecular weight: 35 KDa), NFκB (molecular weight: 60 KDa), and β- 
actin (42 KDa). Statistical analyses were performed to determine the difference in 
protein expressions of each marker at baseline and 6 months post- (A) Sleeve 
gastroctomy – (B) laparoscopic adjustable gastric banding (C) and biliopancreatic 
diversion. (* Represents p-value: * p≤0.05, ** p≤0.01, *** p≤0.001) 
 85 
3.3.4 Effects of bariatric surgery on LPS, CRP and IL-6  
 
The findings from assessment of systemic LPS concentrations determined that there was some apparent reduction in SG and BPD across 
these surgeries but did not achieve significance, whilst no change was observed in LAGB participants at 6 months post-surgery. 
Inflammatory marker IL-6 appeared increased in SG and LAGB post-surgery but this did not achieve significance, however, there was a 
significant increase in the BPD participants at 6 months post-surgery. CRP concentration remained unchanged from baseline to 6 months 
post-surgery in SG and LAGB participants, while this concentration significantly reduced in the BPD participants.     
 
 
    3.3. 4 LPS, IL-6 and CRP concentrations at pre (baseline) and post (6 months) stratified by SG, LAGB and BPD. 
    Variables are presented as means and standard error. Within group statistics (pre-post) was measured by two-tailed paired t-test.  
    (* Represents p-value: * p≤0.05).   
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3.3.5 IL-6 inversely correlates with HDL post BPD, but not in the other two surgeries.  
 
There were no correlations identified between inflammatory marker IL-6 and any of the weight markers in all three surgeries. There was 
however a significant negative correlation between IL-6 and HDL cholesterol in the BPD participants, which was not observed in SG and 
LAGB participants.      
 
 
 
 
                    
                   3.3. 5 Correlation between Δ IL6 with Δ weight markers and lipid markers in all three surgeries. 
Pearson’s correlation coefficient analysis was preformed using absolute change (Δ) variables (pre-post surgery percentage 
change) in each surgery. The correlation was between inflammatory marker IL-6 with weight markers (body weight, BMI, fat 
mass) and lipid markers (HDL cholesterol and triglycerides). (* Represents p-value: * p≤0.05) 
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3.3.6 Low-grade inflammation persists in BPD at 6 months post-surgery.  
 
There was a positive correlation between inflammatory/cardiovascular marker CRP and waist to hip ratio (WHR) in the BPD, this 
correlation was not observed in the other two types of surgeries.     
 
 
 
 
3.3. 6 Correlation between Δ CRP with Δ anthropometric weight markers in all surgeries. 
Pearson’s correlation coefficient analysis was preformed using absolute change (Δ) variables (pre-post surgery percentage change) in 
each surgery. The correlation was between inflammatory/ cardiovascular marker CRP with weight markers (body weight, BMI, fat 
mass and WHR). * Represents p-value: * p≤0.01) 
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3.4 Discussion 
 
This study was designed to investigate the effects of different bariatric surgery 
procedures on metabolic outcomes of morbidly obese women. The main findings of this 
study indicate that the number of improvement in cardio-metabolic components, and the 
resolution in this disease was higher in SG and LAGB at 6 months post-surgery. All 
three surgeries resulted in significant reduction of their MYD88-dependent 
inflammatory pathway in abdominal SAT. However, there was a persistence of mild 
inflammation due to circulating LPS and IL-6 at 6 months post- BPD. Therefore this 
can explain the lack of improvements that were observed in the number of cardio-
metabolic components and the resolution of this disease in the BPD participants in 
comparison to the SG and LAGB participants. 
 
The effects of the three surgical interventions in this study resulted in significant 
reduced adiposity and T2DM remission at 6 months, however, unexpectedly, these 
reductions were not in line with significant improvements in other cardio-metabolic 
components unanimously post all surgeries. It appears at 6 months SG and LAGB 
participants had a more rapid improvement in their systolic blood pressure and lipid 
profile (triglycerides and triglyceride/HDL ratio) and therefore more improved cardio-
metabolic outcomes. In contrast, post-BPD participants still appear to be at 
cardiovascular risk compared to the other two surgeries based on the findings of three 
specific lipid markers; triglycerides, triglyceride/HDL ratio, and HDL. These markers 
are routinely used to predict the increased risk in development of cardiovascular disease 
in adults (Gaziano, J. M. et al.,1997, Cooney, M. T. et al.,2009, Salazar, M. R. et 
al.,2012), and since there is an increase in triglycerides and triglyceride/HDL ratio and 
a significant decrease in HDL levels, these participants continue to be at risk, despite 
reaching normal LDL and total cholesterol levels at 6 months post-surgery (Arsenault, 
B. J. et al.,2011).   
 
Similar to lipids, CRP is regarded as a marker of inflammation and plays a major role in 
cardiovascular disease assessment and prediction(Albert, M. A.,2000). Therefore, in the 
present study, CRP concentration was measured for this cohort in line with other pro-
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inflammatory markers. These findings indicate that CRP remained unchanged in SG 
and LAGB and significantly reduced in BPD post-surgery, however as this value is still 
greater than 3 mg/L, it is considered to be above normal and therefore these participants 
are at moderate-high risk of cardiovascular disease at 6 months post-surgery (Ridker, 
Paul M,2003, Abdellaoui, A. et al.,2007). In the BPD group there was a positive 
correlation between CRP concentration and WHR, which is in line with the results 
reported by other studies (Selvin, E. et al.,2007, J., Choi et al.,2013). This finding 
highlights the continued presence of low-grade inflammation in the BPD participants, 
as they still remain in the high BMI range (BMI≥30 kg/m2) at 6 months. The lack of 
change in CRP concentration in LAGB and especially in SG at the 6 months could be 
due to the duration of the observation period, with some studies reporting that less than 
6 months is too early to observe a major reduction in CRP concentration after SG (van 
Dielen, F. M. et al.,2004, Iannelli, A. et al.,2011). An additional factor that may 
influence these findings may arise due to the percentage of excess body fat or weight 
loss achieved at 6 months, with SG and LAGB groups attaining an average of 17% and 
20% excess weight loss respectively, this might not be significant enough to promote a 
reduction in this marker. One particular study has determined that SG participants had 
significant reduction in CRP concentrations only after an excess weight loss of more 
than 40% at 6 months post-surgery (van Dielen, F. M. H. et al.,2004), and as such for 
the present study it might be more accurate to measure CRP levels at 1 year 
postoperatively.   
 
As a surrogate to CRP, IL-6 a pro-inflammatory marker with a strong association with 
coronary heart disease was also measured (Danesh, J. et al.,2008, 2012). The finding 
for the current study suggest that IL-6 levels in SG and LAGB did not change due to 
surgery at the points measured, while the BPD participants achieved a significant 
increase in this marker at 6 months post-surgery. Since it has been reported that 25% of 
IL-6 is secreted from adipose tissue (Mohamed-Ali, V. et al.,1997), and all of our 42 
participants had significant fat mass reduction post-surgery, it was anticipated that IL-6 
would decrease in all surgeries. It was especially surprising that IL-6 was significantly 
increased in the BPD participants as CRP, which is produced due to IL-6 stimulation in 
the liver was significantly reduced in these participants. The increase in IL-6 levels in 
this current study could have been due to a number of possibilities. Firstly, lengthy 
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surgical duration (Anderson, Blaire et al.,2013), followed by the prolonged healing 
process which are all due to more invasive nature of surgeries, such as BPD compared 
to others is likely to promote an inflammatory state during the first 6 months post-
surgery. Secondly, accelerated weight loss can lead to elevated intracellular fatty acid 
concentrations, which can cause inflammatory lesions in the liver post-weight loss. 
Severe form of these inflammatory lesions, as well as, liver failure have been observed 
in BPD participants especially post-surgery (Grimm, I. S. et al.,1992). A third possible 
explanation can be the accelerated weight loss in SG and BPD is comparable to 
starvation status that occurs in anorexia nervosa participants. Many studies have 
reported that inflammatory markers were elevated in the malnourished environment of 
anorexia nervosa, and post-feeding, these markers return back to normal levels (Opara, 
E. I. et al.,1995, Allende, L. M. et al.,1998, Nakai, Yoshikatsu et al.,1999). Therefore, 
at approximately 12 months of recovery as the body weight in parallel with metabolic 
instability improves, it is then most likely that IL-6 would reduce.  
 
Furthermore a fourth scenario could be that translocation of bacterial DNA and pro-
inflammatory LPS into the blood of severely obese participants may cause persistent 
increase in IL-6 levels and other inflammatory markers in some of these participants 
independent of the significant weight reduction they have achieved via bariatric surgery 
(Ortiz, Sergio et al.,2014). As LPS can exert its damaging effects through activation of 
TLR-4 and the MYD88-dependent pathway (Yang, Y. et al.,2016) causing up-
regulation of IL-6 production and secretion, the inflammatory status of LPS, and the 
markers in this pathway (TLR-4, MYD88, TRAF6, IκB and NFκB) was investigated. 
This current study showed that LPS levels remained unchanged in LAGB and only 
slightly reduced in SG and BPD, however these concentrations still remained high 
enough to up-regulate inflammatory markers such as IL-6 (Li, Yang et al.,2016).  
 
The findings of MYD88-dependent pathway have shown significant reduction in all the 
markers in this pathway in all three surgeries. With both LPS and IL-6 remaining at 
levels that represent the presence of inflammation, in contrast to the results of MYD88-
dependent pathway, it can be therefore assumed that LPS is up-regulating IL-6 through 
the MYD88-independent pathway also known as the Toll/interleukin-1 receptor-
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domain-containing adapter-inducing IFN-β (TRIF)-dependent pathway (Yang, Y. et 
al.,2016).  
 
The final explanation for the IL-6 increases in all the participants, specifically the BPD 
group, is the dyslipidaemia that occurs as the result of this surgery. These current 
findings show a significant negative correlation between HDL cholesterol and IL-6 in 
BPD and not in the other two surgeries. This could arise due to lipid metabolism being 
affected by IL-6 mechanism through inhibiting lipoprotein lipase activity and lipolysis 
stimulation, leading to triglycerides and free fatty acids accumulation, and therefore 
resulting in low-grade inflammation (Sola, E. et al.,2009).  
 
Post SG and LAGB surgeries there was a significant decrease in the prevalence of the 
number of components in cardio-metabolic risk factors, and an increase in the number 
of participants that have had resolution of their cardio-metabolic disease post these two 
surgeries. However in BPD participants the prevalence of half of the number of these 
components were significantly increased, while fewer participants were in cardio-
metabolic resolution at 6 months post-surgery in comparison with the other two 
surgeries. Although rapid weight loss is one of the beneficial outcomes of the BPD 
surgery, the prolonged inflammatory status and the disrupted lipid metabolism during 
the initial 6 months post-surgery, can put these participants at further risk of 
cardiovascular disease.  
 
There are a number of study limitations to this study including; 1) the participants of 
this study were not placed on a certain dietary regiment and had a relatively sedentary 
lifestyle pre and post-surgery. 2) This cohort included only European women with 
T2DM, therefore the results of the surgeries might be different in other ethnicities and 
men. 3) Weight loss post-bariatric surgery often has a nonlinear pattern in the first year, 
and rebounds subsequently; therefore long-term data is required to determine whether 
the cardio-metabolic effects of these different types of bariatric surgeries are maintained 
in this population.  
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3.5 Conclusions  
 
This study has demonstrated that equal resolution of inflammation in adipose tissue was 
achieved post all surgeries, however systemic pro-inflammatory markers appear to 
persist in BPD participants at 6 months. The following factors such as; technical 
complexity of the BPD surgery and the operation being time consuming, metabolic 
disturbances such as dyslipidaemia and malnutrition, in addition to endotoxin activity 
post-operatively, appears to extends the inflammatory state irrespective of the extensive 
weight loss that occurs with BPD procedure. Therefore, as BPD participants may still 
be at risk of cardiovascular disease, participants selected for this surgery need to be 
monitored closely for markers of inflammation at least for the first 6 months post- 
surgery.  
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CHAPTER 4: 
Effects of Bariatric surgery on FGF-19 & FGF-21 levels in 
obese T2DM women 
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4.1 Introduction 
 
Lipid and glucose metabolism is governed by a number of metabolic hormones, which 
are secreted from adipose tissue and various other organs such as the pancreas, as well 
as the gastrointestinal and adrenal glands. These hormones form a combined network 
for the regulation of substrate utilization and energy balance in response to nutritional 
status. In the state of obesity, the abnormal secretion and the dysfunction in these 
metabolic hormones is a major contributing element in the development of obesity 
related cardio-metabolic disease.  
 
Playing an important role in the regulation of these metabolic hormones are two 
members of the FGFs superfamily. FGF-19 and FG-F21 have been identified as being 
involved in various cellular activities such as metabolic regulation. The FGF heparin-
binding proteins function mainly through autocrine or paracrine activity, however FGF-
19 and FGF-21 display unique structural properties, allowing them to function as 
endocrine hormones different to other FGFs. FGF- 19 is synthesized in the ileum, (-15 
mouse ortholog) which is regulated by bile acids, and also regulates glucose and lipid 
metabolism (Potthoff, M. J. et al.,2011). Previous studies have highlighted the effect of 
FGF-19 on metabolism, work with obese mice has shown that administration of human 
FGF-19 to such mice induces a significant dose-dependent decrease in BMI, blood 
glucose, triglyceride, and insulin sensitivity (Fu, L. et al.,2004). This negative 
correlation between obesity and FGF-19 has been further confirmed in human studies, 
whereby obese participants have been shown to have a significantly lower FGF-19 level 
in comparison to the healthy control participants (Gallego-Escuredo, J. M. et al.,2015).  
 
FGF-21 regulation within insulin target tissues mainly appears to be active in the liver. 
Its role in the liver appears to support improvement of metabolic functions by 
promoting lipid metabolism, insulin sensitivity, and energy expenditure (Angelin, B. et 
al.,2012, Owen, B. M. et al.,2015). As this hormone increases during obesity, it has 
been suggested that obesity coupled by insulin resistance may induce a FGF-21 resistant 
state (Fisher, ffolliott M. et al.,2010). Additionally, studies have shown that patients 
with cardiovascular disease exhibit significantly elevated FGF-21 levels, which has a 
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positive correlation with risk factors such as adverse lipid profile and CRP (Chow, W. 
S. et al.,2013, Shen, Y. et al.,2013).  
 
Various studies have demonstrated that FGF-19 and FGF-21 are potentially involved in 
the cardio-metabolic recovery post bariatric surgery (Kyrou, I. et al.,2017, Patton, A. et 
al.,2017). It has been suggested that post-bariatric alterations in the metabolism of bile 
acids and possibly in the gut microbiome, stimulate an elevation in circulating FGF-19, 
which then leads to the regulation of glucose and lipid metabolism and body adiposity 
(Kuipers, F. et al.,2014, Ryan, K. K. et al.,2014, Owen, B. M. et al.,2015). However 
this behaviour of FGF-19 post bariatric surgery is not unanimously supported, with at 
least one study stating that an increase in FGF-19 levels is stimulated more post 
bariatric surgery regardless of surgery type (Gomez-Ambrosi, J. et al.,2017); whilst 
another study suggests that changes in FGF-19 levels are surgery dependent (Martinez 
de la Escalera, Lucia et al.,2017). Mice studies have also indicated that FGF-21 might 
be involved in preventing increased hunger and weight regain post-bariatric surgery 
(Morrison, Christopher D. et al.,2016). In humans FGF-21 has been labelled as the 
marker of metabolic stress (Crujeiras, A. B. et al.,2017), with most studies reporting a 
reduction in this hormone after specific bariatric surgeries (Fjeldborg, K. et al.,2017, 
Gomez-Ambrosi, J. et al.,2017).  
 
Currently, there is limited insight on the changes in both FGF-19 and FGF-21 across 
bariatric surgery types, and the associated influence this may have on anthropometric 
and biochemical biomarkers.  
 
Therefore, the aims of this study were to:   
 
1. Investigate the effects of SG, LAGB and BPD on FGF-19 and FGF-21 levels at 
6 months post surgery. 
 
2. Define the changes in FGF-19 and FGF-21 levels in participants at high, 
medium and low risk of cardio-metabolic disease within each surgery. 
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3. Compare the effects of FGF-19 and FGF-21 on cardio-metabolic risk factors, by 
using glucose and lipid profile markers, within all three surgeries. 
 
 
4.2 Subjects and Methods 
 
For this study the same cohort along with anthropometric and biochemical 
measurements as chapter 3, section 3.2 were used.   
 
4.2.1 Cardio-metabolic disease criteria 
 
Cardio-metabolic disease was characterised by using IDF standards (Alberti, George et 
al.,2006). A high-risk group was defined as participants that had resolution in one 
component, medium risk group had resolution in 2 components, and low risk group had 
resolution in 3 or more components of cardio-metabolic disease post surgery.    
 
4.2.2 Quantitation of inflammatory markers 
 
The concentrations of CRP were assessed through ELISA (DCRP00, R&D Systems), 
with the assay detection range of 0.8-50 ng/mL, coefficient of variance of 3.8% intra-
assay, and 7% inter assay precision. 
 
4.2.3 FGF-19 and FGF-21 Serum levels 
 
Serum FGF-19 (pg/mL) was measured by using ELISA kit (DF1900, R&D Systems). 
Measurements were preformed in duplicates based on the manufacturers instructions. 
This assay has a detection range of 15.6-1000 pg/mL, and a coefficient of variation of 
4.5 % for intra-assay and 5.5 % inter-assay precision.  Serum FGF-21 (pg/mL) was 
measured by using ELISA kit (DF2100, R&D Systems). Following the manufacturers 
instructions measurements were preformed in duplicates. The detection range of this 
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assay is 31.3-2000 pg/mL, and the coefficient of variation of the intra-assay is 2.9% 
with 6.4% inter-assay precision.  
 
 
4.2.4 Statistical Analysis 
 
Data were reported as mean and SE. Shapiro-Wilks test was applied to normalise the 
data. Within surgery group statistical significance (pre to post) was determined by 
paired two-tailed t-test or one-way ANOVA  (if parametric) and Kruskal-Wallis test (if 
non-parametric) was used for the comparison of between surgery groups. Welch’s t-test 
was used for high, medium and low risk group comparison. Pearson correlation analysis 
was done between changes in variables (Δ), which were calculated as percentage 
absolute change [((post surgery-pre surgery)/pre surgery) x100]. Multivariate linear 
regression (forward model) was preformed for ΔFGF-19 and ΔFGF-21 as dependent 
variables with the variables (Δ) that had shown significant correlation with ΔFGF-19 
and ΔFGF-21 as independent variables. All statistical analysis was preformed by using 
SPSS 24.0.  
 
4.3 Results 
4.3.1 Body composition and metabolic variables  
 
The results in this section are same to that of chapter 3, section 3.3.1.  
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4.3.2 SG caused an increase in FGF-19 level post surgery   
 
Percentage absolute change in FGF-19 increased by 29% in the SG, LAGB decreased 
by 39% and BPD had the least increase with 10%. The percentage change in pre-to post 
FGF-19 was not significant in any of the three surgeries, however there was significant 
difference between SG and LAGB in FGF-19 absolute change (p=0.004).  
 
 
 
4.3. 1 Effect of SG, LAGB and BPD serum FGF-19 absolute change pre- to post 
surgery. 
Paired two-tailed t-test was used for the within group comparison of pre to post surgery 
levels, while ANOVA test determined the significant difference in serum FGF-19 
between SG and LAGB groups (p=0.004) SG: sleeve gastrectomy, LAGB: laparoscopic 
adjustable gastric banding, biliopancreatic diversion.  
(* Represents p-value: ** p ≤ 0.01) 
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4.3.3 SG caused a decrease in FGF-21 levels post surgery 
 
Percentage absolute change in FGF-21 decreased by 57% in the SG, LAGB decreased 
by 26% and BPD had the least decrease with 6%. The percentage change in pre-to post 
FGF-21 was not significant in any of the three surgeries, however there was significant 
difference between SG and BPD in FGF-21 absolute change (p=0.050).  
 
 
 
4.3. 2 Effect of SG, LAGB and BPD on serum FGF-21 absolute change pre- to post 
surgery. 
Paired two-tailed t-test was used for the within group comparison of pre to post surgery 
levels, while ANOVA test determined the significant difference in serum FGF-21 
between SG and LAGB groups. (p=0.050) SG: sleeve gastrectomy, LAGB: 
laparoscopic adjustable gastric banding, biliopancreatic diversion. (* Represents p-
value: * p ≤ 0.05) 
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4.3.4 In SG participants, significant increase in FGF-19 and significant decrease in 
FGF-21 was in the low risk group. 
 
In the SG group there was an overall increase in FGF-19 concentration, however, there 
was a significant increase in FGF-19 in the individuals who are at low risk of cardio-
metabolic risk at 6 months post surgery. FGF-19 decreased in LAGB participants in 
both medium and low risk groups. In the BPD group, FGF-19 had decreased in the 
high-risk group, while there was a significant increase of this hormone in the medium 
risk group (4.3.4 A). There was an overall decrease in FGF-21 in the SG participants; 
however, there was a significant decrease in the low risk participants in this group. 
LAGB participants had a decrease in FGF-21 in both medium and low risk participants, 
although this was not significantly different between these two risk groups. In the BPD 
group, FGF-21 was significantly increased in the medium risk group; while this 
hormone was significantly decreased in the low risk group at 6 months post surgery 
(4.3.4 B). 
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4.3. 3 FGF-19 and FGF-21 concentrations absolute change pre- to post surgery 
stratified by cardio-metabolic risk. 
These figures illustrate the Δ FGF-19 (A) and Δ FGF-21 (B) concentrations, which are 
divided into SG participants at low cardio-metabolic risk (n= 6 of 14), medium cardio-
metabolic risk (n=4 of 14) and high cardio-metabolic risk (n=4 of 14). LAGB was 
divided into low risk (n= 10 of 14) and medium risk (n=4 of 14). BPD was divided into 
low risk (n=4 of 14), medium risk (n= 5 of 14) and high risk (n=4 of 14) groups. 
Welch’s t-test was used for the comparison of high, medium and low risk groups. (* 
Represents p-value: * p ≤ 0.05) 
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4.3.5 FGF-19 correlation with anthropometric and metabolic variables  
 
Percentage change in pre-to post FGF-19 was positively correlated with HDL in the SG 
group. There was also a positive correlation between FGF-19 and triglyceride/HDL 
ratio in the LAGB group, while this hormone had a negative correlation with BMI, 
plasma insulin and HOMA-IR in the BPD group.  
 
 
 
 
4.3. 4 Correlation between FGF-19 and anthropometric and metabolic variables. 
Pearson correlation analysis was used to determine the correlation between surgical-
induced changes in pre-to post FGF-19 concentration and the changes in other 
variables. BMI, body mass index; WHR, waist to hip ratio; MAP, mean arterial 
pressure; HbA1c, glycated haemoglobin; HOMA-IR, Homeostatic assessment model of 
insulin resistance; CRP, C-reactive protein. (* Represents p-value: * p ≤ 0.05, ** p ≤ 
0.01)  
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4.3.6 FGF-21 correlation with anthropometric and metabolic variables   
 
Percentage change in pre-to post FGF-21 was positively correlated with body weight, 
BMI and WHR, additionally this hormone has a positive correlation with plasma 
glucose in the SG group. FGF-21 correlates negatively with diastolic blood pressure in 
LAGB. In the BPD group, FGF-21 is positively correlated with fat mass percentage and 
HDL.  
 
 
4.3. 5 Correlation between FGF-21 and anthropometric and metabolic variables. 
Pearson correlation analysis was used to determine the correlation between surgical-
induced changes in pre-to post FGF-21 concentration and the changes in other 
variables. BMI, body mass index; WHR, waist to hip ratio; MAP, mean arterial 
pressure; HbA1c, glycated haemoglobin; HOMA-IR, Homeostatic assessment model of 
insulin resistance; CRP, C-reactive protein. (* Represents: P-Value: * p ≤ 0.05, ** p ≤ 
0.01 
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4.3.7 FGF-19 predicted by HOMA-IR in BPD participants 
 
The model that best predicted the change in FGF-19 concentration included only the 
changes in HOMA-IR as predictive variable. Based on this model 61% of the BPD 
surgical-induced change in FGF-19 can be predicted by the changes in HOMA-IR.  
 
 
 
4.3. 6 Multiple liner regression analysis with ΔFGF-19 as dependent variable in the 
BPD group. 
Variables that were excluded in the forward model were: ΔBMI and Δ plasma insulin. 
Values are presented as adjusted r2 (r2), standardized coefficients (β) and associated p 
values, absolute change in homeostatic assessment model of insulin resistance (HOMA-
IR). (* Represents p-value: * p ≤ 0.05, ** p ≤ 0.01) 
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4.3.8 FGF-21 predicted by HDL cholesterol in BPD participants 
 
The model that best predicted the change in FGF-21 concentration was the change in 
HDL cholesterol. Based on this model 41% of the changes in the BPD surgical-induced 
change in FGF-21 can be predicted by the change in HDL. 
 
 
 
Variables that were excluded in the forward model were: Δfat mass%. Values are 
presented as adjusted r2 (r2), standardized coefficients (β) and associated p values, 
absolute change in high-density lipoprotein (HDL). (* Represents p-value: * p ≤ 0.05, 
** p ≤ 0.01) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable r2 β P value 
Model 0.412  0.033* 
ΔHDL  -0.642 0.033* 
 
4.3. 7 Multiple linear regression analysis with ΔFGF-21 as dependent variable in 
the BPD group. 
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4.4 Discussion 
 
This study addressed the impact of FGF-19 and FGF-21 status pre and post surgery, and 
whether the type of surgery may have influenced a change in these hormones. The 
findings determined that FGF-19 was altered by surgery type, with the highest FGF-19 
concentration in SG participants, who also shown to have the best cardio-metabolic 
outcomes at 6 months. Concurrently FGF-21 was also affected by surgery type, with the 
lowest concentration observed in SG participants that were in low risk of cardio-
metabolic disease post surgery. Additionally, the results of this study indicated that 
potentially FGF-19 status could be used as a marker for the prediction of metabolic 
improvement in glucose, while FGF-21 can be utilised as marker for prediction of lipid 
status post BPD surgery. 
 
In this study, FGF-19 concentration increased as an effect of SG and BPD, whilst it 
decreased as the result of LAGB surgery. Studies have suggested that LAGB surgical 
procedure does not apply the gastrointestinal anatomy changes, which is needed in 
order to elicit an effect for this particular endocrine hormone to increase (Pournaras, 
Dimitri J. et al.,2012, Lips, M. A. et al.,2014).  Interestingly as BPD participants had 
the most substantial weight loss in comparison to SG participants, it was expected for 
FGF-19 concentration to be higher in these participants, however this was not the case.  
The possible underlying reasons for the apparent disconnect between FGF19 
concentration in BPD patients could be due to the gastrointestinal rearrangement, which 
takes place as part of the surgery. The physical separation of bile acids from nutrients 
(Albaugh, VL et al.,2016) can change nutritional absorption and therefore the intestinal 
microenvironment resulting in altered FGF-19 concentration. 
 
Bile acids are synthesized from cholesterol in hepatocytes, and are highly regulated by 
FXR activation, which results in stimulation of FGF-19 transcription in the ileum. There 
might be a possibility that BPD surgery has an effect on bile acid transport since 
reduced surface area of ileum, as a result of this surgery, which would lessen the 
exposure and absorption of bile acids. It is predicted that BPD simulates the effects of 
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blocking intestinal bile acid absorption through the use of bile acid sequestrants, which 
increases the cholesterol into bile acids conversion (Einarsson, K. et al.,1991, Root, C. 
et al.,2002) and, therefore reduces total cholesterol levels post surgery (Scopinaro, 
N.,2012). These effects disrupt hepatic bile acid synthesis leading to bile acid 
sequestrants causing reduced FGF-19 concentration in fasted or fed state (Brufau, G. et 
al.,2010, Beysen, C. et al.,2012). This mechanism may in effect be in the present study 
as well, since BPD participants have had the most significant reduction in total 
cholesterol and the least increase in FGF-19 in comparison with SG.   
 
Secondly, bile acid antimicrobial activity can affect the composition and quantity of gut 
microbiota (Merritt, M. E. et al.,2009, Islam, K. B. et al.,2011, Li, T. et al.,2015). This 
means that there is a close integrated relationship between bile acids and gut microbiota, 
in that bile acids affect the colonisation and development of intestinal bacteria, while 
bacteria get involved in the biotransformation of bile acids (Li, T. et al.,2014). This 
equilibrium between gut microbiota and bile acid pool size gets disrupted post BPD 
surgery, due to increased bile acid flow into the colon and the gut microbiota 
overgrowth. In such environment, metabolic effect of bacteria results in deconjugation 
of bile acids and secondary bile acids production (Tomkin, Gerald H. et al.,2016). 
Hepatocytes reabsorb majority of these unconjugated bile acids, however, some manage 
to affect the intestinal barrier permeability and enter the systemic circulation (Kaska, L. 
et al.,2016), resulting in high plasma bile acid concentration. Importantly, the secondary 
bile acid compounds produced by these bacteria are potent FXR antagonists thus 
lowering the FXR-FGF-19 expression (Sayin, Sama I et al.,2013, Flynn, Charles Robb 
et al.,2015).    
 
Although the mentioned mechanisms affect the bile acid transport and synthesis, which 
blunts the increase of FGF-19 at 6 months post BPD, it is possible that the bile acid 
sequestrants actively play a role in improving glycaemia (Chen, L. et al.,2012, Prawitt, 
J. et al.,2014). The activity of these bile acid sequestrants appears to be influenced by 
increased glucose uptake or increased secretion of glucagon-like peptide 1 (GLP-1), 
which arises with elevated bile acids or free fatty acids signalling within the intestine 
(Hofmann, A. F.,2011, Prawitt, J. et al.,2014). Therefore, there is a possibility that the 
reduced bile acid or nutrient uptake in the ileum contributes to the GLP-1 increase, post 
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BPD surgery (Valverde, I. et al.,2005, Astiarraga, B. et al.,2013). Additionally glucose 
metabolism is further improved post BPD surgery due to the exclusion of the longer 
intestinal limb from the alimentary passage followed by concentrated bile acid 
transition and extreme caloric restriction, which collectively result in a greater impact 
on improvement of HOMA-IR (Kaska, L. et al.,2016). In line with these findings, in the 
present study BPD participants have had the most significant improvement in their 
HbA1c, and a similar significant improvement in their HOMA-IR in comparison with 
SG. Additionally, similar to what has been reported in other malabsorptive bariatric 
procedures (Gerhard, Glenn S. et al.,2013), the results of this study indicates that in 
BPD participants changes in FGF-19 is a predictor of HOMA-IR status post surgery. 
Therefore, this endocrine hormone can potentially be a predictor of T2DM 
improvement in this category of participants.   
 
The increase in FGF-19 concentrations in SG and BPD participants seems to be 
concurrent with the decrease of FGF-21 concentrations in the same groups. However, it 
was surprising that FGF-21 had the least decrease in the BPD group as they had the 
most substantial weight loss and glucose homeostasis improvement compared to SG 
participants. There are a few mechanisms that may explain this observation. Firstly, the 
mechanical changes to the gastrointestinal anatomy, which results in the extreme calorie 
restriction post BPD triggers both amplified postprandial insulin followed by increased 
free fatty acid and glucagon secretions. These “ fed and fasted signals” activate hepatic 
PPAR α, which in return could activate the hepatic FGF-21 expression, and therefore, 
can maintain the elevated levels of this hormone (A., Lips Mirjam et al.,2014) at 6 
months post BPD. In this environment an increase in glucagon stimulates the increase in 
lipolysis (Perea, A. et al.,1995, Duncan, Robin E. et al.,2007), resulting in 
dyslipidaemia (hypertriglyceridemia and low HDL cholesterol) (Ryden, M. et al.,2017), 
which may explain the observations in this study of BPD participants at 6 months post 
surgery. The maintained elevated FGF-21 concentration is beneficial as this hormone 
has an inhibitory effect on lipolysis, which can help to retain the distribution of lipids 
between adipose tissue and liver thus preventing lipotoxicity caused by continuous 
increase of free fatty acids (Ge, Xuan et al.,2012) after BPD.   
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Additionally, in this study the small reduction in FGF-21 levels (6%), followed by the 
significant decrease in BMI at 6 months post BPD could indicate a partial normalisation 
of FGF-21 sensitivity, therefore, stimulating further secretion of FGF-21 and 
maintaining the increased levels of this hormone. The normalization of FGF-21 
sensitivity has also been reported after other malabsorbitive and restrictive surgeries 
(D., Haluzíková et al.,2013, Gómez-Ambrosi, Javier et al.,2017).     
 
In the present study, the participants that were still at high risk of cardio-metabolic risk 
at 6 months post BPD had the least reduction in their FGF-21 concentration, and the 
most reduction in this hormone was in the low risk group. 
 
Mounting evidence from animal and human-based research indicates that increased 
FGF-21 levels are associated with cardio-metabolic disease (Kharitonenkov, Alexei et 
al.,2005, Kharitonenkov, A. et al.,2007, Zhang, X. et al.,2008, Gallego-Escuredo, J. M. 
et al.,2015). One study has demonstrated that increased FGF-21 concentration can 
independently be a risk factor for cardio-metabolic disease. Furthermore, it was shown 
that this association was significantly more effective than the impact of individual 
components of this disease (Zhang, X. et al.,2008). This FGF-21 and cardio-metabolic 
risk factor trend was observed in SG and LAGB as well.    
 
The effect of FGF-21 on cardio-metabolic disease, especially its regulatory role in lipid 
metabolism has been further demonstrated by genetic studies. Genetic association 
analysis on a white European hypertensive cohort was preformed in order to analyse 
whether polymorphisms in the FGF-21 signalling pathway may be associated with 
cardio-metabolic risk. The findings of this previous study showed that few single 
nucleotide polymorphisms in genes reside in the FGF-21 pathway (FGFR1, FGFR2, 
FGFR3, and KLB), which are associated with LDL, HDL, and triglycerides (Kaess, B. 
M. et al.,2010). In the present study, although genetic analysis was not undertaken, 
regression analysis showed that 41% of the changes in HDL could be predicted by FGF-
21 change in the BPD participants. Therefore FGF-21 could be used as a marker for 
cardio-metabolic improvement, in specific, for a more in depth lipid profile assessment 
at least for the first 6 months post BPD surgery, as this group may still be at risk of this 
disease in comparison with SG and LAGB groups.    
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The limitation of this study was the small sample size in regards to the grouping of the 
participants based on the cardio-metabolic risk factor.  
 
4.5 Conclusions  
 
Bariatric surgery types impact endocrine hormones in different ways. At 6 months post 
surgery, SG resulted in a higher increase in FGF-19 concentration, specifically in 
participants that were at low risk of cardio-metabolic, in comparison to BPD surgery. 
Additionally in the SG group, especially the low risk participants had a significantly 
lower FGF-21 concentration than the BPD group.  The lack of significant increase in 
FGF-19 and decrease in FGF-21 post BPD at 6 months post surgery in combination 
with micro and macro-nutrient deficiencies can still place these participants at risk of 
cardio-metabolic disease despite the significant weight loss that these participants had. 
Therefore, emphasizing the lack of suitability of BPD, especially when procedures such 
as SG can achieve significant weight loss along with higher resolution of cardio-
metabolic components without the long-term complication rates and nutritional 
malabsorption.   
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Chapter 5: 
Effect of liraglutide on adipose tissue angiotensinogen protein 
in mature adipocytes 
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5.1 Introduction 
 
The RAS has been well documented in human physiology for its role in regulating 
blood pressure along with electrolyte and fluid balance.  Within RAS the protein AGT, 
as a key precursor to derive all bioactive angiotensin peptides, is primarily synthesised 
in the liver and undergoes enzymatic cleavages to produce other components of this 
system (Lavoie, J. L. et al.,2003). It has also been shown that all components of RAS, 
including derivatives of AGT are produced in adipose tissue and secreted from mature 
adipocytes (Engeli, Stefan et al.,2003, Gustavo-Salom et al.,2013). This has led to 
studies examining the role of RAS as an important influence in the pathogenesis of 
obesity related cardio-metabolic disease (Must, A. et al.,1999, Schmieder, R. E. et 
al.,2007). Studies to date have shown that with increasing weight gain increased AGT 
secretion occurs from mature adipocytes. This production of AGT and ANG II, the 
active metabolite, are considered a relevant contributing source in the development of 
hypertension (Harte, et al, 2005). Studies in mice have also shown that excess secretion 
of adipose specific AGT contributes to as much as a 30% increase in plasma ANG II 
levels, with mice developing hypertension and insulin resistance. While adipose-
specific AGT knockout mice appear to lead to a 25% decrease in AGT plasma levels, 
demonstrating the endocrine effect of adipose AGT (Kalupahana, N. S. et al.,2012). 
Beyond blood pressure changes adipose specific AGT also appears to reduce lipolysis 
and stimulate lipogenesis whilst inhibiting adipogenesis and promoting production of 
pro-inflammatory adipocytes (Kalupahana, N. S. et al.,2012). These effects of adipocyte 
AGT synthesis influences and contributes significantly to the systematic RAS, which is 
important in developing obesity related hypertension.   
 
To date it is known that various nutrients, such as elevated salt intake and high fat diets 
(Serazin-Leroy, Valérie et al.,2000) as well as hormones (Harte, A. et al.,2005) can 
regulate adipose AGT expression. In addition, the inflammatory mediator, LPS may 
also play an important role in inducing adipose AGT expression in obesity related 
hypertension (Gao, Meng et al.,2014), although studies to date have been limited to 
explore this concept in human metabolism. A prior study of spontaneously hypertensive 
rats has shown that pre-treatment with LPS results in elevated AGT mRNA levels in 
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adipose tissue. Furthermore LPS can induce pro-inflammatory cytokines such as TNF-
α, as the hypertensive rats were noted to increase their TNF-α mRNA levels in adipose 
tissue. Overall, this implied that LPS might induce TNF-α to affect AGT gene in 
adipose tissue of hypertensive rats (Nyui, N. et al.,1997).     
  
GLP-1 agonist liraglutide used as T2DM therapy, has similarly been demonstrated to 
have the capability to exert metabolic effects on RAS components of various tissues. 
Studies have shown that liraglutide appears to decrease renal tissue angiotensin II 
concentration in T2DM, which results in protection from the kidney damage (Skov, J. et 
al.,2016). Whilst in rodent models of T2DM with pulmonary disorder, liraglutide 
appears to have a significant effect in increasing lung tissue ACE2 expression, which 
leads to improvements of the cardiopulmonary complications, associated with diabetes 
(Romaní-Pérez, Marina et al.,2015). Perhaps less well studied are the metabolic effects 
of this medication on adipose specific AGT.  
 
Prior molecular studies have also shown that liraglutide can influence inflammation and 
adipogenesis, however these effects appear dependant on the origin and the 
differentiation stages of adipocytes. Studies with mature adipocytes, have identified 
liraglutide to affect inflammation through reducing TNF-α and elevating adiponectin 
expression (El Bekay, Rajaa et al.,2016); whilst in obese stem cells it also elevates 
adiponectin expression (Cantini, G. et al.,2015). In addition, other studies have shown 
that liraglutide appears to have an anti-adipogenic effects on adipose stem cells derived 
from obese patients (Cantini, G. et al.,2015) causing a reduction in adipogenesis and 
lipogenesis-related genes, while increasing lipolytic gene expression (El Bekay, R. et 
al.,2016). Whilst rodent adipocyte cells studies using 3T3-L1 has shown that liraglutide 
causes reduced apoptosis, while stimulating adipocyte differentiation and proliferation in 
pre-adipocytes of these cells (Challa, T. D. et al.,2012).  
 
The primary effect of liraglutide on insulin sensitivity appears to be cell type dependent 
as well. It has also been reported that in 3T3-L1 adipocytes (Gao, H. et al.,2007) and 
pre-adipocytes (Yang, J. et al.,2013), treated with GLP-1 causes enhanced glucose 
uptake and insulin sensitivity, whereas in human adipocyte stem cells it appears to have 
an inhibitory effect on glucose uptake. Although these studies demonstrate the 
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beneficial effect of liraglutide on RAS and its components in other tissues, the influence 
of this drug on AGT, specifically in human adipocytes has not been explored in detail.   
 
As such, the aims of this study were to: 
 
1. Investigate the potential in vitro effects of different concentrations of liraglutide 
with and without the insult of LPS on AGT of lean and obese human SAT 
mature adipocytes.  
2. Evaluate whether liraglutide interferes with cellular proliferation of human lean 
and obese mature adipocytes. 
3. Assess the role of liraglutide on improving insulin sensitivity  
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5.2 Subjects and Methods 
 
5.2.1 Subjects 
 
SAT samples were obtained from 3 lean female participants (mean age ± SD: 35 ± 3 
years; BMI ± SD: 21.7 ± 2.4 kg/m2), and 3 obese female participants (mean age ± SD: 
32 ± 2 years; BMI ± SD: 43 ± 4.2 kg/m2). All human tissues were obtained through 
elective surgery in accordance with ethical committee approval, at University Hospital 
Coventry and Warwickshire. Lean participants on endocrine, T2DM, or 
antihypertensive therapy were excluded. Additionally obese participants affected by 
insulin resistance, infections, or on cancer and steroid therapies were also excluded.        
 
5.2.2 Isolation and culture of primary adipocytes    
 
The isolation of adipocytes from abdominal SAT was collected as previously reviewed 
(Rodbell, M.,1964). Adipogenesis was induced in the primary preadipocytes for 14 
days. Mature adipocytes were treated with different concentrations of liraglutide (10 
nM, 100 nM) which was gifted by Novo Nordisk, LPS (10 ng/ml, 100 ng/ml) (Sigma 
L2630), and different combinations of liraglutide and LPS: (LPS 10 ng/ml + Liraglutide 
10 nM), (LPS 10 ng/ml + Liraglutide 100 nM), (LPS 100 ng/ml + Liraglutide 10 nM), 
and (LPS 100 ng/ml  + Liraglutide 100 nM) for the following lengths of time: 24, 48 
and 72 hours, with fresh treatment exposure every 24 hours. Adipocytes in untreated 
media were used as controls.  
 
 
5.2.3 Cell count 
 
Seeded adipose SAT cells were treated for 24, 48 and 72 hours, then trypsinized and 
counted by the hemocytometer. The mean of cell number was attained by performing 
four replicates for each point of every experiment.  
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5.2.4 Glucose uptake measurement  
 
Seeded cells were grown to confluence, and glucose uptake assay method was 
performed as previously described (Liu, Fang et al.,2001). SAT cells were grown to 
confluence. These cells were washed with PBS and incubated at 37 °C for 3 hours with 
KHB with BSA (0.01%) and glucose (5 mmol/L) and for insulin and serum starvation. 
At 37 °C, cells were incubated for 30 minutes with KHB either without glucose or BSA, 
and further treated with DMSO (control) or 100nM of insulin (Sigma # 19278) in the 
presence of 10nM or 100nM of liraglutide. 2-deoxy-[3 H]D-glucose [1 μCi/μl) 
(PerkinElmer) was then added and cells were incubated for 10 minute. Finally cells 
were washed and harvested, and cell lysate was then transferred to scintillation and 
radioactivity was then measured.  
 
5.2.5 Protein isolation, immunoprecipitation and western blotting   
 
Following treatments, cells were harvested for protein extraction and quantified 
(Jaubert, A. M. et al.,1995). Immunoprecipitation was preformed by the use of 
SureBeads, Protein A magnetic beads (Bio-Rad #161-4013), based on the 
manufacturers standard protocol. AGT antibody was added to the magnetic beads and 
re-suspended and rotated in room temperature. The magnetized and washed beads 
containing the antibody were then added to liraglutide/LPS samples and incubated and 
rotated in room temperature. The beads were then washed, magnetized, and centrifuged. 
Residual buffer was removed and the cells were incubated in laemmli buffer for 10 
minutes at 70 °C. Finally, the cells were magnetized and the eluent was ready for the 
western blot.  
 
For protein analysis, primary antibody AGT 1:5000 (ab103549) was utilised for western 
blot method as previously described (Alhusaini, Saif et al.,2010).  This procedure was 
replicated at least three times for each sample for all the time points.       
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5.2.6 Statistical analysis 
 
The data was reported as mean and SE. Shapiro-Wilks test was applied to normalize the 
data. Two-tailed paired sample t-test was used for the statistical analysis of between two 
groups and one-way ANOVA was used for multiple comparisons. All statistical 
analyses were preformed by using SPSS 24.0 software.   
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5.3 Results 
5.3.1 AGT protein expression in cultured mature SAT lean and obese adipocytes  
 
AGT protein expression was significantly higher in both lean and obese adipocytes at 
24 hours post treatment with LPS 10 ng/mL (p<0.05), however, obese adipocytes 
seemed more sensitive to the insult of LPS than lean adipocytes. This elevated AGT 
expression was significantly reduced at 48 and 72 hour treatments in lean and obese 
adipocytes in comparison to the 24 hour treatment (Figure 5.3.1.1 A). The effect of LPS 
100 ng/ml on AGT expression similarly to LPS 10 ng/ml is more dependent on time 
rather than the dose used (Figure 5.3.1.1 B).  
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5.3.1. 1 Angiotensinogen (AGT) protein expression in lean and obese adipose tissue 
treated with different concentrations of lipopolysaccharides over 24, 48 and 72 
hours. 
The graph shows the expression of AGT (molecular weight 50 kDa) in mature SAT 
adipocytes of lean and obese, treated with; A) LPS 10 ng/ml, B) LPS 100 ng/ml, three 
different time points. The absence of treatment was taken as the control. The data is 
expressed as mean  ± SEM (lean n=3, obese n=3); comparison between lean/obese and 
control group was analysed by t-test (* Represents p-value: *≤0.05, **≤0.01, 
***≤0.001). The comparison between lean and obese groups was performed by 
ANOVA analysis (# Represents p-value: #≤0.05, ##≤0.01, ###≤0.001).  
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The 24 hour treatment of liraglutide 10nM exerted a significant increase in AGT 
expression in obese adipocytes, while this treatment did not have any effect on the lean 
adipocytes in comparison to the control. However, despite the early rise in AGT 
expression, 72 hour treatment significantly reduced this expression in the adipocytes of 
lean and obese compared to the control (Figure 5.3.1.2 C). The effect of liraglutide 100 
nM on AGT expression similarly to the lower dose of liraglutide is more dependent on 
time rather than the dose used (Figure 5.3.1.2 D).   
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5.3.1. 2 Angiotensinogen (AGT) protein expression in lean and obese adipose tissue 
treated with different concentrations of liraglutide over 24, 48 and 72 hours. 
The graph shows the expression of AGT (molecular weight 50 kDa) in mature SAT 
adipocytes of lean and obese, treated with; C) Liraglutide 10 nM, D) Liraglutide 100 
nM, over three different time points. The absence of treatment was taken as the control. 
The data is expressed as mean  ± SEM (lean n=3, obese n=3); comparison between 
lean/obese and control group was analysed by t-test (* Represents p-value: *≤0.05, 
**≤0.01, ***≤0.001). The comparison between lean and obese groups was performed 
by ANOVA analysis (# Represents p-value: # ≤ 0.05, ## ≤ 0.01, ### ≤ 0.001).  
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Treatment with LPS 10 ng/ml + Liraglutide 10nM in obese adipocytes maintained an 
increase in AGT expression that was time dependent, with a significant increase at 24 
and 48 hours and a significant reduction at 72 hours in compared to the control. The 
effect of this treatment on lean adipocytes significantly increased the AGT expression at 
24 hours, while this expression was significantly reduced at 48 and 72 hours in 
comparison to the obese adipocytes and control (Figure 5.3.1.3 E). Treatment with LPS 
10 ng/ml + Liraglutide 100nM in obese and lean adipocytes on AGT expression had a 
similar time dependent effect as in LPS 10 ng/ml + Liraglutide 10nM (Figure 5.3.1.3 F).  
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5.3.1. 3 Angiotensinogen (AGT) protein expression in lean and obese adipose tissue 
treated with different concentrations of lipopolysaccharides and liraglutide over 
24, 48 and 72 hours. 
The graph shows the expression of AGT (molecular weight 50 kDa) in mature SAT 
adipocytes of lean and obese, treated with; E) LPS 10 ng/ml  + Liraglutide 10 nM, F) 
LPS 10 ng/ml + Liraglutide 100 nM, over three different time points. The absence of 
treatment was taken as the control plus vehicle. The data is expressed as mean  ± SEM 
(lean n=3, obese n=3); comparison between lean/obese and control group was analysed 
by t-test (* Represents p-value: *≤0.05, **≤0.01, ***≤0.001). The comparison between 
lean and obese groups was performed by ANOVA analysis (# Represents p-value: # ≤ 
0.05, ## ≤ 0.01, ### ≤ 0.001).  
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Compared to the control, AGT expression in obese adipocytes significantly elevated at 
24 and 48 hours, and was significantly reduced at 72 hours with LPS 100 ng/ml + 
Liraglutide 10nM treatment. While the effect of this treatment on lean adipocytes 
caused a significant increase in AGT expression at 24 hours and reduced significantly 
with 48 and 72 hours compared to the control (Figure 5.3.1.4 G). The effect of LPS 100 
ng/ml + Liraglutide 100nM treatment on AGT expression in obese and lean adipocytes 
were time dependent similar to the LPS 100 ng/ml + Liraglutide 10nM treatment 
(Figure 5.3.1.4 H). 
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5.3.1. 4 Angiotensinogen (AGT) protein expression in lean and obese adipose tissue 
treated with different concentrations of lipopolysaccharides and liraglutide over 
24, 48 and 72 hours. 
The graph shows the expression of AGT (molecular weight 50 kDa) in mature SAT 
adipocytes of lean and obese, treated with: G) LPS 100 ng/ml + Liraglutide 10 nM, H) 
LPS 100 ng/ml + Lira 100 nM, over three different time points. The absence of 
treatment was taken as the control. The data is expressed as mean  ± SEM (lean n=3, 
obese n=3); comparison between lean/obese and control group was analysed by t-test (* 
Represents p-value: *≤0.05, **≤0.01, ***≤0.001). The comparison between lean and 
obese groups was performed by ANOVA analysis (# Represents p-value: # ≤ 0.05, ## ≤ 
0.01, ### ≤ 0.001).  
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5.3.2 Liragutide stimulates proliferation in obese mature adipocytes 
 
Liraglutide at 10 nM and 100 nM did not alter lean adipocytes cell count over time in 
comparison with the control (Figure 5.3.2.1A). However, in the obese adipocytes 
liraglutide at both concentrations reduced cell proliferation significantly at both 24 and 
48 hour time points, however, by 72 hours proliferation rate appeared to increase in 
these cells with no significant difference with the control (Figure 5.3.2.1 B).  
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5.3.2. 1 Liraglutide inhibited obese adipocyte proliferation. 
Figure A and B represent liraglutide at 10 nM and 100 nM concentrations having an 
effect on cell count of lean and obese mature adipocytes, post 24h, 48h and 72 hours of 
treatment. The absence of treatment is represented as control. The cell count was 
performed by hemocytometer and the results are expressed as mean ± SEM (lean n=3, 
obese n=3); comparison between lean/obese and control group was analysed by t-test (* 
Represents p-value: *≤0.05, **≤0.01, ***≤0.001).  
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 5.3.3 Liraglutide increases glucose uptake  
 
Stimulating with 100nM of insulin in the presence of 10nM (Figure 5.3.3.1 A) and 
100nM (Figure 5.3.3.1 B) concentrations of liraglutide caused a significantly higher 
increase in glucose uptake in lean compared to the obese mature adipocytes treated for 
24, 48, and 72 hours. Glucose uptake in obese adipocytes treated with 100nM of 
liraglutide is significantly higher than adipocytes treated with 10nM, in all treatment 
periods (Figure 5.3.3.1 C).   
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5.3.3. 1 Liraglutide increased glucose uptake post insulin stimulation. 
Glucose uptake was performed in lean and obese mature SAT adipocytes after 
stimulation with insulin 100nM, in the presence of A) liraglutide 10nM and B) 
Liraglutide100nM. C) Comparison of glucose uptake between liraglutide 10 nM and 
100 nM in obese adipocytes. Results are expressed as means ± SEM (lean n=3, obese 
n=3) of glucose uptake fold increase versus the adipocytes without insulin treatment 
(control). The significant difference between lean/obese adipocytes versus the control 
has been evaluated by ANOVA analysis (* Represents p-value: *≤0.05, **≤0.01, 
***≤0.001).    
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5.4 Discussion 
 
This study investigated the effects of a GLP 1 agonist, liraglutide on the impact of 
inflammatory insults, cell proliferation and insulin sensitivity in differentiated mature 
adipocytes from obese and lean individuals. The immediate findings of this study 
highlighted that AGT expression was increased by LPS, which was not substantially 
mitigated by the acute (24 hours) co-treatment with liraglutide, in both lean and obese 
adipocytes. However as a consequence of longer treatment time, liraglutide did appear 
to reduce AGT expression overall. Additionally, in the obese adipocytes, liraglutide also 
appeared to initially reduce proliferation to a state less than the control, which only to 
returned to control levels by 72 hours. The lean and obese adipocytes subjected to 
liraglutide were observed to enhance insulin sensitivity, although this was more 
pronounced in the lean individuals than the obese subjects; highlighting the existence of 
partial insulin resistance within the obese adipocytes. Clearly the effects of liraglutide 
on Adipose-specific AGT, as well as regulating body weight via altering adipocyte 
proliferation, and, enhancing insulin sensitivity collectively plays an important role in 
making this drug beneficial for obesity related hypertension.  
 
 
In the present study, the LPS-induced endotoxemia effected AGT expression in both 
lean and obese mature adipocytes in a dose and time dependent manner. The 24-hour 
treatment with high dose of LPS stimulated significant increase in AGT levels, while 
the lowest expression was with the 72 hour treatment. It was expected that with longer 
exposure to LPS especially at a high dose, AGT expression would increase. However, 
mouse studies have shown that although adipocytes are extremely sensitive to LPS, pre-
adipocytes are significantly more responsive to LPS treatment especially at lower doses 
of LPS (20 ng/ml), whereas mature adipocytes are not greatly reactive to even the 
highest doses (2000 ng/ml) (Berg, A. H. et al.,2004). Additionally longer treatment time 
of these mature primary adipocytes with LPS has proven to be even less effective 
(Hoareau, Laurence et al.,2010).  
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The effect of Liraglutide treatment without the presence of LPS on AGT expression in 
obese adipocytes showed a dose and time dependent change. The 24-hour treatment 
with high dose of liraglutide led to a significant up-regulation, while the 72-hour 
treatment resulted in a significant down-regulation of AGT expression in obese 
adipocytes. These findings could be due to the effect that liraglutide has on adipocyte 
proliferation. With the 24 hour treatment, liraglutide does not initiate proliferation and 
appears to acts as an inhibitor, while by 72 hour treatment, it appears to lose this 
inhibition, therefore the proliferation of mature adipocytes returns to that as of the 
control cells. This effect may in part be explained through the involvement of PPARγ, a 
key adipocyte differentiation and proliferation regulator. Studies have shown that GLP-
1 (100nM) treatment increases the expression of PPARγ, in SAT (El Bekay, R. et 
al.,2016). PPARγ also as a human AGT promoter has been shown to regulate the 
activity of RAS and AGT in the same tissue (Safonova, I. et al.,1997, szer, Tamás et 
al.,2010, Gustavo-Salom et al.,2013). Therefore, it is possible that activating PPARγ by 
liraglutide requires a longer treatment period (72-hours), in order to result in a 
significant down-regulation of AGT expression in obese adipose tissue or adipocytes.  
 
The delay in stimulating proliferation at 24 hours can also be due to the specific doses 
used in the present study. The dose range (10-100nM) of liraglutide is compatible to 1.2 
-1.8 mg subcutaneous injections used in diabetic patients (Watson, E. et al.,2010, Jiang, 
J. et al.,2011). However a higher dose of 3.0 mg, which is recommended for obesity 
with co-morbidities such as hypertension (NICE,2017), may stimulate in-vitro obese 
adipocyte proliferation with the 24-hour treatment. In addition, this behaviour of 
liraglutide at 24 hours on proliferation in the present study may be specific to mature 
adipocytes. As liraglutide has been reported to have varying effects on differentiation 
and proliferation between species (rodent versus human) (Yang, J. et al.,2013, El 
Bekay, R. et al.,2016) and even between cell types (pre-adipocytes versus mature 
adipocytes) (Challa, T. D. et al.,2012, Cantini, Giulia et al.,2015).  
 
Obese mature adipocytes treated with liraglutide in the presence of LPS resulted in 
AGT expression to be up-regulated less than when these cells were treated with LPS 
alone at 24 hours, which would appear to be as a result of liraglutide treatment. The 
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high dose of liraglutide was significantly more effective at down-regulation of AGT 
expression at 72 hours even with the high dose of LPS present.     
 
Lean mature adipocytes treated with liraglutide did not result in any significant effect 
on AGT expression, nor did it have any significant effect on cell proliferation. 
Additionally, liraglutide with the presence of LPS mainly appeared to represent similar 
effects of that of LPS treatment alone on AGT expression in the lean adipocytes, where 
AGT expression was up-regulated at 24 hours, and reduced as the effect of LPS 
subsided with longer exposures. Studies have reported that obese adipocytes contain 
more GLP-1 receptor than the lean adipocytes (Vendrell, Joan et al.,2011, El Bekay, R. 
et al.,2016), which might explain the lack of effect that liraglutide had on lean 
adipocyte AGT expression in the present study.  
 
In this study, similar to other GLP-1 agonists, liraglutide stimulated glucose uptake in 
the obese and lean mature adipocytes. Although it can be speculated that the gradual 
increase in glucose uptake observed in lean adipocytes is mainly due to the origin of 
these cells and not the effect of liraglutide as such, as lean are more insulin sensitive 
than the obese adipocytes (Horowitz, Jeffrey F. et al.,2001). It appears that in the obese 
mature adipocytes liraglutide enhances insulin sensitivity, with the higher response at 
the 72 hour treatment, which may also relate to the rate of proliferation at this treatment 
time. Changes in insulin are known to directly effect AGT and blood pressure, with 
genetic studies noting that the AGT gene is directly associated with insulin sensitivity 
and resistance, and therefore changes in insulin resistance appear relevant to changes in 
AGT expression (Guo, X. et al.,2005, Underwood, Patricia C. et al.,2013). There maybe 
a possibility that in addition to liraglutides’ effect on changing proliferation that led to 
AGT down-regulation, reducing insulin resistance also contributes to the AGT 
reduction with the 72 hour treatment, in the obese adipocytes.  
 
There are a number of limitation to this study including: 1) the low number of lean and 
obese SAT samples. 2) Only adipocytes from women were used and therefore the 
effects on men could not be directly determined by this study. 3) SAT samples were 
obtained from non-menopausal women, therefore the results might differ in menopausal 
women.  
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5.5 Conclusions  
 
In-vitro, liraglutide appears to have a different impact depending on the origin and type 
of adipocytes. In mature adipocytes, 72 hour treatment with liraglutide 100 nM is 
capable of overcoming the inflammatory insult of LPS even at high dose, it is also 
effective at reducing insulin resistance and altering proliferation, all of which play a 
critical role in reducing AGT expression in obese adipose tissue. Therefore, these 
studies contribute to the beneficial effect of this multifunctional peptide, and the effect 
it has in adipose tissue in order to reduce obesity related hypertension.  
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CHAPTER 6: 
Biomarker assessment to detect T2DM status pre and post 
remission using urinary based analysis 
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6.1 Introduction 
 
An important factor to reduce the impact that T2DM has on individuals is early 
detection of non-diabetic hyperglycaemia, also known as the “pre-diabetes” state. Many 
studies suggest that the long-term complications of T2DM have already started to 
develop during the pre-diabetic stage, as the risk of cardiovascular disease is 2-3 fold 
higher in pre-diabetics in comparison to those with normal glucose levels (Pratley, R. 
E.,2013). As obesity is clearly the single most important and relevant risk for 
progression to T2DM (Gillett, M. et al.,2012), screening for pre-diabetes in overweight 
and obese individuals could be a cost effective approach to health care disease 
prevention. It has been estimated that NHS could save £132 million per year over 10 
years with the early detection and prevention of this disease (diabetes.org,2014). 
However, there is a worldwide inconsistency regarding which test is appropriate for 
diagnosis of pre-diabetes and, which diagnostic thresholds is more suitable (Barry, 
Eleanor,2017).  
 
Current accurate tests rely on a physician and/or allied healthcare professional to 
conduct an invasive blood based test to diagnose T2DM status, which may include 
fasting plasma glucose test, oral glucose tolerance test, and HbA1c test. These current 
tests also carry limitations, both in detection sensitivity and accuracy (Barry, E. et 
al.,2017). Furthermore there is reluctance by participants to undertake an invasive blood 
collection by needle use, as well as the need to provide a fasted sample with 
confirmation of diabetes status through oral glucose tolerance test and repeated sample 
acquisition. Therefore, there is a need for a convenient, non-invasive, and cost effective 
test that would act as an indicator of T2DM and stratify individuals, allowing only those 
with determined need to undergo further investigations. The use of urine as an 
alternative method to assess diabetes risk is seen as more acceptable and patients often 
provide such samples for other tests both at home or in primary care centres. 
 
In recent year there has been significant development in analytical procedures for 
identifying VOCs in urine, which has created the opportunity for participants’ urine to 
 136 
be used as a screening and detection tool in different types of cancer (Arasaradnam, R. 
P. et al.,2014, Khalid, Tanzeela et al.,2015, Mazzone, Peter J.,2015, Navaneethan, U. et 
al.,2015) and infectious diseases (Guernion, N. et al.,2001, Banday, K. M. et al.,2011). 
This same methodology to use urinary VOCs as a non-invasive early detection-
screening test could be used to detect T2DM. This method of detection may encourage 
those at risk to seek suitable diagnosis for any disease they are likely to have, something 
they may not have otherwise undertaken. This insight could therefore, result in an 
earlier diagnosis and more importantly better prognosis for participants.  Beyond the 
use of VOCs to detect T2DM status, it could also be further considered as a factor to 
assess whether T2DM remission has occurred following lifestyle, medical or surgical 
weight loss (Rubino, F. et al.,2016, Schauer, P. R. et al.,2016).  
 
Currently the most successful way to achieve T2DM remission appears to be through 
surgery. As surgery is expensive, many healthcare systems have eligibility criteria in 
place to ensure that the majority of participants’ achieve a successful outcome. 
Predicting who will achieve the best outcome is challenging, however, most bariatric 
clinics worldwide have a preoperative weight loss requirement, which participants must 
meet in order to be eligible for surgery. This requirement is put in place as it increases 
the probability of weight loss maintenance post-surgery (Ali, M. R. et al.,2007, Alger-
Mayer, S. et al.,2008, Solomon, H. et al.,2009). It may also improve the status of 
diabetes and other co-morbidities post-surgery, however the evidence on this is 
inconsistent (Brethauer, S.,2011, Ochner, C. N. et al.,2012). Therefore a predictive test 
that would identify the participants likelihood of improving their T2DM status post 
bariatric surgery would be beneficial in supporting the preoperative weight loss criteria, 
and identifying individuals that may need more support post-operatively to sustain good 
health outcomes. Urinary VOCs may suggest a means for such a medical test due to 
their potential alignment to metabolic health risk markers.  
 
Therefore the aims of this study was to investigate whether,  
 
1) Urinary VOCs can act as a convenient, non-invasive indicator of T2DM status and 
any change within the same individual over time. 
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2) Urinary VOCs be a predictive test that can be used as a pre-bariatric surgery indicator 
of post-surgery health and a means to stratify appropriate post care support. 
 
6.2 Subjects and Methods 
 
A cohort of 42 Caucasian adult women participants with morbid obesity (BMI ≥ 35 
kg/m2) and T2DM, who underwent different types of bariatric surgery; LAGB (n=14), 
SG (n=14) or BPD (n=14), were recruited. 
 
6.3 Study Design 
 
The participants of this study were recruited and had surgery in the Obesity clinic, 
Prague, Czech Republic. The urine was collected in standard universal sterile specimen 
containers and frozen at – 80 °C within a 2 hour of collection with subsequent batch 
analysis undertaken pre-surgery and 6 months post-surgery.   
 
6.4 Anthropometric and biochemical measures 
 
All measurements were performed at baseline and at 6 months post surgery. Blood was 
taken from all participants after a 10 hour fast.  HbA1c, serum glucose and lipids were 
measured using the Cobas 6000 analyzer. HOMA-IR was used to quantify insulin 
resistance by the following equation: HOMA-IR= fasting glucose (mmol/L) x fasting 
insulin (μU/L) / 22.5 (Matthews, D. R. et al.,1985). LDL cholesterol was calculated by 
using the Friedwald formula (Friedewald, W. T. et al.,1972). Height and weight were 
measured via standardised protocol. BMI was calculated as weight (in kilograms) / 
height2 (meters), and percentage excess weight loss was calculated by using the 
following equation: (preoperative weight - postoperative weight) / (preoperative weight 
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- ideal body weight) x 100. Body fat mass was measured using the bioimpedance 
method (Tanita TBF-300; Tanita corporation).  
Blood pressure data, which is presented as systolic over diastolic values, is the average 
of three BP readings with 5-minute resting period in between; these readings were taken 
by using an automated device. MAP was calculated by using: [(2diastolic BP + systolic 
BP) / 3] (Brzezinski., Walter A.,1990).  
 
6.5 Chemical Analysis and Instruments 
 
6.5.1 Field Asymmetric Ion Mobility Spectrometry (FAIMS) 
 
A Lonestar (Owlstone Ltd, UK) FAIMS unit was used to analyse the headspace of pre 
and post-operative urinary VOC samples from all participants. The FAIMS device used 
a 63Ni ionization mechanism. Unlike traditional analytical techniques, FAIMS is 
capable of separating gas molecules at both atmospheric pressure and room 
temperature.  Upon ionisation, the sample is passed through an oscillating electric field 
with an asymmetric high voltage waveform. Ions “zigzag” through the field and only 
ion species with no overall transverse motion pass through without deionising, based on 
properties of the waveform and the ion species. Certain properties of the waveform are 
then manipulated to identify the different ion species present in the analyte. 
 
6.5.2 FAIMS Analysis 
 
Urine samples were defrosted overnight to 5°C. For each sample a 5ml aliquot was 
pipetted into a 20ml glass sample bottle. This was then placed into an Owlstone ATLAS 
At-Line Sampling module attached to the Lonestar FAIMS unit. The ATLAS module 
heats the sample to 40°C, and introduces the headspace of the sample into the FAIMS 
for analysis. Four full sweeps of the dispersion field strength were carried out in 
succession for each sample. Before the first sample and between each sample, an air 
blank was run for three sweeps to allow any residue from the previous sample or other 
experiments to clear from the machine. No data was collected for these sweeps. 
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6.5.3 Data Analysis 
 
Each sample yielded eight 512 × 51 matrices, four positive and four negative ion counts 
across the tested compensation voltages and dispersion field strengths, for a total of 
208,896 variables per sample. As an initial step in the analysis of this data, the matrices 
were transformed using a discrete wavelet transformation. The levels of the transform 
corresponding to the two smallest-bandwidth passes were discarded to eliminate noise. 
Wavelet transformation is a common step in signal processing, and can help in 
separating structure from noise in an image, compressing the informative variables into 
fewer dimensions and consequently reducing the dimensionality of the data. After 
transforming the data, there were 52,224 variables per sample. Similarly to Fourier 
transforms, wavelet transforms create a representation of an image in an alternative 
basis space. However, in comparison to Fourier transforms, wavelet transforms capture 
information about both the size (or wavelength) of structures in the image, and 
information about where those structures occur. This helps to concentrate the useful 
information in the image into fewer predictors, which helps when selecting relevant 
features for classification tasks. To assess the ability of FAIMS analysis of urine 
samples in predicting diabetes status post-surgery, HOMA-IR was considered as a 
classification task. For HOMA-IR, the cohort was divided into two classes. Binning the 
data was necessary due to the small sample size (both FAIMS and indicator data were 
available for 25 participants) and the high dimensionality of the FAIMS data (52,224 
features), which hampered regression analysis. To perform the binning for this 
indicator, participants were divided into those with an indicator value which was less 
than or equal to the median value of the cohort (the “Low” group for that indicator), and 
those with a value above the median value of the cohort (the “High” group for that 
indicator). Participants who lacked data for this indicator were excluded from further 
analysis. FAIMS data was available for 25 participants, and indicator data was available 
from at least 24 participants for each indicator.  
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6.5.4 Statistical analysis 
 
This analysis was followed by the MWW test to rank features according to how well 
they separate the cohort into High and Low classes. The top number features were then 
taken forward and used to train a classification model, with n and the classification 
model selected using a separate cross-validation analysis. Four learning algorithms were 
considered: radial SVM, sparse logistic regression, logistic regression, and random 
forests. To assess the performance of HOMA-IR, 10-fold cross validation was used to 
produce predicted classes for each participants, with both feature selection and model 
creation being carried out in the cross-validation. Classification performance was 
assessed by using the Receiver Operating Characteristic (ROC) curve, which is defined 
by the area under the curve (AUC).  
 
6.6 Results 
 
6.6.1 Body composition and metabolic variables 
 
Clinical and anthropometric data obtained from 42 obese-T2DM women participants 
before undergoing bariatric surgery and 6 months after were collected and analysed 
(Table 6.6.1). All participants had significant reduction in all weight indices, except 
waist to hip ratio (WHR). Participants showed improvements in their blood pressure, 
with systolic and mean arterial pressure (MAP) markers significantly reduced. There 
was a significant improvement in HbA1c, plasma glucose, plasma insulin, HOMA-IR, 
and all participants were in T2DM remission at 6 months post surgery. Although lipid 
markers overall reduced; only total cholesterol and triglycerides were shown to 
significantly reduce (P<0.01).  
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            6.6. 1 Anthropometric and metabolic variables at pre (baseline) and post (6 months) bariatric surgery. 
Continues variables are represented as mean and standard error. BMI-body mass index; WHR-waist to hip ratio; MAP-mean arterial  
pressure; HbA1c-glycated haemoglobin; HOMA-IR- Homeostatic assessment model of insulin.  LDL-low density lipoprotein; HDL-high 
density lipoprotein.(*Represents P-Values: * p≤0.05, ** p≤0.01, *** p≤0.001).  
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6.6.2 Volatile organic compounds differentiated between pre and post-operative 
urine 
 
The findings from the urine VOC analysis identified the change between pre and post-
operative VOCs, with sensitivity of 0.72 (95% CI: 0.51-0.88) and specificity of 0.70 
(95% CI: 0.50-0.86). The AUC was 0.76 (95% CI: 0.62-0.9).  
 
 
 
 
6.6. 2 Receiver operator characteristic (ROC) curve for pre and post operative 
urine. 
Receiver operator characteristic (ROC) curve analysis illustrates the accuracy for 
identifying pre operative VOCs verses 6 months post operative urinary VOCs, 
which was established by using a classification algorithm.   
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6.6.3 Identification between pre- operative VOCs and post-operative T2DM status  
 
Urinary VOCs highlight the change between pre-operative VOCs and the participant’s 
T2DM status at 6 months post-surgery, with the sensitivity of 0.83 (95% CI: 0.52-0.98) 
and specificity of 0.82 (95% CI: 0.48-0.98). The AUC=0.88 (95% CI: 0.74, 1.00).  
 
 
 
6.6. 3 Receiver operator characteristic (ROC) curve for pre-operative VOCs 
and post operative T2DM status. 
(ROC) curve analysis illustrates the accuracy for identifying between pre-
operative VOCs and post-operative HOMA-IR status, by using a classification 
algorithm. 
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6.6.4 Identification between post-operative volatile organic compounds and post-
operative T2DM status 
 
Further analysis indicated the urinary VOCs at 6 months post-surgery identifying the 
T2DM status of the participants at 6 months post-surgery with sensitivity of 0.80 (95% 
CI: 0.44-0.97) and specificity of 0.80 (CI: 0.52-0.96). The AUC= 0.93 (95% CI: 0.83-
1.00). 
 
 
 
 
6.6. 4 Receiver operator characteristic (ROC) curve for post-operative VOCs 
and post operative T2DM status. 
(ROC) curve analysis illustrates the accuracy for identifying the between post-
operative VOCs and post-operative HOMA-IR status, by using a classification 
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6.7 Discussion 
 
The findings of this study indicate that urinary VOCs could firstly act as a non-invasive 
indicator of T2DM status, but also be a factor to determine probable health outcome 
following bariatric surgery. It is known that urinary VOC profiles differ with health 
conditions, which is also confirmed in this study with regards to alignment to T2DM. 
This distinction was demonstrated due to assessment of VOCs pre- and post- bariatric 
surgery and the correlation that urinary VOCs have with T2DM status at 6 months post 
bariatric surgery.  
 
The current data suggests a method to provide a highly correlated VOC profile to 
T2DM status as a convenient, non-invasive and cost effective test for T2DM that would 
identify individuals that are in need of further investigations much earlier than it is 
currently occurring. The results of this study suggest that VOC analysis of urine 
samples could fulfil this need, leading to earlier diagnosis and better prognosis. This 
would also reduce the cost to healthcare system, as less co-morbidity would occur with 
early diagnosis.  
 
Additionally with the significant correlation between pre-surgery urinary VOCs and 
diabetic status at 6 months post-surgery, which was observed in this study, can reveal an 
exciting potential to use VOC analysis as part of the selection criteria for individuals 
undergoing bariatric surgery. Utilised alongside the current weight loss criteria most 
hospitals have in place, VOC profiles could identify those participants who, despite 
losing the required weight, may need more assistance post-surgery to improve their 
diabetic status.  
 
Whilst the potential of VOC analysis for diagnosis of T2DM has been discussed before, 
the main focus of this study is the analysis of VOCs emanating from exhaled breath, 
and not the use of FAIMS technology (Phillips, M. et al.,2004, Minh Tdo, C. et 
al.,2012, Kim, iI-Doo et al.,2015, Das, S. et al.,2016). Many studies use techniques that 
are time consuming, expensive, and require highly trained specialist staff, such as gas 
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chromatography-mass spectrometry. Several researchers have used Electronic Nose 
(eNOSE) technology to detect T2DM in breath samples (Arasaradnam, R. P. et 
al.,2011, Sabeel, T. M. A. et al.,2013, Seesaard, Thara et al.,2016), however this 
technique suffers from poor intra-device repeatability, limited temporal stability and 
poor chemical selectivity (Boyle, Billy et al.,2018). FAIMS technology does not suffer 
from these problems and is highly sensitive, measuring parts per trillion rather than 
parts per billion (Khalid, Tanzeela et al.,2015), as it measures the physical composition 
of the analyte as opposed to the chemical composition. This results in it being much less 
susceptible to adverse interactions between the analyte and the sensor, and thus 
provides more consistent measurements over time. Urinary VOC analysis using FAIMS 
technology has previously been shown to successfully detect colorectal cancer in 
individuals (Khalid, Tanzeela et al.,2015), as does the results of this study with regards 
to T2DM. 
 
Whilst these results reveal the potential for the use of VOCs in the future of T2DM 
diagnosis and bariatric surgery, the limitation was that the cohort of participants in this 
study consisted only of post-menopausal female Caucasians. As such, this work may 
benefit from a future study with a more diverse and greater number of participants.  
 
 
6.8 Conclusions 
 
This study has demonstrated that the unique chemical fingerprint of VOCs present in 
urine can be used to identify individuals with T2DM, as well as to predict the T2DM 
status following bariatric surgery. This highlights the potential of using urine as a 
screening tool to identify individuals who are at risk of T2DM, as well as to identify 
those that may benefit from further assistance to improve diabetic status following 
bariatric surgery in the future. 
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Chapter 7: Conclusions 
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This current thesis explored and evaluated the effects that different types of bariatric 
surgery on cardio-metabolic improvements as well as disease resolution, inflammatory 
markers and endocrine hormones in women with obesity and cardio-metabolic 
comorbidities. Additionally this thesis sought to consider a way to monitor such 
changes as a predictive tool using urinary VOCs as a detection tool.  
 
A prior literature review into the outcomes of different bariatric surgeries indicated the 
effectiveness of the three procedures as treatments for obesity and obesity related 
cardio-metabolic disease. Specifically studies have reported that BPD which is a 
combination of restrictive and malabsorpative procedures, results in a greater weight 
loss than compared with restrictive surgeries such as SG and LAGB. However, BPD 
patients are often reported to have metabolic related complications (Anderson, Blaire et 
al.,2013, Roslin, Mitchell et al.,2018). Therefore since white adipose tissue plays a 
fundamental role in inflammation and metabolic health in obesity, it was hypothesised 
that various types of bariatric surgery impact adipose tissue inflammatory markers 
differently, which can directly influence the improvement in cardio-metabolic disease, 
despite the amount of weight loss post-operation. Therefore, initial studies in chapter 3, 
analysed the inflammatory MYD88-dependent pathway in abdominal SAT (pre and 
post-surgery) from bariatric patients as a mechanism for resolution of inflammation. 
Whilst all participants across the three surgery types led to significant weight loss, with 
BPD surgery resulting in the highest weight loss, the improvement in cardio-metabolic 
components, and the disease resolution was lower in these participants in comparison 
with the individuals that underwent the other two surgeries, SG and LGB. Further 
investigation of circulating endotoxin and pro-inflammatory/cardiovascular marker such 
as IL-6, revealed continued inflammation at 6 months post BPD. The elevated IL-6 
concentration explained the subsequent dyslipidaemia, and therefore the lack of 
improvement in the cardio-metabolic components observed at 6 months post-surgery. 
This study offers an insight into the fact that all aspects of BPD surgery (surgical 
procedure and time, recovery time, accelerated weight loss, post-surgical malnutrition) 
maintained an inflammatory response in their abdominal SAT for at least the first 6 
months post-surgery. As a result of this the individuals that underwent BPD surgery 
could still be at risk of cardiovascular disease posed by adipose tissue.  
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Subsequent studies explored the effects of SG, LAGB and BPD surgeries on endocrine 
hormones that govern cardio-metabolic disease recovery post-surgery. Although there 
are studies supporting the involvement of FGF-19 and FGF-21 in cardio-metabolic 
recovery post bariatric surgery (Kyrou, I. et al.,2017, Patton, A. et al.,2017), there exists 
conflicting data on the behaviour of FGF-19 post-bariatric surgery, in addition, to the 
lack of research on the effect of LAGB on these hormones. Therefore, the aims in 
chapter 4 of these studies were firstly to define the effects of SG, LAGB and BPD on 
FGF-19 and FGF-21 concentrations pre and post-surgery, and evaluate the changes in 
these endocrine hormones based on the cardio-metabolic risks at 6 months post surgery. 
Secondly, by using glucose and lipid markers, the effects of FGF-19 and FGF-21 were 
compared with cardio-metabolic risk factors. The findings from these studies 
demonstrated that the highest post-operative FGF-19 and the lowest FGF-21 
concentrations were noted in SG participants, these subjects were also observed to have 
the lowest cardio-metabolic risk at 6 months post-surgery. Both FGF-19 and FGF-21 
reduced in LAGB participants, this unexpected effect on FGF-19 could have been due 
to the lack of gastrointestinal anatomy changes in this surgery. Despite the amount of 
high weight loss in BPD, FGF-19 increase and FGF-21 decrease was not more than 
observed in the SG participants. As such these studies may offer a potential novel 
prospect for the use of FGF-19 status post-surgery as a marker for the prediction of 
metabolic improvement in glucose, while FGF-21 could be used as a marker of lipid 
status prediction at 6 months post BPD surgery.  
 
Collectively the findings from Chapters 3 and 4 of this thesis emphasized that despite 
achieving great weight loss, BPD could be considered as an unsuitable and somewhat 
harmful procedure. As this surgery type leads to lack of significant improvement in 
FGF-19 and FGF-21, in addition to persistence of an inflammatory status, with less 
improvements in cardio-metabolic components, lower disease resolution than other 
surgeries; whilst it may still place patients at risk of cardiovascular disease at 6 months 
post surgery. Although unlike BPD surgery, SG surgery does not result in as much 
weight loss in comparison to BPD in the first 6-month post-surgery, it is more 
beneficial for the cardio-metabolic disease resolution, as well as improvements in FGF-
19 and FGF-21 endocrine hormone.  
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Besides bariatric surgery consideration to reduce cardio-metabolic risk and 
inflammation, evidence suggests liraglutide may have positive effects on white adipose 
tissue metabolism and inflammation, which would appear to enhance this anti-diabetic 
medication as an effective anti-obesity agent as well. Studies with liraglutide have 
shown this medication has modest impact on reducing blood pressure in obese-
hypertensive individuals. In addition, in-vitro studies have shown the metabolic effects 
of liraglutide on RAS, and its components in various tissues as well (Harte, A. et 
al.,2005). Secreted by mature adipocytes, adipose specific AGT influences and 
contributes to the systemic RAS, therefore plays an important role in the development 
of obesity related hypertension and insulin resistance. Furthermore, as endotoxin can 
induce AGT expression this adds weight to inflammation’s influence on hypertension. 
As such in these studies it has been hypothesised that liraglutide may exert its 
antihypertensive influence by firstly mediating a direct effect on AGT, and reducing the 
insult of endotoxin LPS on obese mature adipocytes. Secondly liraglutide can enhance 
insulin sensitivity in adipose tissue. Therefore, this thesis, in, explored the role of 
liraglutide in adipocyte, which down-regulated AGT alone and in response to LPS 
given chronically. In addition, liraglutide initially appeared to reduce cell proliferation 
with acute treatment, whilst this effect was observed to lessen over a longer duration. 
Liraglutide also appeared to enhance insulin sensitivity in lean and obese mature 
adipocytes although this effect was reduced in adipocytes from obese patients.  
 
Ultimately early detection and diagnosis of T2DM is greatly beneficial at reducing the 
onset of additional obesity related cardio-metabolic disease, and therefore reducing 
mortality rates. Review of current early detection methods revealed that current tests 
appear invasive, time consuming and often unreliable due to lack of appropriate 
sensitivity. Urinary VOCs have been successfully used for the detection and screening 
of diseases such as different cancers and infection diseases. Therefore chapter 6 
investigated whether urinary VOCs could be utilized as a convenient, non-invasive 
indicator of T2DM status, as well as detecting any change in this status over a period of 
time within the same individual. Additionally whether urinary VOCs have the potential 
of being used as a predictive test that can be used as a pre-bariatric surgery indicator of 
the post-surgery health outcome, for a more appropriate post care support and treatment 
method. The findings from VOC profiling of urine headspace indicated that urinary 
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VOCs could be used with good reliability and specificity in detection of T2DM status. 
Urinary VOCs showed the capability of differentiating between pre-and post bariatric 
VOCs, as well as post-bariatric T2DM status was predicted with the use of pre-bariatric 
VOCs. Therefore this unique chemical fingerprint has the potential to be used as a 
convenient, non-invasive, cost effective tool for screening and detection of T2DM, and 
as a predictive test for the outcome of T2DM status post-bariatric surgery.  
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7.1 Limitations 
 
There are several limitations in these studies, in that the current cohort although 
clinically well characterised, only examined white Caucasian females therefore the 
effect that ethnicity and gender may have had on the surgical and tissue responses could 
not be examined. Ethnicity is important, as we know for a given BMI South Asian 
subjects would be at higher cardio-metabolic risk, which is also comparable for male 
participants compared with pre-menopausal women.  These studies were also not able 
to directly extract adipocytes to culture cells from the bariatric patients’ pre and post-
surgery due to the logistical of collecting appropriate sample sizes. As such, the cell 
culture studies utilised a group of lean and obese individual’s adipocyte cells, which 
evaluated cell insulin sensitivity prior to any treatment and analysis. However the use of 
lean and obese derived adipocytes cells did allow the differences in insulin sensitivities 
to highlight how this altered cellular function responses. This would not necessarily 
have been observed in the bariatric adipose tissue samples, as despite the loss in weight 
the tissue remained inflammatory.  
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7.2 Future work 
 
This thesis has highlighted a few areas that may be useful to study in the future. In 
regards to the liraglutide study it would be useful to design a larger range of liraglutide 
concentrations with longer series of treatment times, in order to analyse the effect of 
this medication on adipogenesis. It may also be beneficial to compare the effect of this 
medication in different human cell types such as; mature adipocytes versus pre-
adipocytes, subcutaneous adipocytes versus visceral adipocytes, obese adipocytes 
versus morbidly obese adipocytes. This would allow studies to evaluate depot and 
cellular differences in response to medication on RAS. Additionally investigating into 
vital transcription factors that strongly regulates differentiation such as PPARα and 
adipocyte differentiation-related protein (ADRP) and fatty acid binding protein 4 
(FABP4), could provide a further insight into the effect of liraglutide on these 
mechanisms.  
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7.3 Final conclusions  
 
In conclusion, this thesis investigated the impact of various treatment types from 
invasive bariatric surgery to pharmaceutical therapies such as liraglutide on the insult of 
endotoxin LPS and adipose tissue inflammation, and therefore, obesity related cardio-
metabolic risk. This thesis further investigated the potential of utilizing VOCs as 
biomarkers for detection of T2DM status.  
 
The findings of these studies highlighted:  
 
1. SG in comparison to BPD is more suitable for the improvements of endocrine 
hormones FGF-19 and FGF-21 and for obesity related cardio-metabolic disease 
resolution, post surgery.  
2. Liraglutide subsides LPS inflammatory effect and down-regulates adipose 
specific AGT expression, while enhancing insulin sensitivity in obese mature 
adipose tissue in a time dependent manner.  
3. Urinary VOCs have the potential of being used as a non-invasive, cost effective, 
early detection test for T2DM and possibly as a predictive test for the outcome 
of T2DM status post bariatric surgery.   
 
The initial aims that were set for this thesis were met according to the findings 
established. In regards to the bariatric studies, the findings of this thesis adds a new 
dimension to the numerous limitations of the BPD surgery, and although the rate of 
BPD performance has reduced worldwide, this study highlights the importance of 
keeping a close observation and follow-up of patients that have to undergo this 
procedure, especially for the first 6 months post-operation.  
 
This study sets the foundations for understanding the mechanisms involved in the 
beneficial effect of liraglutide on hypertension. Since liraglutide is already used for the 
treatment of T2DM and obesity, the potential use of this medication as an anti-
hypertensive therapy as well, could be useful for obese-T2DM hypertensive individuals. 
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Liraglutide in a form of a monotherapy for obese individuals could reduce the burden of 
multi-medication use, which may be more cost effective and time efficient for patients. 
Furthermore, the simplicity and the non-invasiveness of urinary VOCs as an early 
detection test for T2DM, could encourage far more individuals to get tested, resulting in 
early detection and management of disease, and delaying the onset of severe disease 
complications that would reduce life expectancy. Additionally, utilizing VOCs as a 
predictive test for the outcome of T2DM post bariatric surgery can provide the 
opportunity for selecting the patients that would benefit from further assistance in 
improving their diabetic status following bariatric surgery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 156 
Bibliography 
 A., L. M., et al. (2014). "Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects." Clinical Endocrinology 81(6): 862-870. Abdellaoui, A., et al. (2007). "C-Reactive Protein (CRP) as a Marker in Peripheral Vascular Disease." European Journal of Vascular and Endovascular Surgery 34(1): 18-22. ADA (2017). "Standards of Medical care in diabetes-2017." Journal of Clinical and applied research and education 40: 82. Adami, G. F., et al. (2003). "Plasma ghrelin concentratin in the short-term following biliopancreatic diversion." Obes Surg 13(6): 889-892. Adams, A. C., et al. (2013). "The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue." Molecular Metabolism 2(1): 31-37. Agustí, A., et al. (2018). "Interplay Between the Gut-Brain Axis, Obesity and Cognitive Function." Frontiers in Neuroscience 12(155). Albaugh, V., et al. (2016). Recent advances in metabolic and bariatric surgery [version 1; referees: 2 approved]. Albert, M. A. (2000). "The role of C-reactive protein in cardiovascular disease risk." Curr Cardiol Rep 2(4): 274-279. Alberti, G., et al. (2006). "The international Diabetes federation consensus worldwide definition of the METABOLIC SYNDROME  ", from https://www.idf.org/e-
library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-
syndrome.html. Alberti, K. G., et al. (2006). "Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation." Diabet Med 
23(5): 469-480. Alger-Mayer, S., et al. (2008). "Preoperative weight loss as a predictor of long-term success following Roux-en-Y gastric bypass." Obes Surg 18(7): 772-775. Alhusaini, S., et al. (2010). "Lipopolysaccharide, high glucose and saturated fatty acids induce endoplasmic reticulum stress in cultured primary human adipocytes: Salicylate alleviates this stress." Biochem Biophys Res Commun 397(3): 472-478. Alhusaini, S., et al. (2010). "Lipopolysaccharide, high glucose and saturated fatty acids induce endoplasmic reticulum stress in cultured primary human adipocytes: Salicylate alleviates this stress." Biochemical and Biophysical Research Communications 397(3): 472-478. Ali, M. R., et al. (2007). "Weight loss before gastric bypass: feasibility and effect on postoperative weight loss and weight loss maintenance." Surg Obes Relat Dis 3(5): 515-520. Allende, L. M., et al. (1998). "Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding." Immunology 94(4): 543-551. Anderson, B., et al. (2013). "Biliopancreatic Diversion: The Effectiveness of Duodenal Switch and Its Limitations." Gastroenterology Research and Practice 
2013: 974762. Anderson, B., et al. (2013). "Biliopancreatic Diversion: The Effectiveness of Duodenal Switch and Its Limitations." Gastroenterology Research and Practice 
2013: 8. 
 157 
Angelin, B., et al. (2012). "Circulating fibroblast growth factors as metabolic regulators--a critical appraisal." Cell Metab 16(6): 693-705. Arasaradnam, R. P., et al. (2014). "Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis." PLoS One 9(9): e108750. Arasaradnam, R. P., et al. (2011). "Insights into 'fermentonomics': evaluation of volatile organic compounds (VOCs) in human disease using an electronic 'e-nose'." J Med Eng Technol 35(2): 87-91. Arner, P., et al. (2008). "FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity." FEBS Lett 582(12): 1725-1730. Arsenault, B. J., et al. (2011). "Lipid parameters for measuring risk of cardiovascular disease." Nat Rev Cardiol 8(4): 197-206. Asamizu, S., et al. (2009). "Angiotensin II enhances the increase in monocyte chemoattractant protein-1 production induced by tumor necrosis factor-{alpha} from 3T3-L1 preadipocytes." J Endocrinol 202(2): 199-205. Astiarraga, B., et al. (2013). "Biliopancreatic diversion in nonobese patients with type 2 diabetes: impact and mechanisms." J Clin Endocrinol Metab 98(7): 2765-2773.  
 158 
Astrup, A., et al. (2012). "Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide." Int J Obes (Lond) 36(6): 843-854. Baker, A. R., et al. (2009). "Epicardial adipose tissue as a source of nuclear factor-kappaB and c-Jun N-terminal kinase mediated inflammation in patients with coronary artery disease." J Clin Endocrinol Metab 94(1): 261-267. Banday, K. M., et al. (2011). "Use of urine volatile organic compounds to discriminate tuberculosis patients from healthy subjects." Anal Chem 83(14): 5526-5534. Banerjee, R. R., et al. (2004). "Regulation of fasted blood glucose by resistin." Science 303(5661): 1195-1198. Barry, E. (2017). "Why the term 'prediabetes' may cause more harm than good." Pharmaceutical Journal. Barry, E., et al. (2017). "Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions." Bmj 356: i6538. Bartelt, A., et al. (2014). "Adipose tissue browning and metabolic health." Nat Rev Endocrinol 10(1): 24-36. Batterham, R. L., et al. (2016). "Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery." Diabetes Care 39(6): 893-901. Bays, H. E., et al. (2007). "The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys." Int J Clin Pract 61(5): 737-747. Bener, A., et al. (2013). "Obesity index that better predict metabolic syndrome: body mass index, waist circumference, waist hip ratio, or waist height ratio." J Obes 
2013: 269038. Bennett, C. M., et al. (2007). "HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review." Diabet Med 24(4): 333-343. Berg, A. H., et al. (2004). "Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity." Am J Physiol Endocrinol Metab 287(6): E1178-1188. Bernal-Lopez, M. R., et al. (2011). "HbA(1c) in adults without known diabetes from southern Europe. Impact of the new diagnostic criteria in clinical practice." Diabet Med 28(11): 1319-1322. Beysen, C., et al. (2012). "Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study." Diabetologia 55(2): 432-442. Blackburn, D. F., et al. (2006). "Antihypertensive medications and blood sugar: Theories and implications." The Canadian journal of cardiology 22(3): 229-233. BonDurant, L. D., et al. (2017). "FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms." Cell Metabolism 25(4): 935-944.e934. Bonora, E., et al. (2011). "The Pros and Cons of Diagnosing Diabetes With A1C." Diabetes Care 34(Suppl 2): S184-S190. Boyle, B., et al. (2018). "owlstone medical." from 
https://www.owlstonemedical.com/science-technology/faims-technology/. Brethauer, S. (2011). "ASMBS Position Statement on Preoperative Supervised Weight Loss Requirements." Surg Obes Relat Dis 7(3): 257-260. 
 159 
Brufau, G., et al. (2010). "Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism." Hepatology 52(4): 1455-1464. Brzezinski., W. A. (1990). Blood Pressure, Clinical Methods: The History, Physical, and Laboratory Examinations. Buchwald, H., et al. (2004). "Bariatric surgery: a systematic review and meta-analysis." Jama 292(14): 1724-1737. Buchwald, H., et al. (2002). "Evolution of operative procedures for the management of morbid obesity 1950-2000." Obes Surg 12(5): 705-717. Callahan, H. S., et al. (2004). "Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans." J Clin Endocrinol Metab 89(3): 1319-1324. Campbell, D. J. (1987). "Circulating and tissue angiotensin systems." J Clin Invest 
79(1): 1-6. Cantini, G., et al. (2015). "Effect of liraglutide on proliferation and differentiation of human adipose stem cells." Molecular and Cellular Endocrinology 402: 43-50. Cantini, G., et al. (2015). "Effect of liraglutide on proliferation and differentiation of human adipose stem cells." Mol Cell Endocrinol 402: 43-50. Cao, Y. (2007). "Angiogenesis modulates adipogenesis and obesity." The Journal of Clinical Investigation 117(9): 2362-2368. Capurso, C., et al. (2012). "From excess adiposity to insulin resistance: the role of free fatty acids." Vascul Pharmacol 57(2-4): 91-97. Carlsson, L. M., et al. (2012). "Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects." N Engl J Med 367(8): 695-704. Carlyle, M., et al. (2002). "Chronic cardiovascular and renal actions of leptin: role of adrenergic activity." Hypertension 39(2 Pt 2): 496-501. Cassis, L. A., et al. (2008). "Local Adipose Tissue Renin-Angiotensin System." Current hypertension reports 10(2): 93-98. Challa, T. D., et al. (2012). "Regulation of adipocyte formation by GLP-1/GLP-1R signaling." J Biol Chem 287(9): 6421-6430. Chau, M. D., et al. (2010). "Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway." Proc Natl Acad Sci U S A 107(28): 12553-12558. Chen, L., et al. (2012). "Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes." Am J Physiol Endocrinol Metab 302(1): E68-76. Chen, W., et al. (2011). "Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes." J Biol Chem 286(40): 34559-34566. Chow, W. S., et al. (2013). "Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors." Arterioscler Thromb Vasc Biol 33(10): 2454-2459. Chrysohoou, C., et al. (2007). "The implication of obesity on total antioxidant capacity in apparently healthy men and women: the ATTICA study." Nutr Metab Cardiovasc Dis 17(8): 590-597. Chung, J. O., et al. (2012). "Associations among body mass index, insulin resistance, and pancreatic beta-cell function in Korean patients with new-onset type 2 diabetes." Korean J Intern Med 27(1): 66-71. 
 160 
Cooney, M. T., et al. (2009). "HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk." Atherosclerosis 
206(2): 611-616. Cosson, E., et al. (2011). "What would be the outcome if the American Diabetes Association recommendations of 2010 had been followed in our practice in 1998-2006?" Diabet Med 28(5): 567-574. Creager, M. A., et al. (1985). "Beta adrenergic-mediated vasodilator response to insulin in the human forearm." J Pharmacol Exp Ther 235(3): 709-714. Creely, S. J., et al. (2007). "Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes." Am J Physiol Endocrinol Metab 292(3): E740-747. Crujeiras, A. B., et al. (2017). "Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress?" Int J Obes (Lond) 41(10): 1570-1578. Cummings, D. E., et al. (2001). "A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans." Diabetes 50(8): 1714-1719. D., H., et al. (2013). "Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects." Obesity 21(7): 1335-1342. Danesh, J., et al. (2008). "Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review." PLoS Med 5(4): e78. Das, S., et al. (2016). "Significance of Exhaled Breath Test in Clinical Diagnosis: A Special Focus on the Detection of Diabetes Mellitus." J Med Biol Eng 36(5): 605-624. Davidson, M. H., et al. (1999). "Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial." JAMA 
281(3): 235-242. Davy, K. P., et al. (2004). "Obesity and hypertension: two epidemics or one?" Am J Physiol Regul Integr Comp Physiol 286(5): R803-813. de Courten, M., et al. (1993). "Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension." Eur J Clin Pharmacol 44(5): 457-462. de Ferranti, S., et al. (2008). "The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences." Clin Chem 54(6): 945-955. De Lima, L. G., et al. (2013). "Beta-blockers for preventing stroke recurrence." Cochrane Database Syst Rev 5: CD007890. de Simone, G., et al. (2001). "[Systolic, diastolic and pulse pressure: pathophysiology]." Ital Heart J Suppl 2(4): 359-362. Degirolamo, C., et al. (2016). "Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23." Nat Rev Drug Discov 15(1): 51-69. Deng, J., et al. (2004). "Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2." Mol Cell Biol 
24(23): 10161-10168. diabetes.org (2014). The cost of Diabetes Report. Dias, V., et al. (2013). "The Role of Oxidative Stress in Parkinson’s Disease." Journal of Parkinson's disease 3(4): 461-491. 
 161 
Dimitriadis, G. K., et al. (2017). "Potential Hormone Mechanisms of Bariatric Surgery." Curr Obes Rep 6(3): 253-265. Duarte, J. D., et al. (2010). "Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics." Expert review of cardiovascular therapy 8(6): 793-802. Duncan, R. E., et al. (2007). "Regulation of Lipolysis in Adipocytes." Annual review of nutrition 27: 79-101. Dutchak, Paul A., et al. (2012). "Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones." Cell 148(3): 556-567. Duvnjak, M., et al. (2007). "Pathogenesis and management issues for non-alcoholic fatty liver disease." World J Gastroenterol 13(34): 4539-4550. Eckel, R. H., et al. (2011). "Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?" Diabetes Care 34(6): 1424-1430. Einarsson, K., et al. (1991). "Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism." Eur J Clin Pharmacol 40 Suppl 1: S53-58. El Bekay, R., et al. (2016). "Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes." Br J Pharmacol 173(11): 1820-1834. El Bekay, R., et al. (2016). "Effects of glucagon‐ like peptide‐1 on the differentiation and metabolism of human adipocytes." British Journal of Pharmacology 173(11): 1820-1834. Eldar, S., et al. (2011). "Bariatric surgery for treatment of obesity." Int J Obes (Lond) 35 Suppl 3: S16-21. Engelgau, M., et al. (2003). "Screening for Type 2 Diabetes." American Diabetes Assosiation 26. Engeli, S., et al. (2003). "The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?" Int J Biochem Cell Biol 35(6): 807-825. Engeli, S., et al. (2003). "The adipose-tissue renin–angiotensin–aldosterone system: role in the metabolic syndrome?" The International Journal of Biochemistry & Cell Biology 35(6): 807-825. Eringa, E. C., et al. (2007). "Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue." Microcirculation 14(4-5): 389-402. Esposito, K., et al. (2006). "Oxidative stress in the metabolic syndrome." J Endocrinol Invest 29(9): 791-795. Farb, M. G., et al. (2011). "Reduced Adipose Tissue Inflammation Represents an Intermediate Cardiometabolic Phenotype in Obesity." Journal of the American College of Cardiology 58(3): 232-237. Farhan, S., et al. (2012). "Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in patients with coronary artery disease." Clin Res Cardiol 
101(8): 625-630. Fernández-Sánchez, A., et al. (2011). "Inflammation, Oxidative Stress, and Obesity." International Journal of Molecular Sciences 12(5): 3117-3132. Filippatos, T. D., et al. (2010). "Combination drug treatment in obese diabetic patients." World Journal of Diabetes 1(1): 8-11. Fisher, f. M., et al. (2010). "Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State." Diabetes 59(11): 2781-2789. 
 162 
Fisher, F. M., et al. (2012). "FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis." Genes Dev 26(3): 271-281. Fjeldborg, K., et al. (2017). "Reduction in serum fibroblast growth factor-21 after gastric bypass is related to changes in hepatic fat content." Surg Obes Relat Dis 
13(9): 1515-1523. Flannery, S., et al. (2010). "The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling." Biochem Pharmacol 80(12): 1981-1991. Flynn, C. R., et al. (2015). "Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery." Nature Communications 6: 7715. Foster, M. C., et al. (2011). "FATTY KIDNEY, HYPERTENSION, AND CHRONIC KIDNEY DISEASE: THE FRAMINGHAM HEART STUDY." Hypertension 58(5): 784-790. Frayn, K. N., et al. (2003). "Integrative physiology of human adipose tissue." Int J Obes Relat Metab Disord 27(8): 875-888. Frederich, R. C., Jr., et al. (1992). "Tissue-specific nutritional regulation of angiotensinogen in adipose tissue." Hypertension 19(4): 339-344. Friedewald, W. T., et al. (1972). "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge." Clin Chem 18(6): 499-502. Fruhbeck, G., et al. (2004). "Fundus functionality and ghrelin concentrations after bariatric surgery." N Engl J Med 350(3): 308-309. Fu, L., et al. (2004). "Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes." Endocrinology 145(6): 2594-2603. Furuhashi, M., et al. (2004). "Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity." J Hypertens 22(10): 1977-1982. Gallego-Escuredo, J. M., et al. (2015). "Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients." Int J Obes (Lond) 39(1): 121-129. Gao, H., et al. (2007). "GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes." Endocrine 32(1): 90-95. Gao, M., et al. (2014). "Prenatal Exposure to Lipopolysaccharide Results in Local RAS Activation in the Adipose Tissue of Rat Offspring." PLoS ONE 9(10): e111376. Garrison, R. J., et al. (1987). "Incidence and precursors of hypertension in young adults: the Framingham Offspring Study." Prev Med 16(2): 235-251. Gay, N. J., et al. (2014). "Assembly and localization of Toll-like receptor signalling complexes." Nat Rev Immunol 14(8): 546-558. Gaziano, J. M., et al. (1997). "Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction." Circulation 96(8): 2520-2525. Ge, X., et al. (2011). "Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes." J Biol Chem 286(40): 34533-34541. Ge, X., et al. (2012). "Metabolic actions of FGF21: molecular mechanisms and therapeutic implications." Acta Pharmaceutica Sinica B 2(4): 350-357. Gerhard, G. S., et al. (2013). "A Role for Fibroblast Growth Factor 19 and Bile Acids in Diabetes Remission After Roux-en-Y Gastric Bypass." Diabetes Care 36(7): 1859-1864. 
 163 
Ghoshal, S., et al. (2009). "Chylomicrons promote intestinal absorption of lipopolysaccharides." J Lipid Res 50(1): 90-97. Gillett, M., et al. (2012). "Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation." Health Technol Assess 16(33): 1-236, iii-iv. Golden, S. H., et al. (2002). "Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study." Diabetes 51(10): 3069-3076. Gomez-Ambrosi, J., et al. (2017). "FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss." Clin Nutr 36(3): 861-868. Gómez-Ambrosi, J., et al. (2017). "FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss." Clinical Nutrition 36(3): 861-868. Gonzalez-Muniesa, P., et al. (2017). "Obesity." Nat Rev Dis Primers 3: 17034. Goossens, G. H., et al. (2015). "Adipose Tissue Dysfunction and Impaired Metabolic Health in Human Obesity: A Matter of Oxygen?" Frontiers in Endocrinology 6: 55. Goossens, G. H., et al. (2004). "Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects." J Clin Endocrinol Metab 89(6): 2690-2696. Goossens, G. H., et al. (2003). "Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders." Obes Rev 4(1): 43-55. Gregor, M. F., et al. (2007). "Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease." J Lipid Res 48(9): 1905-1914. Grimm, I. S., et al. (1992). "Steatohepatitis and fatal hepatic failure after biliopancreatic diversion." Am J Gastroenterol 87(6): 775-779. Guerciolini, R. (1997). "Mode of action of orlistat." Int J Obes Relat Metab Disord 21 
Suppl 3: S12-23. Guernion, N., et al. (2001). "Identifying bacteria in human urine: current practice and the potential for rapid, near-patient diagnosis by sensing volatile organic compounds." Clin Chem Lab Med 39(10): 893-906. Guo, S. (2014). "Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms." J Endocrinol 220(2): T1-t23. Guo, X., et al. (2005). "Hypertension genes are genetic markers for insulin sensitivity and resistance." Hypertension 45(4): 799-803. Gustavo-Salom, et al. (2013). "PPAR and Local Renin-Angiotensin Systems in Cardiovascular and Metabolic Diseases Associated with Obesity: A Unifying Hypothesis." Open Journal of Endocrine and Metabolic Diseases Vol.03No.05: 10. Halberg, N., et al. (2009). "Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue." Mol Cell Biol 29(16): 4467-4483. Hall, J. E. (1993). "Hyperinsulinemia: a link between obesity and hypertension?" Kidney Int 43(6): 1402-1417. Hall, J. E., et al. (2010). "Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins." J Biol Chem 285(23): 17271-17276. 
 164 
Haluzikova, D., et al. (2013). "Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects." Obesity (Silver Spring) 21(7): 1335-1342. Harte, A., et al. (2005). "Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone." Circulation 111(15): 1954-1961. Hartwich, J., et al. (2007). "Effect of supplementation with vitamin E and C on plasma hsCRP level and cobalt-albumin binding score as markers of plasma oxidative stress in obesity." Genes Nutr 2(1): 151-154. Hassan, M., et al. (2012). "Adipose tissue: friend or foe?" Nat Rev Cardiol 9(12): 689-702. Henry, R. R., et al. (2013). "New options for the treatment of obesity and type 2 diabetes mellitus (narrative review) (, , )." Journal of diabetes and its complications 
27(5): 508-518. Herman, W. H., et al. (2012). "Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes." J Clin Endocrinol Metab 97(4): 1067-1072. Hess, D. S., et al. (2005). "The biliopancreatic diversion with the duodenal switch: results beyond 10 years." Obes Surg 15(3): 408-416. Hill, J. O. (2006). "Understanding and addressing the epidemic of obesity: an energy balance perspective." Endocr Rev 27(7): 750-761. Hoang, V., et al. (2015). "Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome." PLoS One 10(5): e0126119. Hoareau, L., et al. (2010). "Signaling pathways involved in LPS induced TNFalpha production in human adipocytes." Journal of Inflammation (London, England) 7: 1-1. Hofmann, A. F. (2011). "Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release." Hepatology 53(5): 1784. Hollander, P. A., et al. (1998). "Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study." Diabetes Care 
21(8): 1288-1294. Horowitz, J. F., et al. (2001). "Whole-body and adipose tissue glucose metabolism in response to short-term fasting in lean and obese women." The American Journal of Clinical Nutrition 73(3): 517-522. Hotamisligil, G. S. (2006). "Inflammation and metabolic disorders." Nature 
444(7121): 860-867. Hu, P., et al. (2006). "Autocrine Tumor Necrosis Factor Alpha Links Endoplasmic Reticulum Stress to the Membrane Death Receptor Pathway through IRE1α-Mediated NF-κB Activation and Down-Regulation of TRAF2 Expression." Molecular and Cellular Biology 26(8): 3071-3084. Iannelli, A., et al. (2011). "Inflammation, insulin resistance, lipid disturbances, anthropometrics, and metabolic syndrome in morbidly obese patients: a case control study comparing laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy." Surgery 149(3): 364-370. 
 165 
Inagaki, T., et al. (2005). "Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis." Cell Metab 2(4): 217-225. Islam, K. B., et al. (2011). "Bile acid is a host factor that regulates the composition of the cecal microbiota in rats." Gastroenterology 141(5): 1773-1781. Izumida, Y., et al. (2013). "Glycogen shortage during fasting triggers liver-brain-adipose neurocircuitry to facilitate fat utilization." Nat Commun 4: 2316. J., C., et al. (2013). "Obesity and C‐reactive protein in various populations: a systematic review and meta‐analysis." Obesity Reviews 14(3): 232-244. J. D. Halverson, et al. (1978). "Jejunoileal bypass for morbid obesity. A critical appraisal." The American Journal of Medicine 64(3): A92. Jain, S. S., et al. (2011). "Evaluation of efficacy and safety of orlistat in obese patients." Indian Journal of Endocrinology and Metabolism 15(2): 99-104. Jaubert, A. M., et al. (1995). "Estrogen binding sites in hamster white adipose tissue: sex- and site-related variations; modulation by testosterone." Gen Comp Endocrinol 100(2): 179-187. Jiang, J., et al. (2011). "The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects." J Clin Pharmacol 51(12): 1620-1627. Jones, B. H., et al. (1997). "Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells." Endocrinology 138(4): 1512-1519. Jones, B. H., et al. (1997). "Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control." Am J Physiol 
273(1 Pt 2): R236-242. Juan, C. C., et al. (2005). "Angiotensin II enhances insulin sensitivity in vitro and in vivo." Endocrinology 146(5): 2246-2254. Kaess, B. M., et al. (2010). "FGF21 signalling pathway and metabolic traits - genetic association analysis." Eur J Hum Genet 18(12): 1344-1348. Kallio, K. A. E., et al. (2015). "Endotoxemia, nutrition, and cardiometabolic disorders." Acta Diabetologica 52(2): 395-404. Kalupahana, N. S., et al. (2011). "(n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights." Adv Nutr 2(4): 304-316. Kalupahana, N. S., et al. (2012). "Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance." Obesity (Silver Spring) 20(1): 48-56. Kalupahana, N. S., et al. (2011). "Overview of symposium "Systems Genetics in Nutrition and Obesity Research"." J Nutr 141(3): 512-514. Kalupahana, N. S., et al. (2012). "The adipose tissue renin-angiotensin system and metabolic disorders: a review of molecular mechanisms." Critical Reviews in Biochemistry and Molecular Biology 47(4): 379-390. Kalupahana, N. S., et al. (2012). "The adipose tissue renin-angiotensin system and metabolic disorders: a review of molecular mechanisms." Crit Rev Biochem Mol Biol 47(4): 379-390. Kang, J. H., et al. (2017). "Effectiveness of bariatric surgical procedures: A systematic review and network meta-analysis of randomized controlled trials." Medicine 96(46): e8632. 
 166 
Karelis, A. D., et al. (2004). "Metabolic and body composition factors in subgroups of obesity: what do we know?" J Clin Endocrinol Metab 89(6): 2569-2575. Karlsson, C., et al. (1998). "Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II." J Clin Endocrinol Metab 
83(11): 3925-3929. Kaska, L., et al. (2016). "Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome." World J Gastroenterol 22(39): 8698-8719. Kawasaki, N., et al. (2012). "Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue." Sci Rep 2: 799. Kershaw, E. E., et al. (2004). "Adipose Tissue as an Endocrine Organ." The Journal of Clinical Endocrinology & Metabolism 89(6): 2548-2556. Kershaw, E. E., et al. (2004). "Adipose tissue as an endocrine organ." J Clin Endocrinol Metab 89(6): 2548-2556. Khalid, T., et al. (2015). "Urinary Volatile Organic Compounds for the Detection of Prostate Cancer." PLoS ONE 10(11): e0143283. Khan, N. I., et al. (2006). "Obesity: an independent risk factor for systemic oxidative stress." Pak J Pharm Sci 19(1): 62-65. Kharitonenkov, A., et al. (2005). "FGF-21 as a novel metabolic regulator." Journal of Clinical Investigation 115(6): 1627-1635. Kharitonenkov, A., et al. (2007). "The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21." Endocrinology 148(2): 774-781. Kim, i.-D., et al. (2015). "Exhaled Breath Sensors." Smart Sensors for Health and Environment Monitoring, KAIST Research Series. Kim, W., et al. (2008). "The role of incretins in glucose homeostasis and diabetes treatment." Pharmacol Rev 60(4): 470-512. Korner, J., et al. (2009). "Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass." Int J Obes (Lond) 
33(7): 786-795. Koska, J., et al. (2010). "Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes." Diabetes Care 33(5): 1028-1030. Kuipers, F., et al. (2014). "FXR: the key to benefits in bariatric surgery?" Nat Med 
20(4): 337-338. Kyrou, I., et al. (2017). "Fibroblast growth factors: new insights, new targets in the management of diabetes." Minerva Endocrinol 42(3): 248-270. LaGuardia, H. A., et al. (2012). "The Metabolic Syndrome and Risk of Chronic Kidney Disease: Pathophysiology and Intervention Strategies." Journal of Nutrition and Metabolism 2012: 652608. Landsberg, L., et al. (2013). "Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension." Obesity (Silver Spring) 21(1): 8-24. Langer, F. B., et al. (2005). "Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels." Obes Surg 15(7): 1024-1029. Lavoie, J. L., et al. (2003). "Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system." Endocrinology 144(6): 2179-2183. 
 167 
le Roux, C. W., et al. (2006). "Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters." Ann Surg 243(1): 108-114. Lee, M. H., et al. (2008). "Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue." Kidney Int 74(7): 890-900. Leonetti, F., et al. (2003). "Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects." J Clin Endocrinol Metab 88(9): 4227-4231. Lewandowska, E., et al. (2016). "[White adipose tissue dysfunction observed in obesity]." Pol Merkur Lekarski 40(239): 333-336. Li, T., et al. (2014). "Bile acid signaling in metabolic disease and drug therapy." Pharmacol Rev 66(4): 948-983. Li, T., et al. (2015). "Bile acids as metabolic regulators." Curr Opin Gastroenterol 
31(2): 159-165. Li, Y., et al. (2016). "Endotoxin contamination: a key element in the interpretation of nanosafety studies." Nanomedicine 11(3): 269-287. Liang, H., et al. (2013). "Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects." J Physiol 591(Pt 11): 2897-2909. Lin, X., et al. (2017). "Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues." Biomedical Reports 6(5): 495-502. Lindholm, L. H., et al. (2002). "Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol." Lancet 359(9311): 1004-1010. Linscheid, P., et al. (2005). "Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue." Endocrinology 146(6): 2699-2708. Lips, M. A., et al. (2014). "Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects." Clin Endocrinol (Oxf) 81(6): 862-870. Liu, F., et al. (2001). "An Extract of Lagerstroemia speciosa L. Has Insulin-Like Glucose Uptake–Stimulatory and Adipocyte Differentiation–Inhibitory Activities in 3T3-L1 Cells." The Journal of Nutrition 131(9): 2242-2247. Liu, M., et al. (2014). "Regulation of adiponectin multimerization, signaling and function." Best Pract Res Clin Endocrinol Metab 28(1): 25-31. Lobstein, T., et al. (2015). "Child and adolescent obesity: part of a bigger picture." Lancet. Lumeng, C. N., et al. (2007). "Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity." Diabetes 56(1): 16-23. Luo, J., et al. (2014). "[Effect of activating Toll-like receptor 4 on renin-angiotensin system in 3T3-L1 adipose cells]." Nan Fang Yi Ke Da Xue Xue Bao 34(6): 787-791. Malkani, S., et al. (2012). "Controversies on how diabetes is diagnosed." Curr Opin Endocrinol Diabetes Obes 19(2): 97-103. Mancia, G., et al. (2013). "2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)." J Hypertens 31(7): 1281-1357. 
 168 
Martinez de la Escalera, L., et al. (2017). "Impact of gut hormone FGF-19 on type-2 diabetes and mitochondrial recovery in a prospective study of obese diabetic women undergoing bariatric surgery." BMC Medicine 15(1): 34. Massiera, F., et al. (2001). "Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation." FASEB J 15(14): 2727-2729. Matthews, D. R., et al. (1985). "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man." Diabetologia 28(7): 412-419. Mazzone, P. J. (2015). "Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer." BMC Cancer 15:1001. McKinsey Consultancy. (01/2015). "McKinsey: Obesity costs UK society 73 billion per year."   Retrieved 01/june/2015, from 
http://www.consultancy.uk/news/1278/mckinsey-obesity-costs-uk-society-73-billion-
per-year. Merritt, M. E., et al. (2009). "Effect of bile salts on the DNA and membrane integrity of enteric bacteria." J Med Microbiol 58(Pt 12): 1533-1541. Messerli, F. H., et al. (1983). "Dimorphic cardiac adaptation to obesity and arterial hypertension." Ann Intern Med 99(6): 757-761. Meylan, E., et al. (2004). "RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation." Nat Immunol 5(5): 503-507. Minh Tdo, C., et al. (2012). "The clinical potential of exhaled breath analysis for diabetes mellitus." Diabetes Res Clin Pract 97(2): 195-205. Mlinar, B., et al. (2011). "New insights into adipose tissue dysfunction in insulin resistance." Clin Chem Lab Med 49(12): 1925-1935. Mlinar, B., et al. (2007). "Molecular mechanisms of insulin resistance and associated diseases." Clin Chim Acta 375(1-2): 20-35. Mohamed-Ali, V., et al. (1997). "Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo." J Clin Endocrinol Metab 82(12): 4196-4200. Mokdad, A. H., et al. (2003). "Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001." JAMA 289(1): 76-79. Moretto, T. J., et al. (2008). "Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study." Clin Ther 
30(8): 1448-1460. Morrison, C. D., et al. (2016). "Roux-en-Y gastric bypass surgery is effective in fibroblast growth factor-21 deficient mice." Molecular Metabolism 5(10): 1006-1014. Morrison, J. A., et al. (2007). "Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study." Pediatrics 120(2): 340-345. Morrow, J. D. (2003). "Is oxidant stress a connection between obesity and atherosclerosis?" Arterioscler Thromb Vasc Biol 23(3): 368-370. Mostafa, S. A., et al. (2010). "The potential impact of using glycated haemoglobin as the preferred diagnostic tool for detecting Type 2 diabetes mellitus." Diabet Med 
27(7): 762-769. 
 169 
Munoz, M. C., et al. (2009). "Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats." J Hypertens 27(12): 2409-2420. Must, A., et al. (1999). "The disease burden associated with overweight and obesity." Jama 282(16): 1523-1529. Nakai, Y., et al. (1999). "Plasma Concentrations of Tumor Necrosis Factor-α (TNF-
α) and Soluble TNF Receptors in Patients with Anorexia Nervosa1." The Journal of Clinical Endocrinology & Metabolism 84(4): 1226-1228. Navaneethan, U., et al. (2015). "Volatile Organic Compounds in Urine for Noninvasive Diagnosis of Malignant Biliary Strictures: A Pilot Study." Dig Dis Sci 
60(7): 2150-2157. Neovius, M., et al. (2012). "Health care use during 20 years following bariatric surgery." JAMA 308(11): 1132-1141. NHS. (2016). "NHS England Impact Analysis of implementing NHS Diabetes Prevention Program, 2016 to 2021 ", from https://www.england.nhs.uk/wp-
content/uploads/2016/08/impact-assessment-ndpp.pdf. NICE (2017). Obses, overweight with risk factors: liraglutide (Saxenda). Nies, V. J. M., et al. (2015). "Fibroblast Growth Factor Signaling in Metabolic Regulation." Frontiers in Endocrinology 6: 193. Nordestgaard, B. G., et al. (2012). "The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach." PLoS Med 9(5): e1001212. Nordisk, n. (27/04/2017). "News Release: Novo Nordisk Receives FDA Approval of Saxenda® (liraglutide) injection 3 mg Label Update Including Long-Term Safety and Efficacy Data from 3-Year Trial." from http://press.novonordisk-us.com/2017-04-
27-Novo-Nordisk-Receives-FDA-Approval-of-Saxenda-R-liraglutide-injection-3-mg-
Label-Update-Including-Long-Term-Safety-and-Efficacy-Data-from-3-Year-Trial. Nyui, N., et al. (1997). "Tissue angiotensinogen gene expression induced by lipopolysaccharide in hypertensive rats." Hypertension 30(4): 859-867. O'Brien, P. E., et al. (2006). "Systematic review of medium-term weight loss after bariatric operations." Obes Surg 16(8): 1032-1040. O'Neill, L. A. (2006). "How Toll-like receptors signal: what we know and what we don't know." Curr Opin Immunol 18(1): 3-9. O'Neill, L. A., et al. (2007). "The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling." Nat Rev Immunol 7(5): 353-364. Ochner, C. N., et al. (2012). "Pre-bariatric surgery weight loss requirements and the effect of preoperative weight loss on postoperative outcome." Int J Obes (Lond) 
36(11): 1380-1387. Opara, E. I., et al. (1995). "Tumor necrosis factor-alpha and total parenteral nutrition-induced anorexia." Surgery 118(4): 756-760; discussion 760-752. Ortiz, S., et al. (2014). "Bacterial DNA Translocation Holds Increased Insulin Resistance and Systemic Inflammatory Levels in Morbid Obese Patients." The Journal of Clinical Endocrinology & Metabolism 99(7): 2575-2583. Overduin, J., et al. (2004). "Gastric Bypass for Obesity: Mechanisms of Weight Loss and Diabetes Resolution." The Journal of Clinical Endocrinology & Metabolism 
89(6): 2608-2615. 
 170 
Owen, B. M., et al. (2015). "Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21." Trends Endocrinol Metab 26(1): 22-29. Pacheco, M. M., et al. (2018). "Anima tissue, Adipose tissue." from 
https://mmegias.webs.uvigo.es/02-english/guiada_a_adiposo.php. Park, C. W., et al. (2011). "Physiology of weight loss surgery." The Surgical clinics of North America 91(6): 1149-vii. Park, H. K., et al. (2017). "Linking resistin, inflammation, and cardiometabolic diseases." The Korean Journal of Internal Medicine 32(2): 239-247. Pasarica, M., et al. (2009). "Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response." Diabetes 58(3): 718-725. Patel, C., et al. (2007). "Prolonged reactive oxygen species generation and nuclear factor-kappaB activation after a high-fat, high-carbohydrate meal in the obese." J Clin Endocrinol Metab 92(11): 4476-4479. Patton, A., et al. (2017). "Impact of Fibroblast Growth Factors 19 and 21 in Bariatric Metabolism." Digestive Diseases 35(3): 191-196. Pearson, T. A., et al. (2003). "Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association." Circulation 107(3): 499-511. Perea, A., et al. (1995). "Physiological effect of glucagon in human isolated adipocytes." Horm Metab Res 27(8): 372-375. Perk, J., et al. (2012). "European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)." Eur Heart J 33(13): 1635-1701. Phillips, M., et al. (2004). "Increased breath biomarkers of oxidative stress in diabetes mellitus." Clin Chim Acta 344(1-2): 189-194. Pihl, E., et al. (2006). "Atherogenic inflammatory and oxidative stress markers in relation to overweight values in male former athletes." Int J Obes (Lond) 30(1): 141-146. Piya, M. K., et al. (2013). "Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin." J Endocrinol 216(1): T1-T15. Pories, W. J., et al. (1992). "Surgical treatment of obesity and its effect on diabetes: 10-y follow-up." Am J Clin Nutr 55(2 Suppl): 582S-585S. Potthoff, M. J., et al. (2011). "FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway." Cell Metab 13(6): 729-738. Potthoff, M. J., et al. (2012). "Endocrine fibroblast growth factors 15/19 and 21: from feast to famine." Genes & Development 26(4): 312-324. Pournaras, D. J., et al. (2012). "The Role of Bile After Roux-en-Y Gastric Bypass in Promoting Weight Loss and Improving Glycaemic Control." Endocrinology 153(8): 3613-3619. Prat-Larquemin, L., et al. (2004). "Adipose angiotensinogen secretion, blood pressure, and AGT M235T polymorphism in obese patients." Obes Res 12(3): 556-561. Pratley, R. E. (2013). "The early treatment of type 2 diabetes." Am J Med 126(9 Suppl 1): S2-9. 
 171 
Prawitt, J., et al. (2014). "Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization." Trends Endocrinol Metab 25(5): 235-244. Raetz, C. R. H., et al. (2002). "Lipopolysaccharide Endotoxins." Annual review of biochemistry 71: 635-700. Rahmouni, K., et al. (2004). "Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity." Am J Physiol Endocrinol Metab 286(6): E891-895. Ramirez-Velez, R., et al. (2017). "Body Adiposity Index Performance in Estimating Body Fat Percentage in Colombian College Students: Findings from the FUPRECOL-Adults Study." Nutrients 9(1). Ramírez-Vélez, R., et al. (2017). "Percentage of Body Fat and Fat Mass Index as a Screening Tool for Metabolic Syndrome Prediction in Colombian University Students." Nutrients 9(9): 1009. Ridker, P. M. (2003). "Clinical Application of C-reactive Protein for Cardiovacular Disease Detection and Prevention." Circulation. Rodbell, M. (1964). "METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS." J Biol Chem 239: 375-380. Romaní-Pérez, M., et al. (2015). "Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats." Endocrinology 156(10): 3559-3569. Root, C., et al. (2002). "Ileal bile acid transporter inhibition, CYP7A1 induction, and antilipemic action of 264W94." J Lipid Res 43(8): 1320-1330. Roslin, M., et al. (2018). Acute and Chronic Complications Following Biliopancreatic Diversion with Duodenal Switch. Complications in Bariatric Surgery. D. Camacho and N. Zundel. Cham, Springer International Publishing: 207-220. Rossner, S., et al. (2000). "Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group." Obes Res 8(1): 49-61. Ruan, H., et al. (2002). "Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance." Diabetes 51(11): 3176-3188. Rubino, F., et al. (2016). "Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations." Diabetes Care 39(6): 861-877. Ryan, K. K., et al. (2014). "FXR is a molecular target for the effects of vertical sleeve gastrectomy." Nature 509(7499): 183-188. Ryden, M., et al. (2017). "Subcutaneous Adipocyte Lipolysis Contributes to Circulating Lipid Levels." Arterioscler Thromb Vasc Biol 37(9): 1782-1787. Sabeel, T. M. A., et al. (2013). Detection of volatile compounds in urine using an electronic nose instrument. 2013 INTERNATIONAL CONFERENCE ON COMPUTING, ELECTRICAL AND ELECTRONIC ENGINEERING (ICCEEE). Saely, C. H., et al. (2012). "Brown versus white adipose tissue: a mini-review." Gerontology 58(1): 15-23. 
 172 
Safonova, I., et al. (1997). "Regulation by fatty acids of angiotensinogen gene expression in preadipose cells." Biochemical Journal 322(Pt 1): 235-239. Safonova, I., et al. (1997). "Regulation by fatty acids of angiotensinogen gene expression in preadipose cells." Biochem J 322 ( Pt 1): 235-239. Salazar, M. R., et al. (2012). "Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women." Am J Cardiol 109(12): 1749-1753. Saltiel, A. R. (2001). "You are what you secrete." Nat Med 7(8): 887-888. Sato, S., et al. (2003). "Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling." J Immunol 171(8): 4304-4310. Sattar, N., et al. (2003). "Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study." Circulation 108(4): 414-419. Saxendapro (2017). "1-year data: significant weight loss results with saxenda." Sayin, Sama I., et al. (2013). "Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist." Cell Metabolism 17(2): 225-235. Schaffler, A., et al. (2007). "Concise review: adipose tissue-derived stromal cells--basic and clinical implications for novel cell-based therapies." Stem Cells 25(4): 818-827. Schauer, D. P., et al. (2017). "Association Between Weight Loss and the Risk of Cancer after Bariatric Surgery." Obesity (Silver Spring) 25 Suppl 2: S52-s57. Schauer, P. R., et al. (2003). "Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes Mellitus." Annals of Surgery 238(4): 467-485. Schauer, P. R., et al. (2016). "Clinical Outcomes of Metabolic Surgery: Efficacy of Glycemic Control, Weight Loss, and Remission of Diabetes." Diabetes Care 39(6): 902-911. Scheen, A. J. (2004). "Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system." Drugs 64(22): 2537-2565. Schmieder, R. E., et al. (2007). "Renin-angiotensin system and cardiovascular risk." Lancet 369(9568): 1208-1219. Schumann, S.-A., et al. (2008). "When not to use beta-blockers in seniors with hypertension." The Journal of Family Practice 57(1): 18-21. Scopinaro, N. (2012). "Thirty-five years of biliopancreatic diversion: notes on gastrointestinal physiology to complete the published information useful for a better understanding and clinical use of the operation." Obes Surg 22(3): 427-432. Seesaard, T., et al. (2016). "Self-screening for diabetes by sniffing urine samples based on a hand-held electronic nose." Biomedical Engineering International Conference (BMEiCON): 1-4. Selvin, E., et al. (2007). "Short-term variability in measures of glycemia and implications for the classification of diabetes." Arch Intern Med 167(14): 1545-1551. Selvin, E., et al. (2007). "The effect of weight loss on c-reactive protein: A systematic review." Archives of Internal Medicine 167(1): 31-39. 
 173 
Serazin-Leroy, V., et al. (2000). "Androgen regulation and site specificity of angiotensinogen gene expression and secretion in rat adipocytes." Am J Physiol Endocrinol Metab 279(6): E1398-1405. Serazin-Leroy, V., et al. (2000). "Androgen regulation and site specificity of angiotensinogen gene expression and secretion in rat adipocytes." American Journal of Physiology-Endocrinology and Metabolism 279(6): E1398-E1405. Shak, J. R., et al. (2008). "The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones." Obes Surg 18(9): 1089-1096. Sharma, A. M. (1992). "Effects of nonpharmacological intervention on insulin sensitivity." J Cardiovasc Pharmacol 20 Suppl 11: S27-34. Shen, Y., et al. (2013). "Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease." Cardiovasc Diabetol 12: 124. Sheng, X., et al. (2014). "Adipocyte differentiation is affected by media height above the cell layer." International journal of obesity (2005) 38(2): 315-320. Shyangdan, D. S., et al. (2011). "Glucagon-like peptide analogues for type 2 diabetes mellitus." Cochrane Database Syst Rev(10): CD006423. Sjöström, L. (2013). "Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery." Journal of Internal Medicine 273(3): 219-234. Sjostrom, L., et al. (2009). "Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial." Lancet Oncol 10(7): 653-662. Sjostrom, L., et al. (2007). "Effects of bariatric surgery on mortality in Swedish obese subjects." N Engl J Med 357(8): 741-752. Sjostrom, L., et al. (2012). "Bariatric surgery and long-term cardiovascular events." Jama 307(1): 56-65. Sjostrom, L., et al. (1998). "Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group." Lancet 352(9123): 167-172. Skov, J., et al. (2016). "Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial." Diabetes, Obesity and Metabolism 18(6): 581-589. Skurk, T., et al. (2004). "Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB." Arterioscler Thromb Vasc Biol 24(7): 1199-1203. Sola, E., et al. (2009). "Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss." Obes Surg 19(5): 571-576. Solomon, H., et al. (2009). "Benefits to patients choosing preoperative weight loss in gastric bypass surgery: new results of a randomized trial." J Am Coll Surg 
208(2): 241-245. Song, K.-H., et al. (2009). "Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression." Hepatology (Baltimore, Md.) 49(1): 297-305. Stamler, R., et al. (1987). "Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program." JAMA 257(11): 1484-1491. 
 174 
Stoeckli, R., et al. (2004). "Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass." Obes Res 12(2): 346-350. Sun, S. S., et al. (2008). "Childhood obesity predicts adult metabolic syndrome: the Fels Longitudinal Study." J Pediatr 152(2): 191-200. Surmi, B. K., et al. (2008). "Macrophage infiltration into adipose tissue: initiation, propagation and remodeling." Future lipidology 3(5): 545-556. Swerdlow, D. I., et al. (2012). "The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis." The Lancet 
379(9822): 1214-1224. szer, T., et al. (2010). "PPARs in the Renal Regulation of Systemic Blood Pressure." PPAR Research 2010: 11. Takeda, K., et al. (2004). "TLR signaling pathways." Semin Immunol 16(1): 3-9. Tatematsu, M., et al. (2010). "A molecular mechanism for Toll-IL-1 receptor domain-containing adaptor molecule-1-mediated IRF-3 activation." J Biol Chem 
285(26): 20128-20136. Thomas, S., et al. (2010). "Bariatric Surgery and the Gut Hormone Response." Nutrition in Clinical Practice 25(2): 175-182. Thomopoulos, C., et al. (2015). "Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses." J Hypertens 33(7): 1321-1341. Tomkin, G. H., et al. (2016). "Obesity diabetes and the role of bile acids in metabolism." Journal of Translational Internal Medicine 4(2): 73-80. Tsuda, K. (2012). "Renin-Angiotensin system and sympathetic neurotransmitter release in the central nervous system of hypertension." Int J Hypertens 2012: 474870. Underwood, P. C., et al. (2013). "The Renin Angiotensin Aldosterone System and Insulin Resistance in Humans." Current hypertension reports 15(1): 59-70. Valverde, I., et al. (2005). "Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects." Obes Surg 15(3): 387-397. van Dielen, F. M., et al. (2004). "Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery." J Clin Endocrinol Metab 89(8): 4062-4068. van Dielen, F. M. H., et al. (2004). "Macrophage Inhibitory Factor, Plasminogen Activator Inhibitor-1, Other Acute Phase Proteins, and Inflammatory Mediators Normalize as a Result of Weight Loss in Morbidly Obese Subjects Treated with Gastric Restrictive Surgery." The Journal of Clinical Endocrinology & Metabolism 
89(8): 4062-4068. Vendrell, J., et al. (2011). "Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance." Endocrinology 152(11): 4072-4079. Victozapro. (2015). "Victoza-a force for changefor 5 years." from 
https://www.victozapro.com/clinical-benefits.html. Wang, H., et al. (2008). "Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing 
 175 
fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes." Mol Cell Biol 28(1): 188-200. Wang, Y., et al. (2009). "Plasma ghrelin modulation in gastric band operation and sleeve gastrectomy." Obes Surg 19(3): 357-362. Watson, E., et al. (2010). "Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide." J Clin Pharmacol 50(8): 886-894. Watt, M. J., et al. (2006). "Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of c-Jun N-terminal kinase in peripheral tissues." Endocrinology 147(5): 2077-2085. Waugh, N. R., et al. (2013). "Screening for type 2 diabetes: a short report for the National Screening Committee." Health Technol Assess 17(35): 1-90. WHO (2004). "Priority Medicne for Europe and the World, "A Public Health Approach to Innovation"." Word Health Organisation. WHO (2013). "Q & A on hypertension." World Health Organization. WHO (2015). "Childhood overweight and obesity." World Health Organization, 
2015(1). WHO (2015). "Obesity and overweight." World Health Organization. Williams, M., et al. (1997). The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Wu, A.-L., et al. (2011). "FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways." PLoS ONE 6(3): e17868. Wu, X., et al. (2009). "Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice." Proceedings of the National Academy of Sciences of the United States of America 106(34): 14379-14384. Wynn, T. A. (2007). "Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases." Journal of Clinical Investigation 117(3): 524-529. Xu, H., et al. (2003). "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance." J Clin Invest 112(12): 1821-1830. Yamamoto, T., et al. (2014). "Functional assessment of the mutational effects of human IRAK4 and MyD88 genes." Mol Immunol 58(1): 66-76. Yamauchi, T., et al. (2001). "The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity." Nat Med 7(8): 941-946. Yang, C., et al. (2012). "Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB." PLoS One 7(3): e33870. Yang, J., et al. (2013). "Glucagon-like peptide 1 regulates adipogenesis in 3T3-L1 preadipocytes." Int J Mol Med 31(6): 1429-1435. Yang, Y., et al. (2016). "The emerging role of Toll-like receptor 4 in myocardial inflammation." Cell Death Dis 7: e2234. Youssef-Elabd, E. M., et al. (2012). "Acute and chronic saturated fatty acid treatment as a key instigator of the TLR-mediated inflammatory response in human adipose tissue, in vitro." J Nutr Biochem 23(1): 39-50. Yvan-Charvet, L., et al. (2006). "Prevention of adipose tissue depletion during food deprivation in angiotensin type 2 receptor-deficient mice." Endocrinology 
147(11): 5078-5086. 
 176 
Yvan-Charvet, L., et al. (2009). "Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue." Endocrinology 150(3): 1421-1428. Yvan-Charvet, L., et al. (2011). "Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity." Kidney Int 79(2): 162-168. Zhang, F., et al. (2015). "Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases." Mol Endocrinol 29(10): 1400-1413. Zhang, X., et al. (2008). "Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans." Diabetes 
57(5): 1246-1253. Zhong, J., et al. (2010). "Temporal profiling of the secretome during adipogenesis in humans." J Proteome Res 9(10): 5228-5238. Zhou, J., et al. (2012). "Adipocyte dysfunction and hypertension." American Journal of Cardiovascular Disease 2(2): 143-149. Zorad, S., et al. (2006). "Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma." Eur J Pharmacol 552(1-3): 112-122.                   
 
